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SUMMARY
Peritoneal exudate appears to be toxic in experimental 
pancreatitis, possibly as a result of overwhelming of its 
antiprotease defences by proteolytic enzymes released frcm the 
pancreas. Removal of this exudate by peritoneal lavage has been a 
uniformly successful therapy. In contrast, the role of the 
protease-antiprotease balance in peritoneal exudate in human acute 
pancreatitis, and its relationship with the early "shock-like" 
illness which may complicate severe attacks, has not been clearly 
defined and the efficacy of peritoneal lavage is unproven.
This thesis has addressed 3 main issues. The nature and extent 
of the problem presented by acute pancreatitis has been investigated, 
as have means for monitoring and predicting the severity of the 
illness. The major part of the thesis has examined aspects of the 
protease-antiprotease balance in the peritoneal exudate that 
complicates severe acute pancreatitis, and the efficacy of treatment 
by the administration of intraperitoneal antiproteases in 
experimental pancreatitis and in man.
Incidence and mortality
The incidence and mortality trends of acute pancreatitis in 
Scotland have been reviewed between 1961 and 1985 using data from the 
Scottish Hospital In-patient Statistics. Over this 25 year period the 
number of patients discharged with a diagnosis of acute pancreatitis 
increased 11-fold in males and 4-fold in females and may be largely
23
explained by an increased frequency of diagnosis (diagnostic 
rate), due to greater clinical awareness and more frequent diagnostic 
testing. The absolute mortality rate has increased slightly although, 
because of the marked increase in incidence, the case mortality rate
has fallen frcm 17.8% to 5.6%.
The incidence and mortality trends were also examined in 
Glasgow Royal Infirmary between 1974 and 1984, over which period the 
diagnostic rate was thought to have been unchanged. Despite a 23% 
fall in the catchment population the annual number of admissions 
remained relatively constant, suggesting a true increase in local 
incidence.
Amongst the fatal attacks, 42% had the diagnosis first made at 
post mortem, the fall in overall mortality frcm 14.9% to 10.8%
reflecting a reduction in the numbers first diagnosed at post mortem.
Mortality amongst patients diagnosed in life was unchanged at 9% 
throughout, thus when the effect of an increased diagnostic rate is 
excluded, improvements in therapy do not appear to have influenced 
the mortality rate.
Prediction of outccme
Investigation of invasive or expensive therapies requires that 
patients with severe pancreatitis and at risk of a carpiicated 
attack, are identified accurately, early in their illness. There is 
also a need to develop means to objectively monitor the course of the 
illness and any response to therapy, which might aid their 
management.
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Simple clinical assessment was shown to have the highest 
overall accuracy in predicting outcome but, even 48 hours 
post-admission, detected under 50% of those developing complications. 
Multiple factor scoring systems provided a useful prediction of 
outcome, particularly for attacks associated with alcohol abuse, but 
provided a "once only" prediction and failed to allow for sequential 
monitoring of the course of an attack.
Sequential monitoring of 5 different complement factors was of 
no value in discriminating complicated from uncomplicated attacks. 
Serum antiproteases demonstrated a falling alpha2 macroglobulin 
concentration and a rising alpha^antiprotease concentration in 
complicated attacks, both providing useful discrimination. C-reactive 
protein provided better discrimination but peak levels (^210mg/l on 
the 2nd, 3rd or 4th day), while providing equivalent accuracy to the 
multiple factor scoring systems incurred a similar delay. C-reactive 
protein concentrations fell with clinical improvement, persistently 
high levels (^120mg/l on day 7) indicating an increased risk of 
carpi ication.
The APACHE II scoring system provided a prediction of outcome 
within a few hours of admission. The peak score recorded in the first 
3 days provided greater accuracy, equivalent to the multiple factor 
scoring systems, but incurred a similar delay. The APACHE II was 
objective, reproducible and appeared to reflect improvement or 
deterioration in the patient's clinical condition and may permit 
sequential monitoring of the course of the illness.
None of the scoring systems or factors examined was able to
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predict complicated attacks earlier and more accurately than 
multiple factor scoring systems. C-reactive protein and APACHE II 
both appear to be of value, C-reactive protein for its simplicity and 
both for objective monitoring during the course of an attack.
Intraperitoneal antiprotease therapy
Retrograde intraductal injection of sodium taurocholate 
produced a severe pancreatitis in rats, death usually occurring 
within 24 hours. Only a small proportion of patients die of such a 
fulminant, rapidly fatal illness but it is this early "shock-like" 
illness which therapy aims to ameliorate and, therefore, this model 
appeared an appropriate one to study.
Saturation of the peritoneal antiproteases by proteases has 
been shown to be associated with the development of shock and death 
in experimental pancreatitis possibly by the activation of 
complement, kininogens and zymogens with release of vasoactive 
peptides, including kinins and histamine, which may escape into the 
circulation to exert a systemic effect.
Saturation of the peritoneal antiproteases was demonstrated by 
the presence of free proteolytic activity in 40-50% of rats one hour 
after the induction of pancreatitis and in 60% of control rats at 
death. Intraperitoneal therapy comprising aspiration of the exudate, 
a single peritoneal lavage and instillation of an antiprotease or 
similar inactive solution, one hour after the induction of 
pancreatitis was found to prolong the median survival suggesting that 
the continued presence of exudate was deleterious.
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Fresh frozen plasma instilled into the peritoneal cavity after 
the lavage was associated with the longest survival and thus appeared 
to confer additional benefit, perhaps because of its antiprotease 
(alpl^macroglobulin and alpha^antiprotease) content. Instillation of 
the antiprotease aprotinin, although possessing a much greater 
trypsin binding capacity, just failed to significantly improve 
survival compared with the control group and was no better than 
instilling saline alone. The nature of the antiprotease administered, 
rather than its trypsin binding capacity, may be of most importance.
Study of the peritoneal exudates from patients with acute 
pancreatitis confirmed proteolytic enzyme activation and reduced 
trypsin binding capacities indicating a degree of saturation of their 
antiproteases. Three patients had marked reduction of their trypsin 
binding capacities, 2 dying of fulminant acute pancreatitis soon 
after sampling and in whom saturation of the antiprotease defences 
may have occurred. Thus similar, although less marked changes in the 
protease-antiprotease balance were observed in man.
Of 160 patients studied prospectively in a clinical trial, 51 
fulfilled the inclusion and exclusion criteria and were randomised to 
receive standard therapy alone (26), or with additional 
intraperitoneal antiprotease therapy (25) comprising peritoneal 
aspiration, a single saline lavage and instillation of aprotinin (5 x 
10DKIU on 2 occasions 8 hours apart). Intraperitoneal therapy with 
aprotinin was found to markedly reduce peritoneal tryptic amidase 
activity during the initial 8 hours of treatment. In this preliminary 
report intraperitoneal therapy with aprotinin produced no benefit in
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terms of the incidence of death or major complication. There 
was a suggestion of a trend towards earlier clinical improvement, 
with a reduced incidence of shock and early death from fulminant 
acute pancreatitis in the treated group but this requires 
confirmation in a larger group of patients.
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PART 1.
usmmjcnoN and aims
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CHAPTER 1. ACUTE PANCREATITIS.
General introduction
Acute pancreatitis appears to be increasing in incidence but 
the case mortality rate has remained unchanged over the past 30 years 
at around 2 0 % ^ ' ^ ^  suggesting that improvements in therapy 
introduced during this period may have failed to influence the 
outcome.
Typically 2 phases of mortality are recognised in acute 
pancreatitis. Death may occur early, within the first week, resulting 
from a "shock-like" illness canplicated by respiratory, 
cardiovascular and renal failure. Trapnell found that 45 (59%) of his 
patients died during this period, 33 within the first 48 hours, the 
majority (67%) having oedematous pancreatitis at post morteirr^. Thus 
a considerable proportion of those dying appeared to do so in the 
presence of a seemingly mild, recoverable, pancreatic lesion.
Patients surviving this early phase may succumb later in the course 
of the attack, due to the local complications resulting fran 
pancreatic necrosis and sepsis.
"Toxic factors" released into the circulation, from the 
inflamed pancreas or frcm the carmonly associated peritoneal exudate, 
are postulated to be the cause of the early "shock-like" illness. 
Therapeutic strategies which have been put forward to influence this 
phase of the illness are numerous and have generally failed to show 
benefit when subjected to controlled clinical trial.
There is a need to increase understanding of the mechanisms
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underlying this early systemic toxicity and to develop means of 
specifically treating this phase of the illness. This thesis examines 
the role of the protease-antiprotease balance in pancreatitis exudate 
as a cause of the toxicity and investigates a novel therapeutic 
approach comprising removal of the exudate by aspiration and a single 
peritoneal lavage, followed by intraperitoneal instillation of an 
exogenous antiprotease solution.
Accurate identification of patients with severe acute 
pancreatitis early in their attack is another priority, so that 
resources, including any potentially invasive therapies, may be 
directed towards these patients.
Acute pancreatitis is defined and its diagnosis and clinical 
features are described in the first part of this thesis. The 
pathogenesis of acute pancreatitis and its complications are 
reviewed, with particular reference to the role of the proteolytic 
enzymes and evidence for the pathogenicity of peritoneal exudate. 
Aspects of therapy including severity prediction and disease 
monitoring are reviewed and the past experience of peritoneal lavage 
and antiprotease therapy are critically assessed.
Historical aspects
The word pancreas derives from the Greek "pan" meaning all, and 
"kreas" meaning flesh or meat. The name has been attributed to Rufus 
of Ephesus (circa 100 AD) although the first description of the organ 
can be traced to Hercphilus of Chalcedon (circa 300 BC).
The function of the pancreas was, for many years, unclear.
31
Niccolo Massa (1536) considered the pancreas to be a pad "upon
which the mouth of the stanach rests lest it touch the hard surface
333of the vertebrae without a buffer between" . Vesalius (1514-1564)
described the pancreas as a glandulous organ but the first
description of the pancreatic duct, thus establishing the glandular
nature of the organ, came frcm Johann Wirsung of Padua in 1642. The
accessory duct was described by Giovanni Santorini in 1724 and both
ducts have cane to be known eponymously. In the 19th century Bernard
first established the importance of the pancreatic secretion in 
55digestion .
Pancreatitis was induced experimentally in dogs by Bernard in 
1855 by injecting bile and other substances into the pancreatic 
duct . Alcohol as an aetiological factor in pancreatitis in man was 
first highlighted in 1878 by Friedreich's description of "drunkard's
115
pancreas" . The description of another mechanism of production of 
pancreatitis was provided in 1901 by Opie who reported a gallstone 
obstructing the ampulla of Vater, thus creating a common channel with 
reflux of bile into the pancreatic duct . However, despite much 
effort since then we are little closer to understanding the 
initiating factor(s) in this and other forms of acute pancreatitis.
The exocrine pancreas 
Embryology
The pancreas is formed frcm the gut endoderm by the fusion of 
two separate primordia (Fig. 1). The dorsal primordium arises first 
frcm the floor of the duodenum, proximal to the smaller, ventral
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FIGURE 1.
Diagram showing stages of pancreatic 
development: formation of the dorsal and 
ventral primordia, rotation of the termination 
of the hepatic diverticulum and ventral 
pancreas to the right where it fuses with the 
dorsal pancreas to form the adult gland.
primordium. The ventral primordium arises frcm the base of the 
hepatic diverticulum, accounting for the cannon opening of the main 
pancreatic duct and bile duct m  the adult .
Growth changes within the duodenum cause the ventral pancreas 
and hepatic diverticulum to swing round to the right where fusion 
between the two primordia occurs, the ventral pancreas forming the 
uncinate process and inferior portion of the head, and the dorsal 
pancreas the remainder of the adult gland. After fusion of the two 
primordia their ducts fuse, the main pancreatic duct (Wirsung) 
arising frcm the duct of the ventral pancreas and the distal portion 
of the duct of the dorsal pancreas. The proximal portion of the 
dorsal pancreatic duct enters the duodenum separately as the 
accessory duct (Santorini).
Structure
The acinus is the secretory unit of the pancreas, each 
comprising a group of pyramidal-shaped acinar cells around a lumen 
lined by flattened centro-acinar cells, into which the acinar cells 
discharge their secretory granules when stimulated to secrete (Fig. 
2). The pancreas is composed of multiple lobules, each made up of 
numerous acini draining into intercalated ducts. These ducts unite to 
form intralobular ducts which join interlobular ducts running in the 
connective tissue between lobules. Finally the interlobular ducts 
join the main pancreatic duct which drains via the ampulla of Vater 
into the duodenum.
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Pancreatic secretion
The pancreatic secretion comprises two separate secretory 
processes - enzyme secretion and electrolyte secretion. Secretion is 
primarily under hormonal control although, as in gastric secretion, 
there is a neural component (cephalic phase) mediated by the vagus. 
Secretin liberated frcm the duodenal mucosa stimulates secretion of a 
watery, alkaline fluid from the ductular cells. Pancreozymin, also 
released from the duodenal mucosa, stimulates secretion of an 
enzyme-rich fluid by the discharge of zymogen granules frcm acinar 
cells.
Pancreatic enzymes
The enzymes produced by the pancreatic acinar cells play a 
major role in intraluminal digestion. The pancreatic enzymes are all 
hydrolases and are classed according to their substrate molecule: 
amylase - starch, proteolytic enzymes - proteins, lipolytic enzymes - 
fats and nucleolytic enzymes - nucleic acids (Table 1). Pancreatic
enzymes make up between 80 and 85% of the protein content of
• • 7Q pancreatic juice .
Definition and classification
Fitz, in 1889, was the first to attempt to classify acute 
pancreatitis describing haemorrhagic, suppurative and gangrenous 
forms-^. Various classifications were subsequently proposed but the 
first unified attempt at classification followed an international
oi 7
symposium at Marseille m  1963-^ .
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Pancreatic inflammatory diseases were classified into 4 
categories: acute pancreatitis, acute relapsing pancreatitis, chronic 
relapsing pancreatitis and chronic pancreatitis^The two acute 
forms - acute and relapsing acute pancreatitis were considered to be 
associated with clinical and biological restitution of the gland, if 
the primary cause or factors had been eliminated whereas in the 
chronic forms, anatomical and/or functional damage persisted. The 
Marseille classification has been helpful in the study of 
pancreatitis but problems remained, one example being the difficulty 
in practice of distinguishing acute relapsing frcm chronic relapsing 
pancreatitis.
The classification of acute pancreatitis has been updated more
recently at symposia in Cambridge and Marseille, during 1983 and 1984 
319 331r e s p e c t i v e l y B o t h  classifications were similar with regard to
their clinical definition of acute pancreatitis but the second
Marseille symposium again stressed the morphological changes within
the pancreas in mild and severe attacks, although such information is
not readily available in clinical practice and is seldan sought in
these patients^. Thus the clinical definition of acute pancreatitis,
319as suggested by the Cambridge group , which can be applied at the 
time of diagnosis, would appear to be the most useful in clinical 
practice and is the one adopted in this thesis.
35
TABLE 1.
The human pancreatic enzymes.
Protein Activator Substrate Function
Alpha-amylase
Lipase
Carboxyl ester 
hydrolase
Ribonuclease
Starch
Tri­
glycerides
Cholesterol
esters
RNA
Hydrolysis of alpha 1,4 
glycosidic bonds
Hydrolysis of C. and Cj 
glycerol ester bonds
Hydrolysis of esters of 
water soluble short 
chain fatty acids
Hydrolysis of phosphate 
ester bonds in RNA
Deoxyribonuclease
Trypsinogen
(Trypsin)
Entero-
kinase
Chymotrypsinogen Trypsin 
(Chymotrypsin)
DNA
Proteins
Proteins
Proelastase
(Elastase)
Trypsin Elastin
Procarboxy­
peptidase A 
(Carboxypeptidase A)
Procarboxy­
peptidase B 
(Carboxypeptidase B)
Trypsin Proteins
Trypsin Proteins
Prophospholipase Aj Trypsin Phospho- 
(Phospholipase Aj) lipids
Kallikreinogen
(Kalllikrein)
Trypsin Kininogens
Hydrolysis of phosphate 
ester bonds in DNA
Hydrolysis of peptide 
bonds at arginine and 
lysine
Hydrolysis of peptide 
bonds at amino acids with 
aromatic side chains
Hydrolysis of peptide 
bonds at amino acids with 
aliphatic side chains
Hydrolysis of peptide 
bonds at C terminal amino 
acids with aromatic or 
branched aliphatic side 
chains
Hydrolysis of peptide 
bonds at C terminal amino 
acids with basic side 
chains
Hydrolysis, of fatty acid 
esters at 2-position of 
phospholipids
Cleavage of kininogen to 
active kinin
Clinical features
"Acute pancreatitis is the most terrible of all the calamities 
that occur in connection with the abdominal viscera. The suddenness 
of its onset, the illimitable agony which accompanies it, and the 
mortality attendant upon it, all render it the most formidable of 
catastrophies" (Moynihan, 1925).
Moynihan went on to describe the characteristic distribution 
of the pain "of fiercest intensity in the epigastrium, but it is felt 
also in the back and often both loins". He also described the 
collapse and shock that may occur in acute pancreatitis and 
considered that vomiting was almost invariably present in these 
patients®^ although this classical picture was observed by Pollock 
in only 50% of cases .
The vast majority of patients present with abdominal pain, the 
proportion ranging frcm 84%®®® to 98%^®. Sane attacks may be
796painless, one study reporting this in 7 (15%) of 47 patients but,
as such cases may not be diagnosed in life, its true prevalence is
difficult to estimate. The abdominal pain is epigastric in around 60%
of cases®*65,305^ j;)Ut ^  right hypochondrial in 2 0 %^®'®®® or,
more rarely, maximal in the left hypochondrium or in the lower
abdomen^®'®®'®®®. Radiation of pain to the back was described in
around half the patients^®'®®®, in 40% of cases®*65,165 ^  few
1 ORas 28% . Vomiting was a frequent association found in between
53%®®® and 90% of patients®^®.
Although there are no specific clinical features which can be 
considered pathognomonic of acute pancreatitis, the presence of body 
wall staining is suggestive. Both Cullen's sign and Grey Turner's 
sign®®® are rare, having been reported in between i%®*165,279 ancj 3 %
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of attacks0  . These signs are seldcm present on admission of the 
patient to hospital and are not generally of value in establishing 
the diagnosis. Therefore, although most patients present with a 
fairly characteristic clinical picture, this is rarely specific 
enough to allow a confident diagnosis to be made.
Diagnosis
Acute pancreatitis can be diagnosed definitively only at 
laparotcmy or post mortem. As most patients recover without recourse 
to surgery the diagnosis is, in practice, based on an abnormal 
pancreatic enzyme elevation in the presence of a compatible clinical 
picture. Most widely used for its diagnosis is estimation of amylase.
Amylase
A "starch-splitting ferment" in the blood was described by 
Magendie m  1846 J and its value m  the diagnosis of acute 
pancreatitis was first reported in 1929^. Serum amylase measurement 
has became the corner-stone of diagnosis but elevated levels do not 
necessarily prove the diagnosis of acute pancreatitis, neither do 
normal levels exclude it®^.
Hyperarny1asaemia is thought to correlate with the presence of 
acute pancreatitis in between 75% and 80% of cases'*^, although many 
other conditions may also be associated with hyperamylasaemia-^'^^. 
The amylase activity selected as the diagnostic cut-off level for 
acute pancreatitis influences this figure, the higher the level set, 
the fewer non-pancreatic causes of hyperamylasaemia will be
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erroneously included.
With the advent of the Phadebas amylase test (Pharmacia 
Diagnostics, Uppsala, Sweden) most recent British series have quoted 
their amylase results in international units (IU/1). In the UK the
ocn
diagnostic cut-off levels have varied between 1,000IU/1 ,
1,200IU/11 5 9  and 2,000IU/1245, (normal range 70-300IU/1).
Amylase isoenzymes
Amylase comprises 2 principle isoenzymes, pancreatic (p-type)
isoamylase and salivary (s-type) isoamylase, each composed of several
slightly different subunits in terms of their chromatographic 
■ • 315mobility . The s-type is the predominant fraction in normal serum
while the p-type predominates in urine. Knowledge of the isoamylase
profile has been reported to provide information which could change
the clinical diagnosis in between 20% and 40% of cases with 
181 375hyperamylasaemia ' . In contrast, amongst patients with
clinically suspected acute pancreatitis 97% had p-type isoamylase 
elevation confirmed^4.
Urinary amylase
Urinary amylase excretion has been considered to be a more
sensitive index of acute pancreatitis than serum amylase
323 315estimations , rising earlier, higher and persisting for longer .
Hyperamylasuria, like hyperarrylasaemia, is not necessarily diagnostic
of acute pancreatitis, nor does a normal urinary amylase exclude its
presence94.
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Amylase-creatinine clearance ratio
The increased renal clearance of amylase by the kidney in acute
pancreatitis was put forward as a more specific diagnostic test and
expressed as the ratio of the amylase clearance to the creatinine
clearance, has become known as the amylase creatinine clearance ratio 
91 9(ACCR) . This finding was attributed to a direct effect on the
170kidney, either on glomerular permeability or tubular reabsorbtion ,
167others implicating a reversible renal tubular defect . The 
specificity of the ACCR has been questioned more r e c e n t l y ^ a n d  
it is rarely employed.
Lipase
Lipase has been considered a more specific test of pancreatic
disease than a m y l a s e ^ b u t  like amylase, a number of other acute
84abdominal conditions may give rise to lipase elevations . The 
elevations of both amylase and lipase parallel each other in the 
majority of cases^' . Others consider that lipase is more closely
correlated to pancreatic p-type isoamylase and that either test is 
more specific than the total amylase^^.
Trypsin
Trypsin may be measured by a radioimmunoassay, the bulk of the
iirimunoreactivity in serum representing trypsinogen and a small
proportion trypsin ccmplexed to circulating inhibitors such as
49alpha^antiprotease (trypsin does not retain its iirimunoreactivity 
when ccmplexed to alph^macroglobulin). Immunoreactive trypsin was
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markedly raised in acute pancreatitis^'191,240 and remained elevated 
for longer than urinary amylase^^. At present the test is more 
expensive and time consuming to perform than the tests for either 
amylase or lipase, and is not in routine clinical use.
Radiology '
Acute pancreatitis may be associated with various non-specific 
appearances on X-ray including the "sentinel locp" and the "colon 
cut-off sign". Either may suggest the diagnosis of acute 
pancreatitis, but are themselves not diagnostic**^. Localised duodenal 
ileus may be of more diagnostic value but may be a feature of other 
inflammatory conditions such as acute cholecystitis-*-^.
The diagnosis can be made on both ultrasound and computed 
tomography by the demonstration of pancreatic enlargement, perhaps 
with loss of density, a surrounding halo or more distant inflammatory 
infiltration.
Incidence and mortality
"The incidence of acute pancreatitis probably reflects the 
thoroughness with which the disease is sought as well as the criteria 
which are accepted to define its existence" (McMahon, 1977).
In the early part of this century acute pancreatitis was 
infrequently diagnosed, and then only with certainty at laparotomy or 
post mortem. With the advent of serum amylase testing, permitting for 
the first time accurate non-operative diagnosis in life, the reported 
incidence of the condition increased^** and has continued to rise.
Trapnell and Duncan examined the incidence and mortality
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trends in Bristol over a 20 year period, finding an average 
annual incidence of 53.8 cases per million population for the period 
1961 to 1967 with a mortality of 9 per million population*^ # Between 
1968 and 1979 the annual incidence had risen to a mean of 73 cases 
per million population with a mean annual death rate of 15.7 per 
million population*^. Thus while the incidence and mortality had both 
increased, the overall case mortality rate had remained unchanged at 
19.6% between 1968 and 1979 compared with 20.5% for the preceding 20
years®*'^*7.
Patients diagnosed in life comprise only a proportion of the 
the total number with the condition. A further group are those first 
diagnosed at post mortem, having been unsuspected and/or undiagnosed 
during life. The number falling into this category has been reported 
at between 2 2 %*^ and 8 6 %^"^ of all pancreatitis deaths, with a mean 
incidence of 41.6% in 7 series reviewed (Table 2). The size of this 
group will depend, amongst other factors, on the proportion of 
patients dying in hospital who are submitted to post mortem 
examination.
A final group have unsuspected acute pancreatitis and remain 
undiagnosed, either surviving, or dying without a post mortem. More 
widespread diagnostic testing will identify more of these patients, 
resulting in an increased diagnostic rate and an apparent increase in 
incidence. Many will have mild pancreatitis and thus be less likely 
to die and their inclusion in epidemiological studies will effect a 
lowering of the case mortality rate. This can be illustrated in 3 
published series from Glasgow Royal Infirmary which point to an
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TABLE 2.
Reported proportion of deaths from acute 
pancreatitis undiagnosed before post mortem.
Undiagnosed
Authors Deaths before post mortem
Trapnell (1966) 76 24 (32%)
Whalen et al. (1971) 50 43 (86%)
Read et al. (1976) 10 4 (40%)
Bourke (1977) 54 22 (41%)
Peterson and Brooks (1979) 40 17 (43%)
Buggy and Nostrant (1983) 32 7 (22%)
Corfield et al. (1985) 125 44 (35%)
Totals 387 161 (42%)
increased diagnostic rate being at least partly responsible for 
the increasing incidence and falling mortality rates (Table 3).
Other factors influencing the mortality include the patient's 
age and underlying aetiology155,157,165,290,355  ^attacks due to
gallstones are associated with a higher mortality than attacks due to 
a l c o h o l b u t  whether this simply reflects the patients' greater 
age is unclear. A higher mortality has been recorded in postoperative 
pancreatitis and pancreatitis secondary to t r a u m a - ^ a n d  
also in attacks in which no aetiological factor is 
i d e n t i f i e d ® ^ W h e t h e r  the patients in this latter category 
are simply older and/or sicker and, therefore, less likely to be 
investigated, is not known. The first attack of acute pancreatitis is 
thought by sane to be more likely to be fatal than the second or 
subsequent attack^^ /322,357 ^ although others have been unable to 
confirm this®^.
Pathology
The histological changes of acute pancreatitis are 
characterised by pancreatic parenchymal destruction, necrosis of 
blood vessels with haemorrhage, fat necrosis and an accompanying 
inflammatory reaction-^.
Investigating the initial lesion in human acute pancreatitis 
Foulis found two distinct patterns of necrosis-^. In alcohol or 
gallstone-associated pancreatitis there was ductal inflammation and 
periductal necrosis suggesting the initiating factors may have been 
"duct-borne" -^9. In contrast other patients demonstrated only
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TABLE 3.
Reported incidence and mortality from 
acute pancreatitis at Glasgow Royal 
Infirmary (1960-1977).
Number Average number 
Type of study Years of cases of cases/year Mortality
Retrospective 1960-70 140* 14 21.4%
Prospective 1971-72* 78 39 11.5%
Prospective 1974-77* 161 54 8.7%
51 cases recorded within last 2 years of study.
* coincided with introduction of Phadebas amylase test.
* study over 34 month period.
Reference
Imrie, 1974
Imrie and 
Whyte, 1975
Imrie et al. 
1978
perilobular necrosis, without ductal inflammation, the 
pancreatitis in these cases having followed an episode of shock. This 
pattern of necrosis has also been observed in patients developing 
pancreatitis following cardiac surgery-^ and appears to have an 
ischaemic basis.
Kloppel and co-workers in a review of 367 autopsy cases and 3 
surgical specimens came to entirely different conclusions regarding 
the initial lesion-*-^. Using immunocytochemical techniques the 
peripheral acinar cells within a lobule neighbouring an area of fat 
necrosis were found to be depleted of enzymes, whereas the more 
central acinar cells retained their enzyme content. No major 
differences were apparent between pancreatitis of varying aetiologies 
and the fact that the ducts appeared intact, seemed to indicate the 
initial lesion was the discharge of enzymes by peripheral acinar 
cells (perhaps by basolateral release) into the surrounding 
interstitial tissue-^.
Aetiological factors
Epidemiological studies have provided evidence of an 
association between acute pancreatitis and a number of conditions or 
factors, seme of which are now considered to be causally related or 
aetiological factors. The list of associated conditions is extensive 
and has been thoroughly reviewed by Durr®^. I propose only to deal 
with the two conditions most widely encountered, namely biliary tract 
disease and alcohol abuse, which together account for the majority of 
cases of acute pancreatitis world-wide. In a cumulative review of
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3836 patients these two conditions were considered to have accounted 
for 6 8 % of attacks®^, the next most important group being those in 
whcm no definite aetiological factor could be identified, accounting 
for 2 2 % of attacks^.
Gallstones
The close correlation between gallstones and acute pancreatitis 
is evident frcm post mortem studies such as that of Bell where the 
incidence of gallstones in 8540 unselected post mortems was 21.9% 
compared with 56.2% in post mortems of 178 patients with acute 
pancreatitis . The incidence of acute pancreatitis m  unselected
OA
post mortems ranged between 0.14 and 1.3% , whereas m  patients with
gallstones the incidence was 4 .7 %1 8 6 .
Gallstone pancreatitis is predominantly a disease of wonen. In 
5 series reviewed the mean female incidence was 72%, ranging frcm 58% 
to 8 3 % ^ ' ^ The incidence of gallstone pancreatitis 
increases with advancing age as does the incidence of gallstones 
which, in every age group, were commoner m  wcmen than m  menJ . In 
contrast, Imrie found that this female predominance disappeared in 
patients over 60 years of age-^.
The description of a gallstone obstructing the ampulla, 
permitting reflux of bile into the pancreatic duct, was first made in 
1 9 0 i2 6 6 . Recent work has shown a frequent association with gallstone 
migration through the ampulla of Vater, gallstones having been 
recovered frcm the faeces after an attack in between 84%-^ and 94%^ 
of patients, compared with 1 1 % and 8 % of control cases respectively.
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Gallstones in these patients are typically smaller and more
numerous than in controls without pancreatitis and their cystic ducts
1 9 99R
are generally wider ' ,  factors which favour gallstone migration. 
The observation that 75% of these patients have ampullary obstruction 
by gallstones if operated on within 2  days of the onset of symptoms, 
falling to 45% after 2 days and 25% after 4 days provides strong 
evidence for the theory of transient ampullary obstruction arising 
secondary to gallstone migration^.
Alcohol-associated pancreatitis
Acute alcoholic pancreatitis tends to occur in young men, often
in their early to mid-thirties, who have been drinking steadily for 8  
151to 10 years . There is seme debate m  the literature as to whether 
alcohol ever causes acute pancreatitis in the absence of pre-existing 
chronic lesions, many believing that acute pancreatitis in an 
alcoholic is a manifestation of pre-existing chronic pancreatitis^^. 
Ccmmonly these "acute" attacks do recur and after several years it is
Q
clear that many of these patients do have chronic pancreatitis .
The effect of ethanol on the pancreas has been extensively
studied in the past but the mechanisms involved in the pathogenesis
of the pancreatitis are still unclear and conflicting. Ethanol has a
variable effect on the intact animal depending on species and the 
• • 127route of administration . Intravenous administration of alcohol 
inhibits basal as well as secretin and cholecystokinin-pancreozymin
oco
stimulated pancreatic secretion . Ingestion of alcohol on the other
542hand stimulates the release of secretin , promoting pancreatic
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secretion. Alcohol has been shewn to increase sphincter of Oddi
ooq 0 7 Q
pressure ' ,  thus the combined effect of alcohol ingesticn may be
secretory stimulation and outflow obstruction. In more recent studies
in humans, however, intragastric alcohol was found to decrease both
peak and basal sphincter of Oddi pressure as assessed by endoscopic 
3fi 7manometry '.
Evidence from a 3-dimensional reconstruction of the pancreatic
ductal system has implicated the deposition and subsequent
calcification of protein plugs, within the smaller pancreatic ducts,
as the earliest lesion in chronic pancreatitis2^ .  Alcoholic men have
a higher protein content in pancreatic juice than normal men2 ^-2  with
31 fireduced concentrations of bicarbonate and citrate . Increased 
concentrations of calcium, total protein and trypsin were found in 
another group following complete recovery frcm an "acute" attack of 
alcohol-induced pancreatitis . Therefore, in the earliest stages of 
chronic pancreatitis the environment exists for the formation of 
protein plugs. The major protein in the pancreatic precipitates is a 
degradation product of trypsinogen-^ suggesting premature 
proteolytic enzyme activation occurs and is an important factor in 
man.
Pathogenesis
The molecular events leading to the initiation of acute 
pancreatitis in man have not been fully elucidated. A large and 
diverse number of conditions have been considered to be aetiological 
factors but it has not been possible to devise a unifying theory to
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account for the initiation of pancreatitis in all. It seems 
likely that the disease which we recognise clinically, biochemically 
and histologically as acute pancreatitis may be a common response of 
the gland to a variety of different insults.
The concept of autodigestion by the digestive enzymes was first 
proposed in 1896 by Chiari and has dominated our thinking about the 
causation of pancreatic necrosis ever since^^. Activation of the 
pancreatic proteolytic enzymes has been demonstrated in pancreatic 
tissue-*-^/2 0 0  ^pancreatic juice^^'^! and most convincingly in 
pancreatitis e x u d a t e ^ b y  the presence of protease-inhibitor 
corrplexes. Others consider that phospholipase A 2  alone, or with 
lysolecithin which it metabolises from lecithin in the bile, may be 
responsible for the necrotizing process and systemic features such as 
shock and the adult respiratory distress s y n d r o m e ^ / 254,3 25 ^
In health several factors act to prevent premature enzyme 
activation within the pancreas. Firstly, all potentially harmful 
pancreatic enzymes are synthesised as inactive precursors or 
zymogens. Secondly these proenzymes are stored in the acinar cell 
within zymogen granules, isolated fron the cytoplasm and other 
intracellular organelles by a phospholipid membrane. Thirdly, the 
acinar cells synthesise an inhibitor, pancreatic secretory trypsin 
inhibitor (PSTI), which prevents premature activation of trypsin 
within the acinar cells and ductal system. Finally, trypsinogen is 
first activated when it cones in contact with enterokinase in the 
duodenum, trypsin subsequently activating all the other zymogens. 
Breakdown or overwhelming of any one of these lines of defence might
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lead to premature pancreatic enzyme activation and 
autodigestion.
In the initiation of acute pancreatitis it has been assumed 
that pancreatic enzyme activation occurs outside cells within the 
ducts or in the interstitial tissues. Theories which have sought to 
explain this have included bile reflux, pancreatic ductal 
obstruction/secretion and duodenal reflux, all of which are possible 
sequelae of gallstone migration with transient arapullary obstruction.
Bile reflux
Reflux of bile into the pancreatic duct was observed to have
occurred at the post mortem of a patient with acute haemorrhagic 
966pancreatitis . The patient had a small calculus impacted at the
ampulla of Vater occluding the common orifice and forming a
continuous closed channel between the carmen bile duct and pancreatic
duct. Opie found evidence of a common channel in 89% of 100 specimens 
967examined but in only 30% did he consider that an impacted
968gallstone would permit bile reflux . Mann and Giordano examining
200 specimens considered that only 3.5% would permit reflux of 
239bile . Other workers have shewn reflux is possible in between 54% 
and 6 6 % of cases'^' .
Patients undergoing cholecystectomy for gallstone pancreatitis
demonstrate reflux of contrast into the pancreatic duct at
19 171cholangiography in 62% and 67% of cases , compared to between 15%
and 17% of controls, thus these patients may have papillary
abnormalities, even in the absence of an inpacted gallstone.
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Papillary abnormalities have also been demonstrated
mancmetrically, during ceruletide infusion, in patients with
77gallstone pancreatitis undergoing cholecystectomy .
Against this theory is the evidence that pancreatic duct 
pressures are usually higher than bile duct p r e s s u r e s ' ^ a n d  
that at physiological pressures bile is not damaging to the 
pancreas^ * 29 7,38 0 ^
Pancreatic ductal obstruction/secretion
Simple ductal ligation produces atrcphy of the pancreatic
noc
exocrine tissue without pancreatitis but extensive pancreatic 
oedema results from concurrently stimulating the gland with
o o i  OQ'i 9 P R
secretin EXictal obstruction alone appears insufficient
for the production of haemorrhagic pancreatitis but ischaemia, by
temporary occlusion of the main pancreatic artery, was found to
transform pancreatic oedema into necrosis
Ductal obstruction with stimulation of the gland could
conceivably occur due to an obstructing gallstone occluding the
pancreatic duct following a meal. Although evidence of such a causal
relationship is lacking, there is circumstantial evidence of
pancreatitis often catling on within an hour or two of a large 
neaj.92,238,301,330 #
Both this and the bile reflux theory fail to explain activation 
of the pancreatic enzymes in the presence of inhibitors such as PSTI. 
Rich and Duff proposed that rupture of the duct/acinar system 
occurred and that enzyme activation occurred in the interstitial
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tissues'*^ but no plausible theories exist to explain this-^.
Duodenal reflux
Pancreatic enzymes are normally activated by enterokinase in 
the duodenum and it is possible that reflux of duodenal contents may 
cause their intraductal activation. Duodenal juice also includes 
activated pancreatic enzymes, bile acids and lysolecithin which, vdien 
infused into the pancreatic duct, are all capable of inducing 
pancreatitis experimentally. This theory has gained ground, not least 
because acute pancreatitis can be induced in experimental animals by 
the creation of a closed duodenal loop. Reflux of duodenal contents 
into the pancreatic duct results from overdistension of the closed 
loop and pancreatitis can be prevented by ligaticn of the pancreatic 
Whether this occurs in man is unknown, the sphincter 
of Oddi and the pressure gradient between the pancreatic duct and 
duodenum serving as a defence mechanism, although the increased 
incidence of pancreatitis following Polya compared with Bilroth I 
g a s t r e c t o m y ^ - * - ^'369 been attributed to this mechanism.
Other theories of enzyme activation
Two recently described experimental models have demonstrated 
that pancreatic enzyme activation by lysosomal hydrolases may in fact 
occur inside the acinar cell. Severe haemorrhagic pancreatitis can be 
induced in young female mice by feeding a choline deficient,
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2 1 5ethionme supplemented diet . Pancreatitis may also be induced in
rats by the administration of supramaximal doses of the
192cholecystokinin-pancreozymin analogue caerulm . In each model 
large vacuoles, containing both pancreatic digestive and lysosomal 
enzymes, develop within acinar cells. Thus it may also be possible 
that the release of activated pancreatic enzymes in acute 
pancreatitis occurs as a result of pancreatic acinar cell necrosis 
and is not necessarily the cause. The relevance of these models, 
however, to human disease is not clear.
Complications
The complications of acute pancreatitis can be divided into 
local and systemic according to vrfiether they affect the pancreas or 
more distant organs or systems. Local carpiications result fron the 
effects of pancreatic necrosis. Systemic effects are thought to be 
mediated indirectly, by pancreatic enzymes, kinins, peptides and 
perhaps other toxic products released from the pancreas and 
peritoneal exudate.
Local complications: necrosis and abscess
Our knowledge of the incidence and natural history of 
pancreatic necrosis is increasing with the advent of 
contrast-enhanced CT scanning and this is helping to define more 
clearly the indications for surgical intervention. Non-enhancement of 
pancreatic tissue following a rapid intravenous bolus of contrast 
media appears to indicate non-perfusing tissue, which has or will
51
become necrotic. These findings can be demonstrated early in 
the course of an attack of pancreatitis^®.
Infection of the necrotic pancreatic and peripancreatic tissue
may supervene early, often within the first week of illness^.
Patients with infected necrotic tissue have a poorer prognosis than
when the necrosis is sterile, with mortalities of 38% and 9%
respectively . Infection will, over a period of time, form pus and
eventually a pancreatic abscess will result. This has, in the past,
been a feared complication of acute pancreatitis with a mortality
when unrecognised or untreated approaching 100% . Trapnell found an
incidence of pancreatic abscess of 5.3% from a study of 581 patients
and others have found a similar incidence ranging between 4.7%0ii and 
"11 9 •6% . Pancreatic abscesses typically manifest m  the second or third
week of the illness but can present much later, 3 of Trapnell's cases 
presenting 6 months after the initial attack^®. Pancreatic abscesses 
typically present with an abdominal mass associated with fever, 
tachycardia, and a leukocytosis.
Necrotic pancreatic tissue may also give rise to bleeding from 
the pancreatic bed which can be life-threatening and call for urgent 
surgical intervention^^. The presence of necrotic tissue, perhaps by 
compromising the arterial blood supply to the colon, may also give 
rise to a number of colonic complications including stricture, 
fistula formation or frank colonic necrosis-*-'-*-^ ®'^ -*-^ .
Pseudocysts
The term pseudocyst is probably best reserved for the mature,
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chronic pseudocyst, a localised collection of pancreatic juice 
usually confined to the retroperitoneal area and characterised by 
possessing a fibrous wall with no epithelial lining. Many of these 
cysts carmunicate with the main pancreatic duct or one of its 
branches and presumably result from necrosis and breakdown of a small 
area of the adjacent gland and duct.
Ultrasound was not available to Trapnell who reported 
pseudocysts developing in 3% of 581 patients with acute 
pancreatitis^^. A higher incidence of 10% was reported in two more 
recent American s e r i e s ^ T h e  majority of pseudocysts presented 
in the second, third or fourth week of illness but, as with abscess, 
could present much later. The majority presented with a mass and 5 
(28%) resolved spontaneously without surgery. The earlier the 
pseudocyst developed the higher the associated mortality"^.
It has been estimated that complications arise in 33% of
Ol f.
pseudoqystsOJ-D. Pseudocysts may rupture acutely or chronically, 
usually into an adjacent viscus or cavity. Rupture has been estimated 
to occur in 11% of cases and as a consequence the pseudocyst may 
resolve, produce a cystoenteric fistula or, if it ruptures into the 
peritoneal or pleural cavities, may give rise to pancreatic ascites 
or a pleural effusion r e s p e c t i v e l y ^ ^ . Pseudocysts may become 
secondarily infected^. Haemorrhage may occur secondary to rupture of 
the pseudocyst or by erosion of an adjacent or contained visceral 
artery and is associated with a mortality of 61%"^. By increasing in 
size, it may compress adjacent structures and giving rise to bile 
duct o b s t r u c t i o n ^ o r  intestinal obstruction.
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Systemic conplications: Shock
Shock has been considered the major cause of early death in 
acute pancreatitis*^ /341,355  ^Hypovolaemia, in addition to other 
cardiovascular factors, is thought to contribute to the shock.
Hypovolaemia
Plasma volume deficits in a canine experimental pancreatitis 
model, calculated by the change in the haematocrit, have been
CQ
estimated to peak at 38% . Intravascular volume measured in another
study fell 19% after 2 hours and 30% six hours after the induction of
pancreatitis*^. It was calculated that in a 70kg man with corrparable
pancreatitis, the intravascular volume deficit would be nearly 2
litres during the first 6 hours of the illness*^. A significant
proportion of the plasma volume loss was fluid exuded from the
finpancreas, accumulating in the peritoneal cavity . Because of the 
retroperitoneal position of the pancreas in man, much of the fluid 
would be sequestered in the peripancreatic and retroperitoneal 
tissues. In addition there may be a more widespread capillary leak 
with loss of fluid into the extravascular space in tissues remote 
from the pancreas, including the lungs'^^ and subcutaneous tissues. 
The proposed mechanism for this fluid leak is altered capillary 
permeability, mediated directly or indirectly by vasoactive agents 
released from the pancreas or peritoneal exudate^'*^.
Thai and co-workers demonstrated vasoactive substances to be 
present in the blood of dogs with acute pancreatitis and suggested
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that these might be kinins (bradykinin or kallidin) or related
peptides . These vasoactive substances were present in increased
amounts in patients with acute pancreatitis and appeared to correlate
with clinical status and may contribute to the hypotension, pain
980and increased capillary permeability .
Because of the rapid action of kinin degrading enzymes
(kininases) in the circulation, kinins are thought to have a
predominantly local effect in mediating inflammation. These defences
can be overwhelmed by infusing increasing amounts of trypsin to dogs.
This results in consumption of alpl^macroglobulin and, following
saturation of this inhibitor, decreasing amounts of kininogen were
found (indicating bradykinin release) associated with a simultaneous
drop in blood pressure .
Such a degree of systemic trypsin release is likely to be a
rare occurrence in human pancreatitis. Kinin activation has, however,
been demonstrated in the peritoneal exudate in human acute 
• • 909pancreatitis . Sustained absorption of kinins from the exudate 
could deplete or overcome the serum kininases and may contribute to 
the shock and altered vessel permeability which characterise the 
early systemic toxicity of pancreatitis.
Myocardial depression
The existence of a myocardial depressant factor, thought to be 
a peptide with a molecular weight of between 800 and 1000 daltons, 
has been demonstrated in the plasma of humans and experimental 
animals in various forms of shock and also in acute
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pancreatitis^^ • 217 #
Haemodynamic studies in man have appeared to confirm myocardial 
depression in patients with severe acute pancreatitis*^'163  ^others 
were unable to prove this conclusively, considering rather that 
patients with severe acute pancreatitis have a high output, lew 
resistance picture resembling that seen in sepsis^. Cobo and 
co-workers considered that depressed myocardial function alone did 
not account for the hypotension in patients with acute pancreatitis, 
rather that myocardial depression compromised cardiac compensation 
for the significantly diminished vascular tone^.
Renal failure
Acute renal failure may complicate acute pancreatitis in up to 
6% of patients and is usually a consequence of s h o c k ^ . Acute tubular 
necrosis appears to be the most common form of renal failure although 
renal cortical necrosis may occur occasionally^. The mortality 
associated with this carpiication is typically high ranging between 
69% and 100%^r31,156^ while hypovolaemia and/or hypotension have 
been almost constant factors in its pathogenesis studies on dogs and 
in man have also shewn increased renal vascular resistance suggesting 
there may be release of a vasopressor^^' 377 ^
Respiratory complications
Respiratory complications are frequently associated with acute 
pancreatitis and in one study were thought to be the most significant 
factor contributing to death^®. Clinical evidence of respiratory
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failure was usually not obvious and only 9 patients (11%) had
OQ1
any radiographic evidence of respiratory complications . The most 
severe form of lung involvement in acute pancreatitis comprises 
pulmonary oedema, atelectasis and diffuse pulmonary infiltrates which 
may give rise to the adult respiratory distress syndrome. In one 
study diffuse pulmonary involvement occurred in 18% of patients and
1 /ih
was associated with a 56% mortality . Possible causes of the lung 
lesion are physical factors such as aspiration, fluid overload, 
hypoproteinaemia, shock, diffuse intravascular coagulation and fat 
embolism . The various pancreatic enzymes have also been 
implicated, in particular phospholipase A 2 , which may have a specific 
action on pulmonary surfactant. Complement breakdown products and 
kinins released in acute pancreatitis may produce capillary 
permeability changes and kinins may, in addition, give rise to 
pulmonary venous hypertension thus exacerbating the increased vessel 
permeability^-*-.
Coagulopathy
Disseminated intravascular coagulation may occur as a rare 
complication but in several of the reported cases there were factors 
other than acute pancreatitis which might have been responsible for 
its occurrence-*--^' 190. Experimental studies in dogs suggest that a 
similar coagulopathy may be induced by the infusion of trypsin but 
not by infusion of lipase or phospholipase-*-^.
In a sequential study of coagulation parameters in 25 patients 
with acute pancreatitis mild changes suggesting a hypercoagulable
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state were found, only one patient shewing features of
747disseminated intravascular coagulation^ . Another stud/ found no 
consistent pattern of change in the various coagulation parameters 
(prothrombin time, partial thromboplastin time and thrombin time)293. 
Alterations in coagulation were greatest in severe attacks and 
because early coagulation measurements could be correlated with 
respiratory, renal and hepatic dysfunction, they suggested that 
enzyme-related intravascular coagulation might be implicated in their 
pathogenesis293.
Deposits of fibrin material, thought to derive from 
intravascular coagulation, have been demonstrated in the glomerular 
capillaries from the kidneys of patients with pancreatitis and may be 
an important factor in the pathogenesis of the renal 
complications3^3.
Unusual Complications
Among other conplications attributed to systemic enzyme release
OQ
are subcutaneous fat necrosis and osteolytic lesions in bones due 
to intramedullary fat necrosis389'32 .^ Psychotic disturbances 
characterised by disorientation, confusion, delirium, delusions or 
hallucinations may be seen in acute pancreatitis and while these may 
simply reflect alcohol withdrawal in alcoholic pancreatitis, there 
appears to exist a distinct entity of pancreatic encephalopathy 
associated with increased levels of lipase in the cerebrospinal 
fluid98.
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The serum antiprotease defences
In several conditions other than acute pancreatitis, including 
sepsis, trauma and shock, proteolytic enzymes may be released into 
the circulation. In many cases this serves as a defence mechanism, 
the proteases activating cascade systems such as the complement, 
haemostatic and kinin systems mediating bacterial opsonization and 
killing, coagulation and inflammation. These effects may be harmful 
to the host and activation of these cascade systems is regulated and 
the body protected against damage from proteolytic enzymes by a group 
of proteins in the bloodstream known as the antiproteases. There are 
7 major antiproteases in serum (Table 4), 3 of these antithrombin 
III, alpha2 antiplasmin and Cl inhibitor are concerned mainly with the 
haemostatic, fibrinolytic and complement systems respectively, and 
will not be dealt with further.
Alpha2 macroglobulin
Alph^macroglobulin is a large glycoprotein molecule consisting 
of 2 pairs of identical subunits. Because of its large size the 
molecule tends to be retained within the intravascular compartment. 
Biologically it is the most polyvalent inhibitor, binding proteases 
irreversibly, but depending on the protease this can be by a 2 : 1 
protease to inhibitor ratio or a 1 : 1 ratio as in the case of 
plasmin and thrombin-^^. Each of the 2 subunits of 
alpt^macroglobulin contains a specific amino acid sequence termed 
the "bait region" which is highly susceptible to proteolytic 
cleavage. Cleavage of this region leads to a conformational change
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TABLE 4.
The major serum antiproteases.
Antiprotease 
Alphazmacroglobul in
Alpha, antiprotease 
Antichymotrypsin
Inter-alpha-trypsin
inhibitor
C, inhibitor 
Antithrombin III
Aiphazantiplasmin
Mol. wt. Enzymes inhibited
725,000 Endopeptidases
55.000 Serine proteases
68.000 Chymotrypsin, 
Cathepsin G
160.000 Trypsin, Plasmin, 
Chymotrypsin, 
Cathepsin G
104.000 Cl”, Cls”, ciF, 
Factors XIa, Xlla, 
Kallikrein, Plasmin
65.000 Thrombin,
Factors IXa, Xa,
XIa, Xlla, Plasmin, 
Trypsin
70.000 Plasmin, Trypsin, 
Kallikrein, Thrombin 
Chymotryps in,
Factors Xa, XIa
Site of 
synthesis
Liver, 
Macrophages 
Fibroblasts 
Adherent 
lung cells
Liver
Liver
Liver
Liver
Liver
Liver
within the molecule which results in irreversible binding of
r\ r ”1
the enzyme but without blocking its active site ' . This has been
termed the "trap hypothesis" . The protease is trapped by the 
molecule but its active site remains open, explaining the 
characteristic persistence of proteolytic activity possessed by the 
alpl^macroglobulin-protease complex. This phenomenon was first 
recognised in 1962 and was designated the trypsin-protein 
esterase*^. Protein-bound trypsin was found to maintain its 
proteolytic and esterolytic activity within the complex yet was 
resistant to inactivation by various trypsin inhibitors'^^. This
0 0 7
protein was shown in 1964 to be alpl^macroglobulin .
The half life of alph^macroglobulin in its free form in the
bloodstream is around 5.5 days . Following protease binding the
conformational change in the molecule leads to its rapid clearance
from the circulation with a half life of 8 minutes in dogs and in
man of 9 and 12 minutes for complexes with trypsin and elastase 
264respectively . In dogs the complexes are largely cleared by cells 
of the reticulo-endothelial system in the liver, spleen and bone 
marrow^^. Clearance is thought to be accomplished by binding of the 
complexes to cellular receptors and rapid internalisation by 
endocy t os is^  ^ .
Levels of alpha^acroglobulin are usually very stable although
low levels have been reported in septic shock, following major bone
202surgery and during streptokinase infusion . Despite large scale
207searches no deficiency states have been reported , suggesting that 
this inhibitor may have an essential physiological role.
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Alpha-^antiprotease is a much smaller, more abundant molecule 
than alpha2 macroglobulin. Alpha-^ antiprotease is an acute phase 
reactant, levels rising in response to illness, injury or trauma. 
Genetic variants of the molecule are recognised, deficiency states 
being associated with pulmonary emphysema and liver disease.
Alpha^antiprotease was originally named alpha^antitrypsin due 
to its ability to inhibit trypsin but despite accounting for 90% of 
the serum antitrypsin activity, it is a relatively poor inhibitor of 
trypsin. Alpha^antiprotease possesses inhibitory activity against a 
number of proteases including chymotrypsin, kallikrein, renin, 
urokinase, plasmin and possibly thrombin but of greatest clinical 
importance appears to be the inhibition of neutrophil elastase and
oco
collagenase . Complex formation with proteases leads to carplete 
inactivation of their proteolytic and esterolytic activities'^. 
Proteases are bound with a molar ratio of 1 : 1^~^.
Being a relatively small molecule it is able to pass freely 
from capillaries into tissue fluid, sane 60% being located in the 
extravascular compartment. It is thought to act as a "carrier 
protein", transporting proteases fran the extravascular to the 
intravascular compartment where the protease may be passed to 
alpha2 macroglobulin prior to its clearance from the circulation . 
This interchange of proteases has been demonstrated by the infusion 
of alpha-^antiprotease-trypsin complexes, which in the presence of 
alpha2 macroglobulin, dissociate with transfer of the protease to
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alpha^ac r og lobu 1 i n2 ^ ' 2*^.
Complexes of alpha^ ant iprotease and trypsin in the circulation 
have a half life of about 3.5 hours and therefore persist much longer 
in the circulation than alpha2 itiacroglobulin-trypsin c o m p l e x e s 2 ^ .  By 
this "carrier" mechanism proteases may be transported more rapidly 
from the tissues and extravascular compartment to the 
reticulo-endothelial system for degradation .
Alpha^ ant ichymotryps in
Alpha-^antichymotrypsin also acts as an acute phase reactant,
exhibiting a very rapid increase in response to injury, similar to
9f)7that seen for C-reactive protein . The affinity of 
alpha^antichymotrypsin for chymotrypsin is not strong enough to 
compete favourably in vivo with alpha^antiprotease, which is present 
in much higher concentrations2^  and it contributes little to the 
total antiprotease capacity.
Inter-alpha-trypsin inhibitor
The concentration of inter-alpha-trypsin inhibitor in serum is 
low and it contributes only about 3% of the trypsin inhibitory 
capacity of serum2^ . Furthermore, the complexes formed with 
proteases are loose and in vivo it probably does not act as a 
physiological inhibitor2^2.
Pancreatic secretory trypsin inhibitor
PSTI is a trypsin-specific inhibitor produced in the pancreatic
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acinar cells and present in the pancreatic exocrine secretion.
Small amounts are normally detectable in serum (<10ug/l) although
oo
much higher levels have been recorded in acute pancreatitis .
Available evidence suggests that PSTI acts purely as a local
inhibitor in the pancreatic juice as, in the presence of the serum
antiproteases alph^macroglobulin and alpha^antiprotease, its ccmplex
99with trypsin is limiediately broken .
Serum antiproteases in acute pancreatitis
Alterations in the levels of the antiproteases have been 
demonstrated in the sera of patients with acute pancreatitis. Levels 
of alpha2 macroglobulin fall during the course of an attack,
1 or) O Q 4  O O Q
particularly during severe attacks presumably reflecting
its consumption as its synthesis does not increase in response to 
illness. In one study the lowest levels in severe attacks occurred 5 
days after admission"^ but could remain low for 14 days"^. Levels 
of inter-alpha-trypsin inhibitor were usually low early in the attack 
returning towards normal in severe attacks after 4 days^^.
Alpha-j^antiprotease and alpha-^antichymotrypsin levels rose in acute 
pancreatitis and were considered to provide useful discrimination 
between mild and severe attacks^^'^^'^^.
Immunoassays provide no information on the amount of free, 
unccmplexed antiprotease available for binding. A functional assay 
can be performed to investigate the overall capacity of serum to bind 
a protease, usually trypsin. The trypsin binding assay was first 
studied in patients in 1972 and while levels of alpt^macroglobulin
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were slightly lower in acute pancreatitis, there was a marked
reduction in the ability of their sera to bind trypsin compared to 
£
controls . This was attributed to the presence of an enzyme bound to 
alpha2 macrogloblin but both trypsin and chymotrypsin were ruled out^.
More recently the serum trypsin binding capacity has been shown 
to increase during the illness, more than doubling within 2 days of 
admission . Alpha-^ ant iprotease accounts for around 90% of the serum 
trypsin inhibitory capacity and as its levels rise, due to the acute 
phase response, this appears a more plausible explanation. Others 
have shown that, in addition to the fall in the alpt^macroglobulin 
levels in acute pancreatitis, the remaining alpl^macroglobulin has a 
reduced trypsin binding capacity indicating the presence of 
alph^macroglobulin-protease complexes^Thus the net effect is a 
fall in the available alpt^macroglobulin and an increase in 
alpha^ant iprotease available for protease binding.
Free proteolytic activity has never been demonstrated in the 
serum of patients with acute pancreatitis but amidase and esterase 
activity has been found, presumably due to alpt^macroglobulin bound 
protease^-*-''^''^. The esterase in Worthington and Cuschieri's 
study was not identified definitively but kallikreins and trypsin 
were considered likely^^ # Active trypsin has been demonstrated 
canplexed to alpt^macroglobulin^ • and immunoreactive trypsin in 
complex with alpha^ ant iprotease^'43,49 ^
The residual proteolytic activity attributed to circulating 
alpha2macroglobulin-protease complexes may by degrading peptide 
hormones produce hypocalcaemia^'-^ or shock‘d ,  may activate other
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302zymogens or the coagulation cascade and may have an
O')
immunosuppressive effect , although their rapid clearance from the 
c i r c u l a t i o n ^ ^ w o u l d  tend to exclude their playing a major role.
Toxicity of the peritoneal fluid
Experimental pancreatitis and severe acute pancreatitis in man 
are both associated with early formation of a peritoneal exudate. 
This comprises an enzyme and protein-rich fluid, much of which is 
presumably exuded from the pancreas. The fluid is typically 
"haemorrhagic" or dark coloured due to the presence of the pigment
■j
methaemalbumin . The exudate has been shewn to possess toxic
properties, at least in experimental pancreatitis, which are
summarised in Table 5.
The balance between the release of activated proteolytic
enzymes from the pancreas and the adequacy of the peritoneal
antiprotease defences has been considered a central factor in this
toxicity, saturation of the peritoneal antiproteases being closely
associated with the onset of shock in canine experimental
pancreatitis. Following the induction of pancreatitis in dogs using
the closed duodenal loop model, large amounts of trypsinogen were
demonstrated first in the exudate and later in lymph and plasma.
Alpha^acroglobulin complexes with trypsin-like activity appeared
early in the exudate and later trypsin-alpha^antiprotease 
2 fi1 2 fi2complexes ' . The proteases were preferentially bound by the
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TABLE 5.
Toxicity of peritoneal fluid: experimental 
evidence.
Effect
Route of 
administration
Suspected 
toxic factor Reference
Hypotension
Haemo-
concentrat ion
IV to dogs 
(0.03ml)
IV to dogs 
(50ml)
IP to rats
IV to pigs
Intradermally
Increased 
vascular 
permeability to puppies
IP to rats
IP to rats
Reduced cell Liver cell 
respiration culture
Toxicity/death IP to mice
IP to mice
IP to mice
Histamine releasing Amundsen et al. 
(large molecule) 1968
Kinin forming 
? kallikrein
Satake et al. 
1973
Histamine releasing Lankisch et al.
1979
Histamine releasing Traverso et al.
1983
Pancreatic enzymes
Small molecule 
<1000 daltons
?
?
PGE,
Takada et al. 
1976
Ellison et al.
1981
Cooperman
1982
Pappas et al. 
1982
Frey et al. 
1982
Satake et al. 
1985
Farias et al. 
1985
alpha2 macroglobulin. During the course of the pancreatitis the 
binding capacity of the alph^macroglobulin was steadily reduced and 
when exhausted all the trypsinogen in the exudate was rapidly 
activated and canplexed by the remaining alpha^antiprotease. On 
saturation of alpt^macroglobulin the animals developed irreversible 
shock from which they ultimately died"^'^^.
Overwhelming of the antiprotease defences occurred relatively 
late in this slowly evolving model of pancreatitis, whereas, in the 
pancreatitis induced by retrograde injection of bile there was a 
rapid release of active pancreatic enzymes (trypsin, chymotrypsin and 
elastase) and early saturation of both alph^macroglobulin and 
alpha^antiprotease with the appearance of free proteolytic activity 
in the peritoneal exudate . This was associated with an early, 
dramatic fall in the blood pressure which recovered again to normal
pzro
levels, before falling once more, just prior to death . The 
protease-antiprotease complexes appeared in the exudate and in lymph 
but could not be detected in venous blood indicating a short 
half-life in the circulation. Local release of vasoactive peptides 
such as bradykinin and histamine in the peritoneal cavity was 
considered a possible explanation for the hypotension.
High degrees of alph^macroglobulin saturation (averaging 65%)
have also been demonstrated in the peritoneal exudate fron patients
with severe acute pancreatitis suggesting that this mechanism might
1 7also be important in man . Complete saturation of peritoneal 
alpha2 macroglobulin has been found although the alpha^ ant iprotease 
saturation did not exceed 25%^. Details, however, of the patients'
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clinical state and, in particular, whether they were shocked was not
on
provided .
Possible mechanisms of toxicity
Proteases complexed to alpha2 inacroglobulin retain esterolytic 
activity and also proteolytic activity against lew molecular weight 
substrates, although the importance of this to the toxicity of the 
peritoneal exudate is not clear. Alternatively, as saturation of 
alpha2 macroglobulin and the other antiproteases has a close temporal 
relationship with the onset of shock, it may be the occurrence of 
uncontrolled proteolysis within the peritoneal cavity which is 
important.
Overwhelming of the antiprotease defences both in vitro and in
pancreatitis exudate has been shown to be associated with complement
1 q of) 909
breakdown and kinin release the products or breakdown
products of which may be absorbed across the peritoneum into the
circulation contributing to the systemic toxicity. Kinins such as
bradykinin cause vasodilatation, increased capillary permeability,
invasion of leukocytes and pain. C3a and C5a are biologically active
fragments which may result from cleavage of complement factors by
trypsin. They are leukotactic, can cause histamine release from mast
cells, contract smooth muscle and increase capillary permeability.
Alternatively, both phospholipase A 2  and chymotrypsin, activated by
302trypsin or possibly by trypsin-alph^macroglobulm complexes , 
could cause histamine release from mast cells and thus explain the 
histamine releasing factor in the pancreatitis exudate10,198.
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Mayer and co-workers have demonstrated in dogs that although 
the bulk of the enzymes released in pancreatitis pool within the 
peritoneal cavity, absorption from the exudate does not appear to 
contribute to the serum enzyme levels . If peritoneal exudate does
contribute to the systemic toxicity, it would need to be by small 
molecular weight intermediates such as kinins, complement breakdown 
products, histamine or other vasoactive peptides.
Others believe transperitoneal absorption to be important'^. 
Proteases absorbed into the circulation would be quickly ccmplexed 
and cleared by the antiproteases but phospholipase A 2 , for which 
there are no natural inhibitors, might mediate toxicity directly.
Several workers have commented that the exudate is more toxic 
the earlier it is s a m p l e d ^ P r o t e a s e s  within the exudate 
undoubtably derive frcm the pancreas itself but the source of the 
antiprotease molecules is unknown. They may, in part, derive from the 
pancreas but may also pass across the peritoneum in response to the 
peritonitis induced by the irritant pancreatic exudate. It is 
possible, therefore, that early in the attack there is a relative 
excess of proteases over antiproteases which may explain why the 
"early" exudate is more toxic.
Therefore, there does appear to be evidence of toxicity 
associated with pancreatic exudate, at least in experimental 
pancreatitis, which may contribute to the early "shock-like" state. 
The exact mechanism of the toxicity is not clear, nor is the nature 
of the toxic substance(s) which may be of high molecular 
weight104,259 or molecular weight1 and which may be heat
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resistant68 or heat labile259. Nevertheless this has fuelled interest 
in peritoneal lavage as a therapy for acute pancreatitis, both in 
esqperimental pancreatitis and in man, and has provided the rationale 
for this thesis.
Prediction of severity
The pancreas is an inaccessible organ and diseases of the 
pancreas have, in the past, frequently been difficult to diagnose and 
stage the severity or extent of. Newer imaging techniques such as 
contrast-enhanced computed tonography have overcome sane of these 
problems, providing both visualisation of the gland's morphology and 
an assessment of the viability of the pancreatic parenchyma. Such 
investigations are expensive and often reserved for those patients 
who are objectively identified as having a severe attack of 
pancreatitis or who are slow to settle.
Clinical factors
The most basic method of judging severity is clinical 
assessment by an experienced clinician. On admission clinical 
assessment, while having a 100% accuracy in predicting mild attacks, 
correctly predicted only 39% of severe attacks226. After 24 hours the 
accuracy had inproved, 73% of the severe attacks being correctly 
predicted and rising to 83% after 48 hours226. Therefore, clinical 
assessment alone early in the course of the attack often fails to 
identify those patients who will develop a severe, complicated 
illness and although the accuracy improves the longer the patient
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remains in hospital, it remains a subjective assessment.
Other clinical factors which have been suggested as useful 
indicators of severity include the presence of s h o c k *165,322^ 
pyrexia-^' ,  increased respiratory rate-^'3^, dyspnoea^, 
respiratory distress'*^, tetany'^, abdominal mass-^'-^''^, 
ascites^7 ileus^“* and body wall staining*^7
Laboratory factors
Acute pancreatitis is a uniquely biochemical disease and since 
the first report of an association between hypocalcaemia and 
pancreatic necrosis^ there has been much interest in the use of 
laboratory parameters as predictors of outcome.
Amylase
The magnitude of the amylase elevation has been found to bear 
no relationship to the subsequent clinical course^7 7 7
whereas others have found it to be inversely related to the severity
c *300
of the attack 7 . Persistent elevation of the serum amylase may be
an indication of pseudocyst formation^^.
Calcium
The prognostic significance of low serum calcium levels in 
acute pancreatitis have been confirmed by several
groups'^^7^ ^ 7^ ^ 7^ ^ 7^ ^ 7' ^ 7^'*. The mechanism of the hypocalcaemia
has been attributed to the binding of calcium in areas of fat 
• 77Qnecrosis 7 • . Others have suggested the hypocalcaemia may be due to
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increased serum glucagon levels in acute pancreatitis^"^, parathyroid 
insufficiency^'^^'*^*^ or to a failure of bone to respond to 
parathyroid hormone, perhaps because of shock and reduced tissue 
perfusion . Parathyroid hormone degradation leading to loss of 
biological activity may occur in acute pancreatitis due to 
circulating alpha2macroglobulin-protease complexes, proteolysis of 
parathyroid hormone by sera from patients with acute pancreatitis 
having been demonstrated in vitro^'*^.
Much of the apparent hypocalcaemia associated with acute 
pancreatitis is due to hypoalbuminaemia which reduces the measured 
calcium by reducing the protein bound fraction. When the serum values 
are corrected for this only about 11% of all the results will show
1 CTO
"true" hypocalcaemia of varying degree °.
Other factors
Other factors which have been suggested as indicators of a
severe attack include h a e m o c o n c e n t r a t i o n - ^ 4 ,  a  ^  or falling 
h a e m a t o c r i t ^ ^ ' 305/355^ leukocytosis*^''^, hyperglycaemia^^,
methaemalbumin^'^^'*^'^^'*^, fibrinogen*^, complement
C O  Ilf) 1 Q Q  . C O  O O O
factors^ ' ' * , serum antiproteases ' , C-reactive
protein*^deoxyribonuclease 1*^, ribonuclease*^^'*^, cyclic
O O O  £1
AMPJ and the absolute lymphocyte count .
Multiple factor prediction of severity
In 1974 Ranson and co-workers reported a study of 43 objective 
clinical, biochemical and haematological criteria in 100 attacks of
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• 2 Q0pancreatitis . Thirteen factors were shewn to be of significant 
prognostic value from which 11 were finally selected'^. For patients 
with fewer than 3 signs positive the risk of death or major 
complication was small at 2.5% and 11% respectively^^. By contrast 
if 3 or more signs were positive, as they were in 21 patients, 62% 
died and an additional 33% were seriously ill^O. These findings have 
been confirmed in subsequent prospective a n a l y s e s ' ^ V a r i o u s  
modifications of the Ranson multiple factor scoring system have been 
described, one being that described by Imrie and co-workers^-.
Modifications have subsequently been made to improve prognostic 
accuracy in patients with gallstone-associated p a n c r e a t i t i s e s / 2 8 6  
bit their usefulness may be limited by the fact that the aetiology of 
the attack is not always known early in the course of the illness. 
Multivariate linear discriminant and multiple regression analyses may 
also be used to increase precision and accuracy in the prognostic
poo
assessment ° but the complexity of such methods limits their use in
0 0 7
daily clinical practice .
Diagnostic peritoneal lavage
The presence of haemorrhagic peritoneal fluid in patients with
severe acute pancreatitis has been recognised for many years and
diagnostic paracentesis with examination of the fluid for colour and
1 70amylase activity was first suggested in 1950x/ . Prediction of the 
outcome of an attack of acute pancreatitis by paracentesis and 
peritoneal lavage has been described more recently from Leeds, the 
presence of. more than lOmls of free fluid or a dark haemorrhagic
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fluid indicating a severe attack22*’'2^.  Following the aspiration of
any free fluid one litre of warm saline was instilled into the
peritoneal cavity and, after turning the patient on each side to
circulate the fluid, a dark straw coloured or brown return fluid was
977also found to indicate a severe attack . Biochemical analysis of 
the return fluid for total protein, albumin and aspartate 
aminotransferase also provided good discrimination between mild and
007 077
severe attacks^ Diagnostic peritoneal lavage has the advantage
of speed but is invasive and associated with a small morbidity, due
most often to inadvertent visceral puncture. In a recent study which
reported on 253 catheter placements there were 2 episodes of visceral
70puncture, an incidence of 0.8% .
Diagnostic imaging
Both ultrasound and computed tonography are invaluable in the 
diagnosis of established pancreatic pseudocysts, abscess and 
necrosis. Both modalities have been studied early in the course of an 
attack to determine their value in identifying cases likely to have a 
complicated clinical course.
Ultrasound
McKay and co-workers found that the appearance of the pancreas 
on early ultrasound examination did not correlate significantly with 
objective assessment of severity by multiple factor scoring although 
patients subsequently developing pseudocysts all had early localised 
pancreatic swelling22 .^ Generalised swelling of the pancreas was
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frequently seen but appeared to be of no major clinical 
220importance . Furthermore in 22 patients (26%) the pancreas could 
not be visualised reducing the value of this technique, which is 
itself very observer dependent.
Computed tomography
Computed tonography appears to be a valuable tool for
predicting outcome in acute pancreatitis. Ranscn and co-workers have
graded the appearances of the pancreas on computed tomography by
analysing the extent of pancreatic and peripancreatic inflammation
and also on the presence and number of peripancreatic fluid 
294collections . The higher the grade the greater the risk of
pancreatic abscess ensuing. Similar results were obtained in another
study of 51 patients in which computed tonography was found to be
superior to ultrasound where, because of bowel gas or obesity, 55% of
25Rexaminations were inadequate .
Perhaps of more practical importance is the information
obtained at contrast-enhanced computed tomography. In this technique
after an initial scan a bolus of contrast material was injected
intravenously and the scan repeated again. Vvhen compared with the
initial scan the pancreas normally shews enhancement and this can be
measured, decreased or absent enhancement suggesting pancreatic
necrosis. This was recorded in 8 of 28 consecutive patients in one
study, all 8 patients having necrosis confirmed at subsequent 
176laparotomy .
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Other illness scoring systems
There has been increasing interest in defining and applying 
scoring systems to various disease states, most notably to trauma 
victims'^ and to septic surgical p a t i e n t s ^ A n  alternative 
approach has been described by Cullen and co-workers whereby the 
severity of an illness is assessed and monitored by the frequency 
with which certain treatments and/or procedures are performed for 
each patient - the therapeutic intervention scoring system^. Its 
value may be diminished by differences in nursing or medical practice 
between different centres and even within one centre at different 
times^^.
Knaus and co-workers in 1981 described a scoring system based
on measuring the degree of abnormality of numerous physiological
variables (acute physiology score) and coupled this with a grading
1 78reflecting the patient's previous health . This was kncwn as the
acute physiology and chronic health evaluation (APACHE)
classification system. The initial description was based on 34
physiological variables, each having a score attributed to it,
depending on the degree of abnormality from a defined normal range.
Higher APACHE scores were shown to be associated with an increased 
1 78mortality . Calculation of the APACHE score was, however, complex
710and prompted simplif ications by other groups . Knaus and colleagues
subsequently modified the APACHE scoring system using the 12 most
important and conmonly recorded laboratory and physiological
variables in addition to the age weighting and a shortened chronic
179health evaluation - the APACHE II scoring system . An increasing
75
score was found to correlate closely with the risk of subsequent
1 on
d e a t h .  They considered that the physiological data when studied 
over a period of time would distinguish patients who were responding
1 7 0
to therapy from those who were notx . If applicable to patients with 
acute pancreatitis, it may permit stratification of risk early in 
their illness, sequential monitoring during the course of their 
illness and an objective assessment of any response to therapy.
Treatment: general and specific therapies
The therapy of acute pancreatitis is largely empirical since 
the effectiveness of many aspects of its treatment has not been 
demonstrated by controlled clinical trial-^. The basic principles of 
therapy consist of relief of pain by analgesics and "putting the 
pancreas at rest" by allowing no oral intake. This may include 
nasogastric suction routinely or, more caimcnly, for persistent 
vcmiting, ileus or gastric distension. Fluids are provided 
intravenously and the patient monitored for hypoxia and adequacy of 
the urine output. These principles have evolved over the past 30 
years and there is sane evidence that they may have contributed to a 
reduction in deaths from acute renal failure and respiratory 
insufficiency, particularly amongst elderly patients-^.
Inhibition of exocrine secretion
Attempts to influence the outcane of pancreatitis by inhibiting 
pancreatic secretion are summarised in Table 6.
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Preservation of the microcirculation
Vascular factors appear to influence progression from 
oedematous to haemorrhagic p a n c r e a t i t i s ^ ! ' 132 # Treatment with 
heparin, fibrinolysin - a streptokinase preparation, sympathectomy or 
dextran 40 all prevented development of haemorrhagic pancreatitis in 
dogs and reduced mortalityl32,384^ In a double-blind study in
man, treatment with dextran 40 was associated with a trend towards 
improvement, but no significant differences with respect to mortality 
or major complication rate23.
Prostaglandins and anti-inflanmatory agents
The steroid hormone cortisone has been investigated in 
experimental pancreatitis, no benefit being found^. Steroids have 
been inplicated as a possible aetiological agent in acute 
pancreatitis and have no present role.
Increased levels of prostaglandins have been demonstrated in 
the exudate and in the pancreatic venous blood of dogs with
I OQ
experimental acute pancreatitis-^ . Indomethacin blocks prostaglandin 
production in vivo and prolongs mean survival in rats with
"I Q f,
experimental pancreatitis . In man indomethacin significantly 
reduced pain and the number of opiate injections required but too few
0 7
patients were studied to compare the outcome .
Others have shewn that prostaglandin PGE2  may be protective in 
diet-induced acute pancreatitis in mice, perhaps by a membrane 
stabilising effect^'231/336 ^ In a preliminary study in man, the
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treated group demonstrated less elevation of several cell 
membrane marker enzymes suggesting an effect on membrane
o of:
stability000. An assessment of this therapy on mortality and other 
clinically relevant endpoints is awaited.
Antibiotics
Ampicillin has been studied in controlled clinical trials in 
patients with mild and moderate pancreatitis, no improvement in 
outcome having been demonstrated^* 105,152#
Peritoneal lavage
Peritoneal lavage inproves survival in dogs with experimental
p a n c r e a t i t i s ^ - * P e r i t o n e a l  lavage was also found to prolong
survival and reduce lethality in rats with experimental 
• • 1Q7pancreatitis Lavage for 24 hours was less effective than lavage 
continued for 48 hours but hypothermic lavage was no more effective 
than normothermic lavage. Lavage commenced early, within 30 minutes 
of the induction of pancreatitis, was more effective than treatment 
starting 6  hours later-*-^.
Peritoneal lavage in man
Lavage of the peritoneal cavity in acute pancreatitis was first 
reported by Wall in 1965°°°. Lavage was associated with clinical 
iirprovement in all 3 patients, 2 of whcm eventually r e c o v e r e d ^ 8 . six 
further patients were reported the following year, the author 
considering that the mortality had been improved by therapy^. Five
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further patients were reported the following year, mast showing 
a dramatic improvement in their clinical condition following 
lavage^. Four further patients were reported in 1970 with only one 
death, peritoneal lavage in these patients being associated with 
gradual improvement in their clinical condition, correction of their 
fluid and electrolyte deficits especially of hypocalcaemia, and a 
fall in their serum methaemalbumin^^.
Following these anecdotal reports of successful treatment by 
peritoneal lavage and the evidence of clear benefit in experimental 
pancreatitis, two studies put the view more firmly that this was 
indeed an important advance. In the first study 24 patients with 
severe pancreatitis ( 6 having laparotomy) underwent peritoneal lavage 
and were compared with 79 control patients, 18 of whan had
O O Q
laparotomy . Lavage resulted in "immediate clinical improvement"
and no lavaged patients died within the first 1 0  days of their
illness. Of the non-lavaged patients 45% of the deaths occurred
within the first 1 0  days, usually frcm cardiovascular or respiratory 
289failure . Closer examination of the data reveals little difference 
in the mortality rates amongst those not having surgery, but 
peritoneal lavage appeared to eliminate early mortality amongst those 
having surgery. However, the two groups undergoing surgery were not 
comparable in that those patients subsequently undergoing peritoneal 
lavage only had an early diagnostic laparotomy with placement of 
dialysis catheters whereas the group who were not lavaged usually had 
more extensive surgery. Thus the early improvement in the mortality 
rate amongst the lavaged patients is perhaps not unexpected as the
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two groups were clearly not equivalent. Furthermore, despite 
the early improvement reported the overall mortality in the two 
groups of patients was identical, explained by the larger number of 
late peripancreatic abscesses amongst the lavaged group^^. Despite 
the apparent weakness of their data the authors stated that 
"peritoneal lavage is a highly effective adjunct to the treatment for 
early complications of severe acute pancreatitis and dramatically
ooq
reduces early mortality" .
The first attempt at a prospective, randomised, controlled 
trial of peritoneal lavage was reported in 1980^^. Of 70 patients 
with alcoholic pancreatitis judged to be severe on a simple scoring 
system, 36 were randomised to receive standard therapy and 34 to 
have, in addition, peritoneal lavage for 24 hours. Of the lavaged 
group 29 patients (85%) had improved within 24 hours whereas of the 
control group only 13 patients (36%) had inproved. Seventeen of the 
control group were then crossed over to receive treatment by 
peritoneal lavage, 14 of them showing subsequent improvement*^. A 
total of 14 patients died; of the 5 dying in the lavage group only 
one died of respiratory insufficiency compared with 6  of the 9 dying 
in the control group. Overall, of 51 patients treated by peritoneal 
lavage, either initially or secondarily, having failed on standard 
therapy, only 8  deaths occurred ccrrpared to 6  deaths amongst the 
remaining 19 patients treated by all other methods. The authors made 
a strong plea in support of peritoneal lavage stating that "the 
results appear to offer vigorous support for the use of peritoneal 
dialysis in.the management of severe, life threatening, acute
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alcoholic pancreatitis"-^. Because so many patients were removed 
from the control group at 24 hours the results are difficult to 
interpret and firm conclusions regarding the efficacy of peritoneal 
lavage cannot be drawn from this data.
The first properly controlled, randomised study of peritoneal
lavage was reported from the UK in 1982; 23 patients were randomised
to receive either peritoneal lavage for 72 hours (9 ) or no lavage 
fn
(14) . Three deaths and 3 major complications occurred in the 9
patients receiving lavage compared to 7 deaths and 3 major 
complications amongst the control patients, no statistically 
significant difference being demonstrated^.
A large multicentre stud/ was subsequently undertaken in the UK 
based at Leeds, Bristol and Glasgow, the results of which were 
reported in 1985^^. Ninety-one patients with severe acute 
pancreatitis were selected from 428 attacks studied, 45 being 
randomised to receive peritoneal lavage and 46 standard therapy. The 
death rate in the lavaged patients was 27% compared with 28% for the 
control patients and the incidence of major complication was 38% and 
35% respectively. No difference was found in the timing of death, 6  
of the lavaged patients and 8  of the control patients dying early 
(within 7 days)^^.
A Swedish group studying a smaller number of patients in a 
randomised, controlled fashion reached similar conclusions, there 
being slightly more deaths (4) in the 19 lavaged patients compared to
1 CO
the c o n t r o l s .
Alcohol was the predominant aetiological factor found in the
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trials supporting lavage, accounting for 5 3 % 2 8 9  and 1 0 0 % 3 3 9  of cases 
compared with 26% in the recent British trial235. It is possible that 
such patients are more likely to respond to lavage but this is not 
supported by the Swedish stud/ where 56% were alcohol abusers353.
It has also been claimed that lavage may reduce abdominal pain 
and improve the patient's clinical condition, indeed this was the 
major claim made in the early anecdotal reports of success with this 
technique. The only group to attempt to evaluate this found no 
difference whether the patient was lavaged or not353.
Criticisms have been made of the UK multicentre study of 
peritoneal lavage, particularly with respect to the delayed 
institution of therapy and the failure to separate the different
0 7 0
aetiological sub-groups . Furthermore, 34 of the 46 patients 
randomised to standard therapy had a diagnostic peritoneal lavage 
prior to randomisation, to assess the severity of the attack228. 
Removing the peritoneal exudate, which in experimental studies is 
most toxic early in the attack, may alone have been therapeutic and 
have obscured any differences between the groups. The same criticisms 
apply to the recent Swedish study where both groups of patients had 
their exudate drained and a lavage with 500mls of saline353.
Although Stone and Fabian's study may be criticised because of
O O Q
the cross-over of control patients to the lavage group-*the early 
response of the lavage group to therapy was striking and suggests 
that in alcohol-associated pancreatitis, peritoneal lavage may be 
beneficial, at least in the short-term. Further studies in patients 
with severe acute pancreatitis comparing peritoneal lavage against a
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control group undergoing no peritoneal intervention appear to 
be justified and strenuous attempts should be made to ensure early 
randomisation and instigation of therapy.
Antiprotease therapy
Activation of the proteolytic enzymes, particularly trypsin, 
has been considered for many years to be central to the initiation of 
pancreatitis, autodigestion and the systemic manifestations of the 
disease. This concept of pancreatitis as a "enzymatic disease" has 
lead to the study of various anti-enzyme preparations directed 
particularly against trypsin.
Soybean trypsin inhibitor
Soybean trypsin inhibitor given to dogs with bile-induced 
pancreatitis appeared to counteract the shock and elevation in
•5(1Q
proteolytic activity observed in the controls although a larger
149study found no benefit .
Antifibrinolytic agents
Antifibrinolytic agents inhibit the action of plasmin and, in 
high concentration, also the action of trypsin. Neither 
epsilon-aminocaproic acid nor p-amincmethylbenzoic acid (PAME&)
I QO
reduced the mortality of experimental pancreatitis m  rats . No 
beneficial effect was found when epsilon-aminocaproic acid was
1 oo
studied in manJ-OJ.
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Aprotinin
A polypeptide inhibiting trypsin and kallikrein was discovered 
by Kraut and co-workers in bovine lymph nodes-^ and independently by 
Kunitz and Northrop in bovine pancreas^. This inhibitor, now known 
as aprotinin, was subsequently found in other bovine organs including 
lung and parotid gland and is prepared commercially from these 
sources by Bayer (Leverkusen, West Germany) and marketed as Trasylol. 
Aprotinin was introduced as a therapy for acute pancreatitis in the 
1950's ^^ and has been extensively studied since then.
One of the first reports of successful therapy with intravenous 
aprotinin reduced the mortality of pancreatitis in rats from 3 7 % in
1 n*7
controls, to 10% w/. Subsequent studies were conducted mainly in 
dogs. Aprotinin was found to be effective in reducing mortality in 
pancreatitis induced by the retrograde injection of bile/trypsin 
mixtures*^' , incubated blood and activated pancreatic
juice^^, and by bile alone-^. Larger doses were found to be more 
effective as was commencement of therapy immediately following 
induction of pancreatitis, rather than delaying for 4 h o u r s . No 
mortality was observed in another study when therapy was commenced 
within 6  hours of the induction of pancreatitis whereas delays of 9 
and 12 hours were associated with mortality rates of 25% and 75% 
respectively^ .
In contrast to the studies of aprotinin therapy in experimental 
animals, where in most cases an appropriate control group had been 
studied and appropriate end-points such as mortality or survival time 
had been reported, in many of the early studies in man the reports
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had been anecdotal, based on subjective assessments and/or the 
measurement of irrelevant parameters^' 145,219,250^
The earliest controlled trials found no benefit from therapy 
but had studied insufficient numbers (particularly of ill patients) 
to assess clinically important end-points such as mortality or major 
morbidity. Furthermore, many of these early trials utilised doses of 
aprotinin which were later considered inappropriately low^''^^'^'^.
Interest in aprotinin was rekindled with the publication in 
1974 of a controlled study in which aprotinin therapy was found to 
have reduced the mortality rate from 25% in the placebo treated group 
to 7.5% in the treated group . The initial dose of aprotinin used 
in this study was 200,000KIU on diagnosis followed by 200,000KIU 6  
hourly for 5 days. Particular value was demonstrated for aprotinin
treatment in the elderly in whom therapy abolished the usual trend
159for mortality to rise with increasing age . Criticisms have been
raised, particularly with respect to the reported mortality of 25% in
the control group, this being much higher than the mortality rate of
around 10% prevalent in other UK centres at that time^~^. Two further
large scale controlled studies were initiated using a similar dosage
159 245regime, each finding no benefit m  terms of mortality ' ,  or m
94 fithe rate of recovery or incidence of complications . This regime
also failed to prevent activation of the kallikrein-kinin system
112castircj doubt on its efficacy m  vivo . Even very large doses of 
aprotinin (4,000,000KIU over 4 hours immediately after diagnosis) 
failed to show any beneficial effect (Imrie CW, personal 
comnunication).
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Intravenous antiprotease therapy with aprotinin has no 
clinically useful effect in man, although apparently efficacious in 
canine pancreatitis. The possible reasons for this have become 
clearer and may include the timing of therapy in relation to the 
onset of the pancreatitis and that pancreatitis induced 
experimentally in animals is basically different from the human 
disease and in some way more amenable to antiprotease therapy. More 
recent evidence points to there also being important interspecies 
variation with respect to the inhibitory effect of aprotinin. In 
vitro work has shewn that while aprotinin at a concentration of 
3jLimol/l is protective against trypsin-induced kininogen consumption 
and complement breakdown in dogs, in humans a 2 0 -fold higher 
concentration was needed to achieve comparable results in serum and 
about 5-fold in plasma (the difference between serum and plasma was 
considered to be due to a potentiating effect of the heparin in
■ j o  O f ) " 5  0 P J 5
plasma) Therefore, pronounced species differences have
been confirmed and as the doses of aprotinin recommended in humans 
had been calculated from those successful in canine pancreatitis, the
ineffectiveness of aprotinin in human pancreatitis was perhaps not
• • 203surprising .
Intraperitoneal aprotinin therapy
Intraperitoneal administration has been studied in rats with 
taurocholate-induced pancreatitis. No difference was found in the 
mortality rate, nor in gross or microscopic pancreatic damage, 
despite increasing amounts of intraperitoneal aprotinin given in 3
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divided doses to a maximum of 1500KIU/100g body weight per day3 .^ The 
addition of aprotinin to peritoneal lavage fluid in another series of 
experiments in rats conferred no additional benefit when compared to 
lavage with a standard dialysate-^. Intraperitoneal administration 
of aprotinin to mice with diet-induced pancreatitis, at a dose of 
10,000KIU or 100,000KIU/kg, 8  hourly for 48 hours influenced neither 
the mortality nor the biochemical or morphological parameters 
studied230.
This therapeutic approach, at first glance, does not appear
particularly promising. Only one study in man has addressed this
question comparing 2  hourly cycles of peritoneal lavage with 2  litres
of a standard dialysate to a dialysate containing aprotinin
500,000KIU. No significant differences emerged with respect to
mortality or clinical outcome although the mortality and number of
complications were less in the aprotinin treated group, suggesting a
2 1trend in favour of this approach .
Other antiproteases
Bacterial protease inhibitors including leupeptin, pepstatin,
chymostatin and antipain are known to have a broad spectrum of
activity and in mice with diet-induced pancreatitis produced a
distinct attenuation of the severity of the pancreatitis^ . A
prolongation of survival was also shown in rats when treated with
168intravenous leupeptin, but not with aprotinin-1-00. These molecules,
being small oligopeptides, are able to enter and complete the
148inhibition of the protease-alpha2macroglobulin complex 0, but they
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are toxic and their efficacy has not been studied in man.
A large molecular weight trypsin inhibitor from human urine has 
also been isolated and has improved survival in dogs and rats with 
pancreatitis .
Administration of natural serum antiproteases in the form of 
fresh frozen plasma given intravenously, has been investigated in an 
uncontrolled study in man. A low mortality rate of 3.7% was reported 
but the lack of a control group and the classification of their 
patients by a previously unreported severity scoring system makes 
their results difficult to interpret^6.
Synthetic antiproteases
Gabexate mesilate (Foy) was the first to be studied in detail 
and the results have been reported mainly in the Japanese literature. 
A comparative trial of Foy and aprotinin in a large multicentre study 
found that an excellent or good clinical result occurred in 71% of 
the Foy treated group and in 44% of the aprotinin treated group2^. 
This trial, however, was not double blinded nor was there any 
standardisation of the dose of aprotinin given. Furthermore the 
assessmsnt of efficacy appeared highly subjective and too few 
patients with severe disease had been studied, the mortality amongst 
the entire group of 150 patients being only 4 (2.6%).
In vitro studies of the effectiveness of both Foy and aprotinin 
in preventing trypsin-induced kinin and complement activation in 
human and canine sera found that aprotinin but not Foy conferred 
protection266. In dogs infused with trypsin intravenously, aprotinin
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but not Foy was effective in preventing the development of 
shock^^.
A newer analogue of Foy, nafamostat mesilate was introduced in 
1977. It appears to be a much more potent inhibitor of pancreatic 
proteases than Foy and reduced the mortality of rat pancreatitis in a 
dose dependent manner-^. The results of a full scale study in man 
are awaited.
Inhibition of other pancreatic enzymes
The phospholipase A 2  inhibitor procaine hydrochloride was 
found to reduce the mortality in rats with experimental
. 7 . . .
pancreatitis . Another similar inhibitor xylocaine was found to 
improve the mortality in piglets when infused at the induction of 
pancreatitis but did not influence the degree of pancreatic 
damage^Uncontrolled studies have suggested that another 
phospholipase A 2  inhibitor calcium disodium edetate may have a 
beneficial effect in human acute p a n c r e a t i t i s * ^  reports of 
controlled clinical studies are awaited.
Aims of the current study
This thesis addresses 3 main issues. Firstly, the size of the 
problem presented by acute pancreatitis and the trends in incidence 
and mortality are examined, both nationally in Scotland, and within a 
single centre.
Secondly, means for more rapid and accurate prediction of 
outcome from an attack and for objectively monitoring the course of
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the attack are examined by sequentially measuring single 
laboratory factors including complement factors, antiproteases and 
C-reactive protein and by comparing clinical assessment, the multiple 
factor scoring systems and the APACHE II system.
The major portion of this thesis examines aspects of the
protease-antiprotease balance in peritoneal exudate, both in
experimental pancreatitis in the rat and in man. Peritoneal exudate
appears to be toxic in experimental pancreatitis, possibly as a
result of overwhelming of the antiprotease defences, and its removal
by peritoneal lavage has been uniformly successful. In contrast, the
role of the protease-antiprotease balance in peritoneal exudate in
man, and its relationship with the early "shock-like" illness which
may complicate severe acute pancreatitis, has not been clearly
defined. Although there are reports of successful peritoneal lavage
in man, properly controlled trials have shown no clear benefit in
terms of survival. Both recent studies suffered from flaws in
methodology which may explain the failure to demonstrate any
1 0
difference between the groups ' .
The adequacy of the peritoneal antiprotease defences are 
examined in an experimental pancreatitis model in the rat and also in 
human acute pancreatitis. A novel therapeutic approach is also 
described comprising removal of the exudate by aspiration and a 
single peritoneal lavage, followed by instillation of an antiprotease 
solution to the peritoneal cavity. The efficacy of this simple 
treatment is examined both in the rat model and in a controlled, 
clinical study in man using the antiprotease aprotinin.
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PART 2.
INCIDENCE AND MORTALITY
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CHAPTER 2. CHANGING PATTERNS OF INCIDENCE AND MORTALITY FROM ACUTE 
PANCREATITIS IN SCOTLAND, 1961-1985.
Introduction
Acute pancreatitis appears to be becaning increasingly cannon
but few studies have examined the changing incidence and mortality
trends. Studies from Bristol are the most comprehensive and over the
18 year period 1950-1967 demonstrated an increasing incidence over
the first 6  years of the study and a second peak of incidence between 
1571961 and 1964 . The earlier increase was attributed to wider
application of amylase testing and the later increase to a locally
heightened interest in the condition, thus both increases were
considered to be due to improvements in diagnosis rather than to an
157absolute change m  incidence .
The study of the Bristol population has recently been updated 
by another group using identical diagnostic criteria. They found that 
the incidence of acute pancreatitis had increased by 26% over the 
previous two decades but that throughout this 30 year period, the 
overall case mortality rate had remained unchanged at around 
2q%69,357.
The aims of the present study were to document the incidence 
and mortality frcm acute pancreatitis in Scotland and to examine any 
emerging trends.
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Methods
Data on the discharge diagnosis of all patients admitted to 
hospital in Scotland have been recorded since 1961 as the Scottish 
Hospital In-Patient Statistics. Details of the number of patients 
with a primary discharge diagnosis of acute pancreatitis (ICD Code 
577.0) have been obtained for each year between 1961 and 1985 (the 
last year for which complete figures were available) from the 
Scottish Health Service Common Services Agency (Information and 
Statistics Division, Edinburgh). The computer print-cut provided 
details of the total number of patients and the number in whcm a 
fatal outcome was recorded each year, with a breakdown of their age, 
sex and health board area. No information was available frcm this 
source on the diagnostic criteria used, cn the underlying aetiology 
or whether the attack was recurrent.
Details of the estimated population of Scotland for each year
9QQ
of the study have been obtained frcm published data .
Results
Overall population trends
Throughout the 25 year period studied the estimated population 
of Scotland remained fairly stable with a mean population of 
5,201,900 + 28,600 (Fig. 3). The population peaked at 5,240,800 
during the 5 year period 1971-1975 and has declined gradually but 
progressively since then, the lowest level of 5,136,500 having been 
recorded in 1985.
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FIGURE 3.
Estimated population of Scotland over 
successive 5 year periods, 1961-1985. 
(Registrar General Scotland. Annual 
Report, 1986).
Incidence and mortality trends
The annual number of discharges from acute pancreatitis 
recorded rose steadily in both sexes throughout the 1960s but the 
largest increase occurred during the 6  year period after 1971 (Fig. 
4). The increase in the numbers of discharges recorded has tended to 
plateau since 1977, particularly amongst females, the number of
discharges in males continuing to increase, albeit at a slower rate.
Since the mid 1970s the diagnosis of acute pancreatitis has been
recorded more frequently in males than in females.
Discharges from acute pancreatitis in males have increased 
almost 11 fold since 1961 fran 69 cases/year to 750 cases/year in 
1985. In wcmen the incidence has increased over 4 fold in the same 
period fron 112 cases/year to 484 cases/year in 1985 (Fig. 4).
The number of deaths recorded frcm acute pancreatitis has not 
shown a corresponding change, doubling in males frcm 15 cases/year in 
1961 to 30 cases/year in 1985 and increasing only slightly in wanen, 
frcm 29 cases/year to 37 cases/year in 1985 (Fig. 4). Taken in 
conjunction with the marked increase in the number of discharges 
recorded this has resulted in a dramatic fall in the overall case 
mortality rate in both sexes (Table 7).
A marked increase in the recorded number of discharges has been 
witnessed amongst adult males of all ages, particularly amongst young 
adult males between 20 and 39 years of age (Fig. 5). In females the 
major increase was observed amongst elderly wcmen over 60 years of 
age (Fig. 6 ), smaller increases being observed amongst young and 
middle-aged adult females.
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FIGURE 4.
Annual incidence and mortality from acute 
pancreatitis in Scotland by recorded 
discharge diagnosis, 1961-1985.
TABLE 7.
Case mortality rate from acute pancreatitis 
in Scotland, 1961-1985.
Males Females Total
Year Number Deaths Number Deaths Number Deaths
1961-65 543 94 (17.3%) 731 133 (18.2%) 1274 227 (17.8%)
1966-70 1009 109 (10.8%) 1156 155 (13.4%) 2165 264 (12.2%)
1971-75 1924 144 (7.5%) 1811 170 (9.4%) 3735 314 (8.4%)
1976-80 3265 155 (4.7%) 2431 189 (7.8%) 5696 344 (6%)
1981-85 3550 161 (4.5%) 2391 170 (7.1%) 5941 331 (5.6%)
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Annual incidence and mortality from acute 
pancreatitis in males analysed according to 
age group. (Excludes patients <2 0 years old)
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FIGURE 6.
Annual incidence and mortality from acute 
pancreatitis in females analysed according to 
age group. (Excludes patients <20 years old)
Regional variations
Examination of the number of discharges recorded in each health 
board area during successive 5 year periods reveals wide regional 
differences, the greatest increase (813%) occurring within Argyll and 
Clyde (Table 8 ). In contrast Dumfries and Galloway recorded only a 
243% increase in successive 5 year periods over the 25 years of the 
study against an average increase nationally of 471% (Table 8 ). The 
regional differences over successive 5 year periods are shown 
graphically in Figure 7. The largest increases in the number of 
discharges were recorded in the health boards of the "central belt" 
area of Scotland, the more remote areas of Highland, Borders and 
Dumfries and Galloway showing the smallest increases.
The mortality recorded in each of the 12 major health board 
regions is documented in Table 9. The overall case mortality rates 
recorded in each region ranged widely during the period 1961-1965, 
frcm 12% in Lothian to 31% recorded in Ayrshire and Arran, with a 
national average of 18%. In the most recent 5 year period the case 
mortality rates were more comparable, although remaining persistently 
higher within Ayrshire and Arran at 11%, against a national average 
of 5.5%.
Discussion
An apparent increase in the incidence of acute pancreatitis may 
be inferred by the increasing number of discharges recorded in the 
Scottish Hospitals In-patient Statistics. This increase in incidence
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TABLE 8.
Incidence and percentage increase of acute 
pancreatitis discharges recorded in the 12 
major health boards, 1961-1985.
Years
1961-65 1966-70 1971-75 1975-80 1981-85
Health Board No. No. (%) No. (%) No. (%) No. (%)
Argyll & Clyde 70 108 (154%) 236 (337%) 433 (618%) 569 (813%)
Forth Valley 37 113 (305%) 141 (381%) 230 (622%) 280 (757%)
Lanarkshire 87 122 (140%) 303 (348%) 443 (509%) 568 (653%)
Fife 73 142 (194%) 243 (333%) 436 (597%) 456 (625%)
Greater Glasgow 254 442 (174%) 876 (345%) 1429 (563%) 1480 (583%)
Tayside 117 223 (191%) 376 (321%) 482 (412%) 505 (432%)
Lothian 211 392 (186%) 528 (250%) 807 (382%) 806 (382%)
Ayrshire & Arran 68 93 (137%) 200 (294%) 274 (403%) 259 (381%)
Borders 40 34 (85%) 68 (170%) 62 (155%) 122 (305%)
Highland 56 71 (127%) 111 (198%) 157 (280%) 168 (300%)
Grampian 181 316 (175%) 453 (250%) 524 (290%) 508 (281%)
Dumfries & 
Galloway
42 54 (129%) 88 (209%) 117 (278%) 102 (243%)
Totals 1236 2110 (171%) 3623 (293%) 5394 (436%) 5823 (471%)
No. - number of patients.
(%) - % change in incidence compared with 1961-65 (100%).
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FIGURE 7.
Variation in incidence and mortality from acute 
pancreatitis by recorded discharge diagnosis in 
the 12 major health board regions of Scotland. 
The bars represent successive 5 year periods 
and are expressed as the percentage increase 
over the period 1961-5, the shaded areas 
denoting the fatal cases. The analysis excludes 
Orkney, Shetland and the Western Isles health 
boards as too few cases were recorded in each 
to permit meaningful analysis of the incidence 
and mortality trends.
TABLE 9.
Changing case mortality rates from acute 
pancreatitis recorded in the 12 major 
health boards, 1961-1985.
Years
1961-65 1966-70 1971-75 1976-80 1981-85
Health Board No.• (%) No.■ (%) No.. (%) No,. (%) No,. (%)
Borders 10 (25%) 8 (23.5%) 3 (4.5%) 7 (11%) 4 (3%)
Argyll & Clyde 17 (24%) 21 (19.5%) 20 (8.5%) 23 (5%) 23 (4%)
Fife 21 (29%) 17 (12%) 19 (8%) 21 (5%) 20 (4.5%)
Dumfries/Galloway 8 (19%) 6 (11%) 10 (11%) 8 (7%) 5 (5%)
Tayside 19 (16%) 25 (11%) 29 (8%) 29 (6%) 27 (5%)
Grampian 24 (13%) 41 (13%) 30 (6.5%) 36 (7% 24 (5%)
Lothian 25 (12%) 32 (8%) 38 (7%) 42 (5%) 38 (5%)
Lanarkshire 22 (25%) 20 (16.5%) 26 (8.5%) 28 (6%) 34 (6%)
Greater Glasgow 36 (14%) 54 (12%) 76 (9%) 85 (6%) 90 (6%)
Forth Valley 5 (13.5%) 4 (3.5%) 14 (10%) 13 (6%) 17 (6%)
Highland 11 (19.5%) 11 (15.5%) 14 (12.5%) 17 (11%) 12 (7%)
Ayrshire & Arran 21 (31%) 20 (21.5%) 26 (13%) 19 (7%) 29 (11%)
Totals 219 (18%) 259 (12%) 305 (8.5%) 328 (6%) 323 (5.5%)
No. = number of deaths recorded. 
(%) *= mortality rate.
has been observed in both sexes during the study and may be 
attributed to many different factors.
Improvements in the accuracy of diagnosis seem likely to 
account for the bulk of this increase. In the early years of the 
study the diagnosis of acute pancreatitis was often made with 
confidence only at laparotany or post mortem. Biochemical tests for 
amylase were, at that time, characteristically complicated, time 
consuming and infrequently utilised. It is interesting to note that 
the largest increase in the annual number of discharges occurred 
after 1971 coinciding with the introduction of the Phadebas Test 
(Pharmacia Diagnostics, Uppsala, Sweden), a simple, reproducible 
assay for amylase. Nowadays the serum amylase activity is measured on 
almost all patients presenting to hospital with upper abdominal pain 
and it is likely that this has led to the diagnosis being established 
in a greater proportion of the patients presenting with acute 
pancreatitis.
The increase in the numbers of discharges recorded with acute 
pancreatitis was clearly rising prior to 1971. Although acute 
pancreatitis has been recognised as a clinical entity since the late 
19th century, throughout the early and mid 20th century there had 
been little reference to the condition either in the standard 
surgical textbooks of the time or in learned journals . The 
increasing interest and awareness of the condition witnessed in the 
UK over the past 20 to 30 years appears to date frcm several 
important publications around that time, including those of 
Pollock279 and subsequently of Trapnell355. Both authors reviewed and
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analysed large series of patients highlighting aspects of 
clinical presentation, aetiology, complications and management. These 
and other publications of that time have stimulated numerous 
publications on all aspects of the disease and increasing awareness 
of the condition appears likely to have been an additional factor 
contributing to the increasing numbers diagnosed.
The Scottish Hospitals In-Patient Statistics are dependent upon 
the accuracy and quality of the data input supplied by doctors and 
clerical staff in many hospitals within the 15 health boards, each 
with differing facilities and procedures for recording and processing 
such data. Computerisation might be expected to improve data 
collection but one recent survey has highlighted deficiencies that 
may remain within this system. The incidence of acute pancreatitis in 
the Grampian region of Scotland was investigated for the years 
1983-1985 by examining the record of amylase examinations carried out 
in the single regional laboratory performing these assays. Only 53% 
of the total number of cases identified in the study had been 
recorded in the hospital's ccmputer linked diagnostic mdexJ . If 
representative of other health boards in Scotland, this may have 
profound implications for the accuracy of disease reporting 
nationally and the number of cases reported here may be 
underestimating the true incidence of the disease in the hospital 
population by up to 100%.
The incidence of acute pancreatitis continued to increase in 
males throughout the late 1970s and early 1980s, whereas in females 
the incidence appears to have levelled out. This differential effect
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would tend to be against an overall change in the diagnostic rate of
acute pancreatitis which might be expected to affect the incidence in
both sexes equally. It is clear that alcohol consumption and abuse is
increasing in our population, and in Scotland there appears to be a
greater persistence of youthful, heavy drinking into early middle 
0 9 7
age which may be contributing to the continuing increase in 
numbers of discharges from pancreatitis amongst males. Recurrent 
attacks requiring repeated admissions are more carmen in association 
with alcoholic pancreatitis and may also be contributing to this 
increasing incidence.
The regional differences in the increasing numbers of 
discharges recorded are more difficult to explain. Predominantly 
rural areas with less easily accessible in-patient hospital care may 
have a greater proportion of the patients with mild attacks treated 
at home (where the diagnosis may not be made and will not be 
recorded) than might be the case in urban areas. This might account 
for the lower increase in the numbers of discharges in Dumfries and 
Galloway, Grampian, Highland and Borders. Differences in life-style, 
particularly with respect to the frequency, extent and nature of 
alcohol abuse in the young, often socially deprived populations in 
the urban areas of the central belt of Scotland may also explain seme 
of these differences. Unfortunately the Scottish Hospital In-Patients 
Statistics do not classify the attacks according to aetiology which 
might aid this analysis.
Despite the marked increase in numbers of discharges from acute 
pancreatitis since 1961, the number of deaths recorded have changed
98
little throughout the 25 year period leading to a marked 
reduction in the overall case mortality rate. The mortality rate was 
consistently higher in females than in males throughout the period of 
the study. In both sexes the mortality occurs predominantly amongst 
patients in the over 60 year age group. In females this age group 
accounted for 56% of the discharges and 81% of the deaths. Discharges 
from acute pancreatitis in males were recorded more frequently 
amongst the younger age groups and were associated with a low 
mortality. The over 60 year age group accounted for only 32% of the 
attacks and 61% of the deaths and thus explains the lower overall 
case mortality rate observed in males.
While improved treatment of acute pancreatitis may have 
contributed to the falling case mortality rate, despite the marked 
increase in the apparent incidence of the condition, a more plausible 
explanation may be that the nature of the disease recorded has itself 
changed. If, as seems likely, more cases of pancreatitis have been 
diagnosed because of increased awareness and more widespread 
diagnostic testing leading to an increased diagnostic rate, it is 
probable that many more mild cases (which previously may have been 
overlooked) have been diagnosed. Patients with severe pancreatitis 
dying of their illness or developing a complication in the early part 
of the study are more likely to have been correctly diagnosed, many 
having cane to surgery or post mortem. Thus the net effect of 
diagnosing more mild cases who are less likely to die would be that 
the proportion of the total cases dying (case mortality rate) will 
fall, even if treatment has remained unchanged.
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The case mortality rates which varied widely between different 
health boards during the early years of the study have became more 
uniform, although remaining slightly higher within Highland and 
Ayrshire and Arran. The reasons for these differences are not 
apparent from this data, although Thompson has suggested that the 
higher diagnostic laparotomy rate may explain sane of the increased 
mortality within the Highland Health Board^O.
Subject to the possible drawbacks mentioned above regarding the 
overall accuracy of the figures, the national statistics presented 
here provide a broad overview of the disease and its apparently 
changing incidence in our society. A closer examination of these 
factors in a smaller, more carefully defined population must be 
undertaken to investigate in detail the patterns of the illness, mode 
of death and to determine whether changes in treatment may have 
influenced the mortality rate of the condition.
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CHAPTER 3. EXAMINATION OF DEATHS FROM ACUTE PANCREATITIS 
AT GLASGOW ROYAL INFIRMARY, 1974-1984.
Introduction
In a mainly retrospective review of acute pancreatitis frcm 
Glasgow Royal Infirmary over the decade to 1970, Imrie reported an
1 cc
overall case mortality rate of 21.4% . A recent review frcm Bristol
69of the decade to 1979 found a case mortality rate of 19.6% , a
367figure little changed from that of the preceding two decades . In 
contrast, in prospective therapeutic trials in Glasgow, mortality
from acute pancreatitis fell frcm 11.5% in 1971-2 to 8.7% m
159 . . .1974-7 . Prospective studies, however, give an incomplete picture
of the true incidence and mortality of acute pancreatitis by 
excluding patients who present atypically and those not diagnosed in 
life.
The past decade has seen many changes in the management of 
acute pancreatitis and its complications but it is unclear whether 
these have influenced the mode and timing of death or the overall 
mortality. A review of all deaths from acute pancreatitis at Glasgow 
Royal Infirmary between 1974 and 1984 has, therefore, been 
undertaken, during which time a series of prospective therapeutic 
trials were being conducted.
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Methods
Patients admitted to Glasgow Royal Infirmary with a diagnosis 
of acute pancreatitis have been documented prospectively since 1971. 
Between the 1st of January 1974 and the 31st of December 1984, 817 
such patients were documented, many of whan have been the subject of 
prospective therapeutic trials^'^^'-^/- ^ ,^5/269> A fatal outcome 
was recorded in 73 (9%) of these patients. Examination of the 
Hospital Activity Analysis (ICD Code 577.0) for these years revealed 
that a total of 975 patients with a recorded diagnosis of acute 
pancreatitis had been treated over this time, including 53 patients 
who who were first diagnosed at post mortem. The 73 deaths documented 
prospectively and the 53 patients first diagnosed at post mortem give 
a total of 126 deaths for an overall mortality rate of 12.9%. The 
diagnosis in these 126 patients was confirmed at post mortem in 99 
(79%), laparotany in 10 (8%) and in the remainder on a clinical 
presentation and course of illness consistent with the diagnosis of 
acute pancreatitis and a serum amylase above 1200IU/1 (normal range 
70-300IU/1).
Catchment population
The estimated catchment population of Glasgow Royal Infirmary 
was 243,763 in 1975, falling to 212,506 in 1978 with the opening of a 
new district general hospital adjacent to the eastern boundary in 
1977. The catchment population has continued to decline to 187,136 in 
1984, an overall fall of 23% since 1975 (Greater Glasgow Health 
Board, Information Services).
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Aetiology of acute pancreatitis
Gallstones were considered to be the underlying cause of acute
pancreatitis when they were recovered at post mortem or laparotcmy,
and in 2 patients on radiological evidence (intravenous
cholangiography - 1,. plain X-ray - 1). Alcohol was incriminated in
patients admitting to, or suspected of drinking an excessive 
157amount . Patients with other recognised causes of acute 
pancreatitis have been studied as a group (see below) as have those 
in whom no definite aetiological factor could be implicated. Table 10 
details the age and sex of the groups and the proportion first 
diagnosed at post mortem.
Pancreatic morphology
Pancreatic morphology was classified according to the 
description of the organ at laparotcmy or post mortem supplemented by 
histological data where available. Pancreatic pseudocyst and abscess 
were defined as a pancreatic or peripancreatic collection of fluid or 
pus respectively. Black pancreatic and peripancreatic tissue either 
apparent superficially or on sectioning of the gland was diagnosed as 
necrosis but included in this group were patients with extensive 
pan-lobular parenchymal destruction on microscopy. The remaining 
patients with less severe parenchymal destruction were labelled as 
having had acute haemorrhagic pancreatitis when haemorrhage was 
apparent on the surface, or on sectioning of the gland, and as having 
had acute interstitial pancreatitis when the pancreas was inflamed
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TABLE 10.
Aetiology of fatal attacks of acute 
pancreatitis in relation to patient age 
and sex and proportion of patients first 
diagnosed at post mortem.
Aetiology Number Male:Female
Mean age 
(yrs)
Proportion 
undiagnosed before 
post mortem (%)
Gallstones *39 (30%) 19:20 68 33%
Alcohol 20 (15%) 16:4 48 40%
Other causes 23 (17%) 12:11 62 74%
Unknnown causes 50 (38%) 21:29 66 42%
Totals *132 68:64 63 42%
* 6 patients with >1 aetiological factor.
with only fat necrosis and focal parenchymal necrosis on 
histology.
Analysis of deaths
Death was categorised as "pancreatic" when it appeared to have 
been a direct consequence of acute pancreatitis and this included 
seme patients in whan events such as myocardial infarction or 
pulmonary embolism complicated severe acute pancreatitis. Where death 
appeared to be a consequence of another unrelated medical condition 
(eg. liver failure or hypothermia) or where pre-existent medical 
disease was a major contributing factor to death (eg. ischaemic heart 
disease, carcinoma or chronic obstructive airways disease) such 
deaths were categorised as "medical". Early deaths were defined as 
those occurring within 7 days of admission and late deaths, as those 
occurring after this time.
Statistics
Statistical analysis was conducted by Fisher's exact test and 
by the Student's 't' test.
Results
The annual incidence and mortality of acute pancreatitis and 
the number of patients first diagnosed at post mortem are shown in 
Figure 8. Mortality is seen to decrease throughout the 11 year 
period. The overall mortality rate for the first half of the study 
(1st January 1974 to the 30th June 1979) was 14.9% compared with
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FIGURE 8.
Annual incidence and mortality of acute 
pancreatitis at Glasgow Royal Infirmary and 
numbers first diagnosed at post mortem.
10.8% for the latter half. The mortality rates for the 73 patients 
documented prospectively were 8.9% and 9% respectively and the fall 
in overall mortality is explained by a reduction in the number of 
patients who were first diagnosed at post mortem, 38 (72%) of whcm 
were recorded in the first half of the study.
Sixty-eight (93%) of the 73 patients documented prospectively 
were first diagnosed on clinical and biochemical grounds and the 
remainder at laparotcmy. Of the 53 patients first diagnosed at post 
mortem 36 (68%) had presented atypically with known or suspected 
medical conditions, 32 (60%) of than to physicians rather than 
surgeons. No particular clinical syndrome emerged as being most 
commonly associated with undiagnosed pancreatitis but rather these 
patients had widely varying presentations which suggested 
neurological disease in 6, respiratory disease in 6 and cardiac 
failure, liver failure and ketoacidosis each in 5 patients. In 10 
(19%) of these undiagnosed patients, pancreatitis was an unsuspected 
cause of postoperative deterioration (see below). Only 7 (13%) of 
these 53 patients had presented with abdominal pain and a serum 
anylase level had been measured in only 5 (9%) of them.
The majority of the patients dying frcm acute pancreatitis had 
presented directly to the medical and surgical units of this 
hospital, only seven patients (6%) being secondary referrals frcm 
other hospitals.
Gallstone pancreatitis
Thirty-nine patients (30%) had acute pancreatitis associated
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with the presence of gallstones. Six patients also had other 
potential aetiological factors, namely alcohol abuse (3), recent 
cardiopulmonary by-pass (1), biliary surgery (1) and hypothermia (1). 
Figure 9 shows the distribution of gallstones in the biliary tree and 
Table 11 the relationship between the distribution of gallstones and 
the pancreatic morphology found at laparotcmy or post mortem. Severe 
pancreatic destruction (abscess or necrosis) was present in 21 
patients (54%) and was found more commonly in the 23 patients (59%) 
with calculi in the extrahepatic ducts than in the remainder in whan 
calculi were confined to the gallbladder. Table 12 details the 21 
patients with severe pancreatic destruction, 16 (76%) of whan were 
diagnosed in life. Gallstones impacted at the ampulla of Vater were 
found in only two patients (both elderly females). Both died of 
septicaemia associated with severe cholangitis as did one other 
patient with gallstones throughout the biliary tree.
Nine patients (23%) had experienced previous attacks of acute 
pancreatitis. Seven presented in the early half of the study, three 
having been discharged only 6, 7 and 12 days prior to their final 
fatal attack. Two patients who had previously undergone 
cholecystectomy developed recurrent acute pancreatitis in association 
with persistent or recurrent calculi.
Alcohol-associated pancreatitis
Twenty patients had a history of chronic alcohol abuse. Three 
of these patients (mentioned above) had gallstones. Sixteen (80%) 
were male and patients with alcohol-associated acute pancreatitis
106
GALLBLADDER ONLY DUCTAL
FIGURE 9.
Distribution of gallstones in the biliary tree 
in the 39 patients with fatal gallstone 
pancreatitis.
TABLE 11.
Relationship between pancreatic morphology 
and the distribution of gallstones in the 
biliary tree in 39 patients with fatal 
gallstone pancreatitis.
Calculi in gall
Pancreatitis morphology Ductal calculi bladder only
(n = 23) (n = 16)
Interstitial pancreatitis 4 (17%) 4 (25%)
Haemorrhagic pancreatitis 2 (9%) 3 (19%)
Pancreatic necrosis 7 (30%) 3 (19%)
Pancreatic abscess 8 (35%) 3 (19%)
Pseudocyst 1 (4%) 2 (12%)
Unknown 1 (4%) 1 (6%)
No significant difference between groups (Fisher's exact test).
TABLE 12.
Incidence of abscess and necrosis within 
each aetiological group in patients first 
diagnosed in life and at post mortem.
Aetiology
Diagnosed
Necrosis
in life 
Abscess
Diagnosed
Necrosis
at post mortem 
Abscess Totals
Gallstones 7 (27%) 9 (35%) 3 (23%) 2 (15%) 21 (54%)
Alcohol 6 (50%) 2 (17%) 2 (25%) 1 (12.5%) 11 (55%)
Other 1 (17%) 0 8 (47%) 2 (12%) 11 (48%)
Unknown 4 (14%) 3 (10%) 6 (29%) 0 13 (26%)
were significantly younger than those with acute pancreatitis 
attributable to other causes (mean age 48 years vs 66 years, 
p <0.001). Eleven patients (55%) had severe pancreatic destruction 
(Table 12). Seven patients had alcoholic liver disease consisting of 
cirrhosis in 5 and acute alcoholic hepatitis in 2; four died in frank 
hepatic failure. Five patients (25%) had a history of previous - 
pancreatitis, three of whcm had required surgery (pseudocyst drainage 
- 2, abscess drainage - 1).
Other identified aetiological factors.
Twenty-three patients had other recognised aetiological factors 
implicated. Four patients had hypothermia, all of whan were elderly 
(mean age 90 years) and 3 of whom were female. One had gallstones and 
acute pancreatitis may have preceded the hypothermia. Eight patients 
developed acute pancreatitis following upper abdcminal surgery. Three 
had undergone gastrectomy (2 with splenectomy), 2 had undergone 
splenectomy and 3 had undergone biliary or pancreatic surgery. Three 
patients developed acute pancreatitis following cardiopulmonary 
by-pass and 2 following translumbar aortography. Only one of the 
patients with post-operative pancreatitis was diagnosed in life 
having been re-explored for suspected anastomotic leakage following 
gastrectomy.
Four patient had acute pancreatitis in association with 
pancreatic carcinoma (primary pancreatic - 3, metastatic from 
bronchus - 1). Two other patients developed acute pancreatitis 
associated with fulminant viral hepatitis and iatrogenic
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intravascular haemolysis respectively. Eleven patients 
(48%) had severe pancreatic destruction (Table 12) and only 3 
patients (those having undergone biliary or pancreatic surgery) had a 
history of previous attacks.
Unknown aetiology
The 50 patients (38%) in whan no definite aetiological factor 
could be implicated (despite laparotomy or post mortem in all but 13) 
comprise the largest single group. Possible aetiologies were thought 
to include ischaemia/hypotension in 6, septicaemia in 3 and steroid 
therapy in 2. Only 13 (26%) had severe pancreatic destruction (Table
12) and none had a history of previous attacks of acute pancreatitis.
Surgery
Surgery for complications was performed in 23 patients (18%) 
during their final illness, 10 requiring multiple operations (Table
13). Six of the seven patients having surgery for abscess had a post 
mortem examination and 5 were found to have a residual abscess and/or 
necrosis. Thirteen patients having surgery had gallstones. In six of 
these patients gallstones were not eradicated at surgery. In 4 
patients gallstones were not identified at surgery, despite multiple 
operations in two of these patients. Only one of these patients had 
been treated during the latter half of the study.
Analysis of deaths
Early "pancreatic" deaths were often associated with fulminant
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acute pancreatitis. Such deaths were most carmonly seen in 
older patients with no identifiable aetiological factors but were 
also common in younger patients in whan alcohol was implicated 
(Figure 10). Late "pancreatic" deaths, usually due to abscess and/or 
necrosis with sepsis and multi-organ failure, were most cannon in 
patients with a gallstone aetiology. Early and late "medical" deaths 
were most often seen in patients with acute pancreatitis due to other 
identified aetiological factors. Significant underlying medical 
disease was present in 71% and 86% of the early and late "medical" 
deaths compared with 46% and 42% of the early and late "pancreatic" 
deaths respectively.
Overall 56% of the deaths were considered directly attributable 
to acute pancreatitis and 32% to "medical" causes. Of the 73 patients 
diagnosed in life, 60% died of "pancreatic" causes and 16% of 
"medical" causes canpared with 49% and 51% respectively of those 
first diagnosed at post-mortem (Table 14). In 17 patients (23%) 
diagnosed in life there were no laparotcmy or post mortem data. Nine 
of these 17 patients (53%) died within the first 7 days predaninantly 
of cardiopulmonary problems, 5 of whcm had underlying cardiovascular 
or respiratory disease. Of the 8 patients dying after 7 days, 5 
succumbed frcm renal failure, 3 of these on a background of 
pre-existing chronic renal failure.
Sixty-two patients (49%) died within the first 7 days of their 
illness comprising 57% of the patients first diagnosed at post mortem 
and 44% of those first diagnosed in life. The pancreatic morphology 
and the time to death in the 2 groups is shown in Table 15. Patients
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FIGURE 10.
Analysis of cause and timing of death within 
each aetiological group. P = pancreatic,
M = medical, ND = no post mortem or laparotomy 
data (see text).
TABLE 14.
Analysis of the cause of death in patients 
diagnosed in life and at post mortem.
Not diagnosed
Diagnosed in life until post mortem
Time to 
death
(days) Pancreatic Medical No data
Time to
death
(days) Pancreatic Medical
Aetiology :
Gallstone 16(1-129) 20(77%) 4(15%) 2(5%) 6(1-28) 7(54%) 6(46%)
Alcohol 5(1-129) 9(75%) 2(17%) 1(8%) 6(1-34) 3(37%) 5(63%)
Other 11(5-136) 2(33%) 3(50%) 1(17%) 12(1-37) 9(53%) 8 (47%)
Unknown 7(2-56) 13 (45%) 3(10%) 13(45%) 5(1-48) 10(48%) 11(52%)
Totals 44(60%) 12(16%) 17(23%) 29(49%) 30(51%)
Time to death =* median (range) .
Includes 6 patients with > 1 aetiological factor.
TABLE 15.
Comparison of the time to death and the 
pancreatic morphology in patients diagnosed 
in life and at post mortem.
Pancreatitis
morphology
Diagnosed 
in life
Time to
death
(days)
Not diagnosed 
until post 
mortem
Time to
death
(days) Total
Interstitial 9 (12%) 4(1-138) 13 (25%) 6(1-33) 22 (17%)
Haemorrhagic 10 (14%) 5(2-26) 20 (38%) 7(1-48) 30 (24%)
Necrosis 17 (23%) 5(1-58) 15 (29%) 4(1-37) 32 (25%)
Abscess 13 (18%) 31(8-129) 5 (9%) 10(2-17) 18 (14%)
Pseudocyst 7 (10%) 40(33-140) - - 7 (6%)
Unknown 17 (23%) 6(2-71) - - 17 (13%)
Totals 73 53 126
Time to death = median (range).
first diagnosed at post mortem tended to have less severe 
degrees of pancreatic parenchymal destruction. Abscesses and 
pseudocysts typically occur later in the course of the illness and 
patients developing these complications survived longer. No 
relationship was found between the severity of pancreatic damage and 
time to death.
Examination of the mode and timing of death in the first and 
second periods of the study revealed that the proportion of late 
"medical" deaths had fallen from 30% to 12% (p <0.05) reflecting the 
reduction in numbers of patients first diagnosed at post mortem. The 
proportion of early "pancreatic" deaths rose slightly during the 
second period of the study from 12.5% to 19% and the patients tended 
to be older (mean age 65 + 17 years vs 62 + 14 years), although 
neither difference was significant.
Discussion
Throughout the eleven year period reviewed the numbers of 
patients treated for acute pancreatitis each year has remained 
relatively constant. Given the 23% reduction in the hospital district 
catchment population that has occurred over this time, the local 
incidence of acute pancreatitis has probably risen and this would be 
in agreement with reports from elsewhere in the uk69/78,357. Whether 
this reflects a real increase in the local incidence of acute 
pancreatitis or whether more patients are being diagnosed because of 
increased investigative zeal is unknown. Interest in acute 
pancreatitis at this hospital predated the period of this current
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study by several years, these patients having been actively
sought and documented prospectively since 1971^*^. A real increase in
the local incidence is therefore thought the more likely explanation.
Overall mortality has fallen reflecting a reduction in the 
numbers of patients first diagnosed at post mortem and this may be 
partly explained by a conccmitant drcp in the hospital's post mortem 
rate. The proportion of pancreatitis deaths that were undiagnosed 
before post mortem fell from 51% in the first part of the study to 
29%, a fall of 43%. During these periods the hospital's post mortem 
rate has fallen frcm 29% of all deaths in the first part of the study 
to 20% of all deaths latterly, a fall of 31%. Our incidence figures 
and mortality rates obviously fail to take account of all patients 
with acute pancreatitis who are undiagnosed in life. Although 
presumably only a proportion of such patients die, improvements in 
diagnosis leading to increased numbers being diagnosed in life might 
also contribute to a reduction in the numbers of patients first 
diagnosed at post mortem.
It is disappointing that the mortality of patients diagnosed in
life and documented prospectively has remained unchanged at around
9%. Deaths frcm gallstone pancreatitis in patients studied
prospectively have, however, fallen by 47% frcm 17 in the first half
of the study to 9. This is partly due to a reduction in the number of
fatal recurrent attacks (7 vs cnly 2 in the latter half of the study)
and particularly to the abolition of early fatal recurrence.
Elimination of these deaths argues in favour of the policy of early
969cholecystectomy for gallstone pancreatitis which we^o:7 and others
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have favoured172,209'354, rather than readmitting these patients for 
surgery 6 to 12 weeks after their original attack.
The fall in the number of deaths attributed to gallstone 
pancreatitis may also be due to the more successful eradication of 
gallstones at operation in the latter half of the study. The aim of 
surgery for gallstone pancreatitis is clearance of all calculi frcm 
the biliary tree. In the early years of the study this aim was 
clearly not achieved. Failure to eradicate gallstones was due to 
cholecystostcmy being performed without operative cholangiography in 
one case and to a choledochoduodenostcmy being performed in another 
after failure of supraduodenal exploration. In four other patients 
gallstones were not identified at operation (abscess drainage - 2, 
pseudocyst drainage - 1 and laparotomy for haemorrhage - 1). 
Gallstones giving rise to acute pancreatitis are often small, can be 
difficult to diagnose by standard imaging techniques and as shown 
here, may be overlooked at laparotarty.
Finally, the fall in the number of deaths associated with 
gallstone pancreatitis may also reflect a decrease in the incidence 
of this diagnosis in our practice, for reasons which are not clear.
In the early years of this study gallstores accounted for 52% of 
first attacks of primary acute pancreatitis . Since 1979 gallstones 
have been incriminated in only 41% of first attacks whereas the 
incidence of attacks of unknown aetiology has increased frcm 13% to 
22%159.
The continued presence of calculi in the extrahepatic ducts 
appears to be associated with more severe pancreatic destruction
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(abscess or necrosis) than when gallstones were confined to the 
gallbladder at the time of laparotomy or post mortem. It is 
conceivable that earlier clearance of these calculi by operation or 
endosccpic sphincterotomy would have favourably altered the outcome 
in seme of these patients. Immediate operation to clear obstructing 
gallstones frcm the ampulla and biliary tree before irreversible 
pancreatic necrosis develops has been proposed by Acosta and
o
co-workers .
This approach, although supported by Stone's groups has not
gained favour and an increased mortality has been reported in
i no 4association with immediate operation , J . The advanced age of the
patients subsequently dying of gallstone pancreatitis (mean age 68
years) also militates against a policy of immediate surgery, although
it may be tolerated by younger patients. Endosccpic sphincterotomy
808 812appears to be a safe alternative in this situation ' and may 
258well be beneficial although its application in fulminant cases
awaits full evaluation.
Five (25%) of the patients with alcohol-associated acute
pancreatitis had liver cirrhosis, a similar incidence to a large
American series where alcohol was a much cautioner cause of acute
801pancreatitis, accounting for 68% of patients overall . Although the 
incidence of alcohol-associated acute pancreatitis increased frcm 12% 
in the period between 1960 and 1970^'* to 26% between 1971 and 
1972-^, since 1974 the incidence has remained at around 32% of 
attacks^ and currently stands at 34%. The number of deaths overall 
frcm alcohol-associated acute pancreatitis has fallen between the
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first and second periods of the study, although when only those 
patients diagnosed in life are considered the proportions remain 
unchanged.
Acute pancreatitis due to other identified aetiologies was
infrequently diagnosed before post-mortem, particularly pancreatitis
developing postoperatively. It is likely that diagnosis of these
patients in life would have altered management and perhaps the
outcome in same. In 1978 better surveillance of patients undergoing
1 60"at risk" procedures was recommended and cnly two deaths frcm 
postoperative pancreatitis were recorded in the latter half of the 
study.
Ischaemia was thought to explain the acute pancreatitis in at
least same of the patients in whom no other aetiological factor could 
171be identified . This was the largest group of patients and the high
percentage with an unidentified aetiology is surprising, although
69similar to the recent Bristol experience . Attention has often 
focused in the past on a comparison of outcome in gallstone and 
alcohol-associated acute pancreatitis while the idiopathic 
aetiological group is regularly shown to have the highest 
m o r t a l i t y * ^ . Improved identif ication of aetiology both 
during life and at post mortem is desirable. Faecal sieving and ERCP 
will increase the detection of gallstones and routine viral screening 
or blood alcohol levels on admission might improve the diagnostic 
rate further. There is also need for a meticulous post mortem 
protocol to avoid overlooking small calculi in the ccmmcn bile duct 
or ampulla and rarer associations such as parathyroid adenomas.
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Death was considered to be due to "medical" causes in 51% of 
the 53 patients first diagnosed at post mortem. In a retrospective 
study such as this it can be difficult to determine the actual 
contribution of the acute pancreatitis to the patient's death and in 
seme it is possible that pancreatitis may have occurred as a result 
of terminal organ failure. In cnly 7 patients (13%) was the 
pancreatitis mild on the pathologist's assessment and considered to 
be an incidental finding at post mortem. In the remainder 
pancreatitis was considered to be either the major factor or a 
significant additional factor contributing to death and in the 
majority of these patients pancreatitis was thought to account for 
the patients' presenting symptoms.
The preponderance of "pancreatic" deaths among the patients 
diagnosed in life, particularly in those with a gallstone or alcohol 
aetiology, suggests scope for further improvements in management. 
Many patients continue to die early of fulminant acute pancreatitis, 
despite seemingly adequate medical treatment. These patients 
presented in a variety of ways, seme with an overtly severe attack, 
others with an apparently mild attack, subsequently deteriorating, 
seme quite rapidly after admission. Prognostic factor scoring systems 
may aid in the identification of such attacks, although the delay of 
up to 48 hours before obtaining an answer may diminish their value in 
practice. There is a need for more rapid and accurate identification 
of such patients.
Early operation with pancreatic resection has been suggested 
for fulminant acute pancreatitis and in a prospective comparison with
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peritoneal lavage (lavage cannulas having been placed at 
laparotcmy) patients undergoing primary resection fared best, with
I7 C
mortality rates of 22% and 47% respectively . These figures were 
achieved in a predominantly young, male alcoholic patient population 
with a mean age of 37 years. Emergency pancreatic resection is 
associated with a much higher mortality elsewhere. Our patient 
population tends to be much older (mean age 63 years) and both 
patients in the current series undergoing pancreatic resection for 
fulminant acute pancreatitis died.
Patients surviving the early phase of the illness may succumb 
later due to the delayed effects of pancreatic necrosis or abscess. 
The limitations of the traditional surgical approaches to the 
management of these problems are highlighted by the frequent need for 
re-operation and the incidence of residual abscess and/or necrosis at 
post mortem. Newer developments in imaging techniques and the 
promising preliminary results of the recently described techniques of
O Q  AO
postoperative lavage or qpen packing following digital 
debridement and necrosectomy for pancreatic necrosis or abscess await 
full evaluation.
A proportion of patients may benefit from improved surgical 
treatment, but a dramatic overall improvement in the mortality rate 
is unlikely to follow. One third of the patients reported here died 
of medical causes and it was considered that surgical treatment had 
little or nothing to offer them. Other patients who might benefit 
frcm surgery were usually old or had concurrent medical disease and 
such patients often do poorly after surgery even with intensive care
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therapy.
The nihilistic attitude has not much to caimend it but a 
realisation of the task ahead is sensible. More careful surveillance 
in diagnostic terms, improved speed and accuracy in predicting severe 
attacks and the application of early ERCP and endosccpic 
sphincterotomy m  gallstone pancreatitis as well as a vigorous
pQ /IQ
surgical policy to infected necrotizing pancreatitis ' must be the 
way ahead. Meanwhile we seek to increase understanding of the 
mechanisms responsible for the early "shock-like" illness 
characteristic of severe acute pancreatitis and continue to search 
for the panacea of an effective medical therapy.
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PART 3.
PATIENTS AND METHODS
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CHAPTER 4. A CLINICAL STUDY OF INTRAPERITONEAL APROTININ IHERAPY 
IN HUMAN ACUTE PANCREATITIS
Introduction
The balance of experimental evidence supports the view that the 
peritoneal exudate in acute pancreatitis possesses sane toxic 
properties. Whatever the exact mechanism of toxicity, its removal 
might be expected to be therapeutic and in experimental pancreatitis, 
there is much evidence that this is the case. In man the evidence is 
conflicting, two earlier studies suggested benefit from peritoneal 
lavage in predominantly alcoholic patient populations^^339, whereas 
the recent studies fron the UK and Sweden have failed to confirm 
this353,235.
Both recent studies examining peritoneal lavage suffered frcm 
drawbacks in their methodology. The majority of the control group in 
the UK study and all the control patients in the Swedish study 
undergoing peritoneal cannulation, aspiration of the exudate and a 
single peritoneal washout. Thus in both studies the control group had 
been "treated" by removal of the exudate which, according to 
e^qperimental evidence, is most toxic early in the attack. This may 
have obscured any difference in outcome between the control group and 
the group who went on to have cycled peritoneal lavage. A further 
trial of peritoneal therapy seems warranted on these grounds alone.
The addition of the antiprotease aprotinin to the dialysate has 
been examined in one study in which both groups of patients underwent 
cycled peritoneal lavage. No significant differences emerged between
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the groups, although the mortality and number of complications 
was lower in the aprotinin treated group^. The present study was set 
up to examine whether a simplified regime of intraperitoneal 
antiprotease administration would improve the outcome and, in 
particular, decrease the incidence of early systemic complications 
compared to patients receiving standard therapy alone.
Intraperitoneal aprotinin
Given intravenously to dogs with bile-induced pancreatitis 
levels of aprotinin achieved in the peritoneal cavity were only about
p p
1% of the initial plasma concentration . To achieve therapeutic
levels of aprotinin within the peritoneal cavity, sufficient to
inhibit trypsin mediated effects, necessitates direct peritoneal 
92administration .
In a pilot study 3 patients received a total dose of 14 xlO^KIU
of aprotinin, administered 3 hourly in divided doses of 4, 3, 3, 2,
2 xlO%IU respectively per administration. This regime produced
intraperitoneal aprotinin levels of >  10jjmol/l, considered to be
22within the therapeutic range . Similar studies performed m  Leeds 
provided equivalent therapeutic levels in the peritoneal cavity, 
maintained for 20 hours using a simpler regime consisting of 2
z:
separate instillations of 5 xlOKIU aprotinin, each in one litre of
0.9% saline, given 8 hours apart (Larvin M, personal ccnmunication) 
(Fig. 11). It is this regime which has been investigated in the 
current study.
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FIGURE 11.
(a) Concentrations of aprotinin in peritoneal
fluid in 5 patients during intraperitoneal 
therapy with aprotinin. Concentrations are 
shown during the first 2 0 hours of therapy 
comprising 2 intraperitoneal instillations of 
aprotinin (5 x 106KIU in one litre of 0.9% 
saline) given 8 hours apart.
(b) Corresponding concentrations of aprotinin 
in plasma in 5 patients during intraperitoneal 
therapy with aprotinin (as above).
Statistical aspects
The vast majority of controlled trials of therapy in human 
acute pancreatitis have failed to show any benefit in terms of 
clinically important end-points such as the incidence of death or 
major complication. Although this may reflect the ineffectiveness of 
the therapies tested, many studies have lacked sufficient statistical 
power for the investigators to have confidence in the negative 
outcomes reported. This has been due to the inclusion of too few 
patients in the studies and/or that the frequency of clinically 
important end-points in the untreated control group was too low to
0 0 7
permit detection of a difference having occurred .
Consideration of the type I and type II error rates allows
111prediction of the required sample sizes ' .  In the recent study 
of peritoneal lavage, 30% of all patients referred to the study died 
or developed a major life-threatening complication . Assuming a 
similar spectrum of disease, to detect a 50% reduction in mortality 
and major morbidity in the treatment group, a total of 242 patients 
would need to be studied to provide an 80% power of detection, rising 
to 90% were 322 patients to be studied.
Selection of a subset of patients with an increased incidence 
of complications would permit the study of fewer patients, but to 
recruit sufficient numbers of such patients within a reasonable 
period of time necessitates a multicentre study design. The current 
study was set up in conjunction with Messrs. M. J. McMahon and M. 
Larvin from the General Infirmary, Leeds and with the support of Mr.
D. Lee, Medical Services Manager for Bayer UK Ltd. The trial
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commenced in February 1986. This chapter details the trial
protocol and analyses the patients I have personally entered into the
study.
Study design
All patients referred to the study were assessed by an 
experienced registrar (based in either Glasgow or Leeds) as soon as 
possible after their admission to hospital. All patients were 
documented using a standard trial proforma and had their clinical 
course and outcome recorded.
Only those patients considered to have moderate or severe 
pancreatitis, on the basis of the initial clinical examination, and 
fulfilling the other inclusion and exclusion criteria (see below) 
were entered into the formal study. The formal study examined the 
incidence of death and major complications in patients randomised to 
receive standard therapy alone compared with those randomised to 
receive additional intraperitoneal therapy with aprotinin.
Methods
Recruitment and documentation
Consultant surgeons at the Royal Infirmary, Glasgow and 5 
nearby general hospitals were contacted at the end of 1985 with 
details of the proposed study and were invited to participate. In 
each hospital a comprehensive trial protocol was submitted to the 
local ethical committee and authorisation obtained prior to 
conmencement of the study.
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Patients admitted with acute pancreatitis to any of the 6 
participating hospitals remained under the care of the admitting 
consultant surgeon but, in addition, were referred for consideration 
of their inclusion in the study, as soon as possible after their 
admission to hospital. To this end, I was available to be contacted 
24 hours a day by a radiopaging device via the switchboard operators 
at Glasgow Royal Infirmary.
The patients referred were usually seen within a few hours of 
my being contacted. A standard proforma was carpieted for all 
patients detailing their current and past medical history and 
inquiring of possible aetiological factors. The assessments made by 
the admitting doctors were recorded as were my own findings on 
examination.
Inclusion Criteria:
Diagnosis of acute pancreatitis
Patients were considered to have acute pancreatitis and to be 
suitable for inclusion in the study based an the presence of a serum 
amylase greater than 1200IU/1 (normal range 70-300IU/1) with a 
compatible clinical picture. Patients in whom pancreatitis had been 
diagnosed at laparotomy were documented but not considered for 
inclusion in the formal study.
Severity of the attack
The patients underwent a clinical assessment when first seen, 
the severity of the attack being recorded as mild, moderate or
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severe. This was repeated at 24 hours and 48 hours 
post-admission. The assessment of mild disease was based on the 
following criteria:-
(a) The patient appeared generally well.
(b) The patient had no pain, or oily mild discomfort.
(c) The patient had only minimal abdominal tenderness.
Patients with mild pancreatitis were considered to be at low 
risk of developing complications and were not considered for 
inclusion in the formal study. Severe attacks comprised those 
patients judged to be clinically unwell and considered to be at risk 
of death or developing a major complication. Attacks were judged as 
moderate when they appeared to fall between these two definitions. 
All attacks judged to be moderate or severe were considered for 
randomisation into the formal study.
Patients judged to have a mild attack on the initial assessment 
but who subsequently deteriorated could be re-allocated into the 
moderate or severe categories and thus be randomised into the formal 
clinical study, providing this decision was made within 72 hours of 
the onset of their attack.
Age
Only patients aged over 16 and under 85 years of age were 
considered for inclusion in the study. Pancreatitis in children is 
rare and usually mild. In the very elderly the outcome of an attack 
often depends on factors such as their chronic health state and on 
the presence of other underlying illnesses and was considered
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unlikely to be influenced by intraperitoneal therapy.
Delays in referral
Patients were only randomised when the delay between the onset 
of symptoms and assessment was less than 72 hours as commencement of 
therapy after this time was considered less likely to be beneficial.
Exclusion criteria
The presence of multiple abdominal scars is a contraindication 
to percutaneous introducti on of a peritoneal lavage cannula and such 
patients were excluded from consideration for the formal study. 
Similarly intraperitoneal therapy was considered inappropriate during 
pregnancy and following recent abdominal surgery.
Because of the slight risk of anaphylaxis in patients who had 
previously received aprotinin, such patients were also excluded frcm 
cons iderati on.
Randomisation
Patients fulfilling the inclusion and exclusion criteria were 
randomised by opening a consecutively numbered sealed envelope 
containing the randomisation details. These envelopes had been 
prepared in advance by Bayer UK Ltd. to provide a random allocation 
of equal numbers of patients into both the intraperitoneal therapy 
and standard therapy groups.
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Standard therapy
Simple guidelines were distributed to each clinician and to 
every ward involved in the management of these patients and a copy 
filed in each patient's case record to standardise their 
investigation and routine care within each of the 6 participating 
hospitals.
All patients received intravenous fluid as crystalloid 
solutions (typically 1 litre 5% dextrose : 500ml 0.9% saline, 4 
hourly), infused more rapidly or supplemented with human plasma 
protein fraction (albumin) as a plasma expander where deemed 
appropriate. The use of fresh frozen plasma (containing clotting 
factors and active antiproteases) was limited to instances of proven 
coagulopathy.
Nasogastric suction was advised for the more severely ill 
patients and in less severe attacks was left to the clinician's 
discretion. The pulse, blood pressure, axillary temperature and 
respirations were charted regularly every 4 to 6 hours. Bladder 
catheterisation was recommended with measurement of the hourly urine 
volumes for the first 24 to 48 hours, or until the patient was 
stable. The fluid balance was recorded daily for the first 7 days or 
until discharge if sooner. Measurement of the central venous pressure 
was suggested for those with clinically severe pancreatitis.
Parenteral analgesia was provided as intramuscular pethidine, 
typically lOOmg every 3 to 4 hours as required. Other agents such as 
H2  receptor antagonists, steroids or antibiotics were not 
administered except for precise indications.
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Routine blood tests including urea, electrolytes, glucose, 
amylase, calcium, liver function tests and a full blood count were 
checked daily. Arterial blood gases were measured every 12 hours 
initially, and thereafter as indicated clinically. Oxygen was 
provided by mask if the pC^ fell below 70 mmHg. Blood samples were 
also withdrawn daily, centrifuged at 4°C and the serum stored at 
-20ct for subsequent assay of C-reactive protein and antiproteases.
Details of the patients clinical condition, recordings, results 
of laboratory investigations and treatment were recorded on the trial 
proforma each day for the first 7 days. All the patients studied at 
the Royal Infirmary were examined personally each day as were the 
majority of the patients in Stobhill Hospital and the Southern 
General Hospital. Elsewhere the patients were examined daily for the 
first 3 days and then every 2 to 3 days until their discharge. In 
addition to the clinical assessment of severity, an objective 
assessment of severity was made based on the established multiple 
factor scoring systems, to permit later comparison of the groups. The 
severity assessments are presented and discussed in chapter 7.
Intraperitoneal therapy
All patients referred to the study received standard therapy as 
outlined above. Patients randomised to the treatment group underwent, 
subject to written informed consent having been obtained, peritoneal 
cannulation and intraperitcneal therapy with aprotinin.
Using sterile technique the skin and linea alba 4cm below the 
umbilicus were anaesthetised with 2% lignocaine and a peritoneal
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dialysis cannula (FG 8, Kimal Scientific Products Ltd.,
Uxbridge, UK) was introduced into the peritoneal cavity and its tip 
directed towards the pelvis.
Any free peritoneal exudate was aspirated into a syringe and 
then a litre of 0.9% saline solution was instilled. The patient was 
tilted head down and then turned on each side to circulate the fluid. 
After 5 minutes the fluid was allowed to drain cut.
One litre of aprotinin solution (700mg of aprotinin in 0.9%
C
saline, equivalent to 5 xlO KIU) was then instilled and the patient 
was tilted and turned as before to circulate the fluid. The catheter 
was clamped and the fluid left in the peritoneal cavity for 8 hours 
before being drained off. A further litre of aprotinin solution (5 x
C
10 KIU) was then instilled into the peritoneal cavity and the 
dialysis cannula removed leaving the aprotinin solution in situ. 
Thereafter these patients were managed exactly as all the other 
patients, with close monitoring of their clinical course and outcome.
The volume of any exudate aspirated at the initial cannulaticn 
was recorded and the colour compared with a standard colour chart 
(Fig. 12) . A sample was sent to the bacteriology department for an
immediate Gram film to exclude the presence of bacteria. The volume 
and colour of the lavage fluids and aprotinin instillations drained 
frcm the peritoneal cavity were also recorded. Samples of all fluids 
withdrawn and the tip of the peritoneal dialysis cannula were 
routinely cultured for organisms. Aliquots of all the samples were 
centrifuged at 4°C and the supernatants separated and stored at 
-20°C. Biochemical analyses of the protein and pancreatic enzyme
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FIGURE 12.
Leeds colour chart for identification of 
severity of acute pancreatitis by diagnostic 
peritoneal lavage. Arrows point to the lightest 
colour of the lavage return fluid or free 
peritoneal fluid for acceptance of a severe 
prediction. (McMahon MJ et a l ., Br J Surg 1980; 
67:22-5. Reproduced by permission of the 
publishers, Butterworth & Co. (Publishers).
contents of all the fluid samples were performed, the results 
of which are presented and discussed in chapters 10 and 11.
Determination of aetiology
Each patient had a chest and plain abdominal radiograph 
performed on admission to hospital. During the admission an 
ultrasound examination of the liver, pancreas and biliary tree was 
performed on each patient.
The aetiology of the attack was determined based on the history 
of the patient's alcohol intake obtained either from the patient or 
from the relatives and on the presence or absence of gallstones on 
ultrasound examination, cholecystography or cholangiography, at 
laparotomy or at post mortem. Patients in whcm the aetiology remained 
obscure often underwent further investigations including fasting 
blood lipids, viral screen and endoscopic retrograde 
cholangiopancreatography or had pancreatitis attributed to a 
recognised antecedent. The remaining patients in whcm no aetiological 
factor could be identified were studied together as a group of 
"unknown aetiology".
Classification of outcome
Death or the development of a major carpi i cat ion were the 
primary end-points by which the effectiveness of therapy was judged.
In addition any short-term effect of therapy which might not be 
reflected in the eventual outcome was investigated by assessment of 
the patient's clinical condition, by documenting the changes in
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physiological and laboratory parameters and by recording the 
analgesic requirements.
Major camplications were defined as follows:
1. pancreatic necrosis - necrotic pancreatic and/or peripancreatic
tissue recovered at laparotomy or post mortem.
2. pancreatic abscess - a pancreatic or peripancreatic collection
where pus was the predominant feature.
3. pancreatic pseudocyst - a pancreatic or peripancreatic fluid
collection of greater than 5cm diameter, diagnosed on ultrasound 
or at laparotomy.
4. acute renal failure - urine volume of less than 400ml/24 hours
with a rising blood urea and no response to 24 hours of 
intravenous fluid therapy.
5. acute respiratory insufficiency - arterial pC^ less than 60 mmHg
requiring ventilation or oxygen therapy by mask for 5 or more 
consecutive days.
6. myocardial infarction - consistent changes on serial ECG records
accompanied by appropriate enzyme changes or when demonstrated at 
post mortem.
7. left ventricular failure - radiologically demonstrated pulmonary
oedema supported by a raised pulmonary capillary pressure where 
diagnostic doubt exists.
8. septicaemia - a positive blood culture with a pathogen in a
patient with an appropriate clinical course.
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Attacks were classified as complicated if the patient died or 
developed a major complication. In addition to the above, minor 
complications were also recorded including acute confusional states, 
delirium tremens and pleural effusions. Note was also made of whether 
the patient appeared to be "slow to settle" from the acute attack, 
this being defined as either requiring a prolonged convalescence or 
requiring parenteral analgesia for more than 5 days following 
admission.
The duration of the hospital stay was recorded, particular note 
being made as to whether this was prolonged due to a complication 
having developed, due to cholecystectomy being performed during the 
index admission, or whether this was due to "social" reasons.
Statistics
Statistical analyses were performed by Fisher's exact test, Chi 
square test, and Mann-VJhitney U test.
Results
During the 20 month period February 1986 to September 1987, 160 
attacks of acute pancreatitis occurring in 151 patients were referred 
to the study and documented (Appendix 1). The attacks occurred in 98 
males and 62 females with mean ages of 48.7 years and 58.5 years 
(p <0.001) respectively.
The majority of the patients had been referred from the Royal 
Infirmary (89 patients), the remainder having been referred as 
follows: Stobhill General Hospital - 34 patients, Monklands District
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General Hospital - 14 patients, Victoria Infirmary - 8
patients, Law Hospital - 8 patients and the Southern General Hospital
- 7 patients.
Clinical features
Pain was the commonest presenting feature being recorded in all 
but 4 patients, 2 of whcm presented in ccma and 2 with a confusional 
state. Of the remaining attacks, 128 (82%) were associated with 
severe pain, 25 (16%) with moderate pain and in 3 instances the 
patients reported only mild pain. The duration of the pain prior to 
admission ranged between 30 minutes and 120 hours with a median 
duration of 9 hours. The pain radiated to the back in 93 (60%) of the 
attacks and 132 attacks (85%) were associated with vomiting. Five 
patients (3%) developed abdominal wall bruising, 3 of these patients 
subsequently died and the other 2 had attacks cctrplicated by 
respiratory insufficiency, m e  of whcm required a period of 
ventilation. One further patient developed body wall bruising cn day 
11 which was subsequently shown to be artefactual (self-inflicted).
Clinical assessment
The delay frcm admission to their initial assessment ranged 
between 1 hour and 60 hours, with a median delay of 5 hours. In 12 
patients this delay exceeded 24 hours due to delays in confirming the 
diagnosis in 8 instances and to delays in referring the patient for 
assessment in 4.
Based on the initial clinical assessment, 104 attacks (65%)
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were considered to be mild and were not randomised. Seven of 
these patients were reassigned the following morning (6 - moderate, 1 
- severe) and ultimately 97 attacks (61%) were considered mild and 
were not, therefore, randomised.
Twelve further patients were excluded, 4 on the basis of a 
non-diagnostic serum amylase concentration, 3 an the basis of age 
(too old - 2, too young - 1), 2 because of recent abdominal surgery 
(diagnostic laparotomy), one because of delayed presentation of more 
than 72 hours from the onset of his attack and one because he had 
previously received aprotinin. The final patient had established 
acute renal failure on a background of recently diagnosed multiple 
myeloma and vriien first seen had just suffered a cardiovascular 
collapse. Randomisation and the possibility of intraperitoneal 
therapy was considered inappropriate under these circumstances and 
she was excluded. The remaining 51 attacks (32%) met all the 
inclusion and exclusion criteria and were randomised. These patients 
are examined in detail in chapter 12.
Thus 3 groups of patients have been considered here: those 
excluded because they were considered to have mild disease on 
clinical examination (97 patients), those excluded because of other 
criteria (12 patients) and those meeting all the criteria and who 
were entered into the formal study and randomised (51 patients) 
(Appendix 1).
Aetiology
Gallstones were documented in 59 attacks (37%) and were the
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commonest aetiological factor identified. Alcohol abuse was 
implicated in 50 attacks (31%) and in 6 other attacks (4%) gallstones 
and alcohol were both implicated. In 13 attacks (8%) other recognised 
antecedents were diagnosed. Hyper 1 ipidaemia was diagnosed in 4 
patients, associated with alcohol abuse in 3 and in one was due to 
familial hypercholesterolaemia. Two patients developed acute 
pancreatitis following blunt abdominal trauma, one following an 
assault and one following a road traffic accident. Two patients 
developed pancreatitis follcwing ERCP. In the remaining patients 
acute pancreatitis followed an operation for total hip replacement in 
one, a viral illness (with rising titres to coxsackie B 2 ) in one, 
coraxiencement of steroid therapy in one, hypothermia in one and was 
associated with carcinoma of the pancreas in one.
No definite aetiological factor could be implicated in the 
remaining 32 attacks (20%). All except 2 of these patients, who died 
without post mortem permission having been granted, had at least an 
abdominal ultrasound performed to exclude the presence of gallstones.
The aetiology of the attack in relation to patient age and sex 
is shown in table 16. Table 17 details the categorisation of the 
patients into trial groupings in relation to the aetiology of their 
attack. Table 18 analyses the aetiologies of the attacks in relation 
to the referring hospital.
Recurrent attacks
Recurrent attacks were most comnonly seen amongst those with 
pancreatitis secondary to alcchol abuse, 18 (36%) giving a history of
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TABLE 17.
Categorisation of patients by trial 
groupings in relation to the recorded 
aetiology.
Trial grouping 
Not randomised 
Mild Other
Aetiology attack exclusions Randomised Totals
Gallstones 40 (41%) - 19 (37%) 59 (37%)
Alcohol 31 (32%) 5 (42%) 14 (27%) 50 (31%)
Gallstones
/alcohol
5 (5%) - 1 (2%) 6 (4%)
Other 5 (5%) 3 (25%) 5 (10%) 13 (8%)
Unknown 16 (16%) 4 (33%) 12 (24%) 32 (20%)
TABLE 18.
Analysis of the recorded aetiologies 
in relation to the referring hospital.
Hospital Gallstones Alcohol
Gallstones
/alcohol Other
Royal Infirmary 
Stobhill Hospital 
Monklands DGH 
Law Hospital 
Victoria Infirmary 
Southern General
24 (30%)
16 (47%)
5 (36%)
5 (62.5%)
4 (50%)
5 (71%)
36 (40%)
7 (21%)
5 (36%)
1 (12.5%) 
1 (14%)
3 (3%) 
2 (6%)
12 (13%)
1 (12.5%)
1 (14%)
Unknown
14 (16%)
9 (26%)
4 (29%)
3 (37.5%) 
2 (25%)
previous attacks. Five of these patients were admitted more 
than once during the period of the study, one having been admitted on 
3 different occasions. In 6 (10%) of the patients in whcm gallstones 
were identified there was a history of a previous attack, 4 within 4 
months of their first attack and in the other 2 within 10 months and 
2 years respectively. Four (12.5%) of the patients in whom no 
definite aetiological factor was identified had a history of previous 
attacks. Two of these patients each had one previous attack and 2 
others had respectively 3 and 12 previous attacks. One of the 
patients with hyper1ipidaemia in association with alcohol abuse also 
had a single previous attack.
Therefore, 29 patients had a history of previous attacks of 
acute pancreatitis and 9 of the total of 160 attacks documented were 
due to second or subsequent admissions during the actual study 
period. The recurrent attacks were often mild. Only 3 patients (10%) 
had a complicated recurrent attack (necrosis - 1, pseudocyst - 1, 
respiratory insufficiency - 1) with no deaths.
Outcome: deaths
A fatal outcome was recorded in 13 attacks (8.1%) overall and 
these patients are analysed in table 19. Nine of these deaths 
occurred amongst the 51 patients randomised into the formal study, 
the other 4 occurring amongst those excluded on the basis of age over 
85 years (in 2), delayed presentation in oie and on the presence of 
acute renal failure and cardiovascular collapse cn initial assessment 
in one.
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TABLE 19.
Analysis of the age, previous medical 
history, mode and timing of death in the 
fatal attacks of acute pancreatitis.
Time of
Patient Aetiology Age Cause of death
death
(day)
Underlying
illnesses
005 Unknown 65 fulminant pancreatitis 3 IHD, COAD, RHD
009 Gallstones 62 necrosis/sepsis/MOF 50 PVD, COAD, 
hypertension
043 Post-ERCP 86 fulminant pancreatitis 
/acute renal failure
3 frail
044* Gallstones 69 fulminant pancreatitis 
DIC
2 -
045* Alcohol 55 fulminant pancreatitis 
/necrosis
9 hypertension
055* Trauma 73 necrosis/sepsis 19 hypertension
057 Steroids 80 acute renal failure 
/septicaemia
10 myeloma, IHD, 
cardiac failure
076* Unknown 57 necrosis/sepsis 64 -
088* Hypothermia 83 hypothermia/cardiac 4 
failure/bronchopneumonia
hypothermia,
IHD
094 Unknown 85 sudden death 5 aortic aneurysm
106* Gallstones 56 necrosis/sepsis/MOF 38 -
151* Alcohol 29 fulminant pancreatitis 
/necrosis
2 fatty liver
156* Gallstones
/alcohol
66 fulminant pancreatitis 
/necrosis
4 -
KEY:
* post mortem performed, MOF - multiple organ failure,
DIC - disseminated intravascular coagulation, PVD - peripheral* 
vascular disease, COAD - chronic obstructive airways disease, 
IHD - ischaemic heart disease, RHD - rheumatic heart disease.
Seven deaths occurred early, within the first week of illness, 
6 of them occurring within the first 4 days of admission. Shock 
associated with fulminant pancreatitis was the usual mechanism of 
death in these patients. One further patient mentioned above who had 
been excluded from the formal study because of age was known to have 
a large abdominal aortic aneurysm but had been turned down for 
surgery on the basis of poor general health. His clinical 
presentation during this admission supported a diagnosis of either 
acute pancreatitis or a leaking aneurysm although his sudden demise 
on his 5th day post-admissicn favoured the latter diagnosis. 
Unfortunately permission for a post mortem examination was declined 
by the relatives and the diagnosis of acute pancreatitis was never 
substant iated.
The other 6 patients died at varying times between 9 days and 
64 days post-admissicn. Two patients dying cn days 9 and 10 
respectively both had a fulminant, shock-like illness with renal 
failure, one undergoing sub-total pancreatic resection prior to his 
death. The remaining patients succumbed of the late effects of 
pancreatic necrosis and sepsis despite surgical treatment in 3 of 
then (necrosectomy/pancreatic debridement in 2, pseudocyst drainage 
in one).
Outcone: major complications
Twenty-six patients developed major conplications and survived. 
Eleven patients developed local pancreatic complications (pseudocysts 
- 7, abscess - 2, pancreatic necrosis - 2). Twelve patients developed
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respiratory insufficiency and 3 septicaemia.
Pseudocysts
Pseudocysts were the commonest pancreatic complication 
encountered and followed pancreatitis of unknown aetiology in 3 
patients, pancreatitis associated with alcohol abuse in 3 and 
followed gallstone pancreatitis in one. In all cases the pseudocyst 
was evident clinically or on ultrasound examination prior to the 
patient's discharge from hospital.
In 4 patients the pseudocyst resolved spontaneously on 
sequential ultrasound examination, the other 3 requiring formal 
surgical drainage. One of these patients was operated on early (day 
21) because of diagnostic uncertainty on ultrasound, the appearances 
having been considered compatible with the presence of necrotic 
retroperitoneal lynph nodes perhaps secondary to tumour. A pseudocyst 
was found at operation, containing much necrotic debris, and was 
satisfactorily treated by external drainage. In the other two cases 
the pseudocysts were drained by cystogastrostomy 2 months after the 
acute attack.
Abscesses
Two patients developed pancreatic abscesses, in both cases the 
diagnosis only becoming apparent following discharge from hospital. A 
pancreatic carpiication had been suspected in one during his initial 
hospital stay because of a palpable epigastric mass although 
ultrasound examination at that time had failed to visualise any
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abnormality other than pancreatic swelling. He was readmitted 4 
months later because of a persistent mass associated with weight loss 
and malaise. At operation he was found to have a small residual 
abscess adjacent to the pancreatic head and this responded 
satisfactorily to drainage.
The second patient had been considered to have a mild attack of 
pancreatitis when first seen and had not been included in the formal 
study. She was slow to settle after her initial attack but was able 
to be discharged hone on day 35. She started vomiting at home and 
when readmitted 2 weeks later was found to have a mass. At subsequent 
laparotomy an abscess was drained and cholecystectomy performed.
Necrosis
Two patients developed pancreatic necrosis and required surgery 
on day 6 and on day 40 respectively. The first patient was treated by 
distal pancreatectomy, requiring in addition a transverse colectomy 
because of involvement of the colon in the necrotizing process. His 
postoperative course was prolonged and carpiicated by a pancreatic 
fistula which eventually settled cn conservative treatment. He was 
finally discharged on day 58 but subsequently developed jaundice due 
to common bile duct obstruction which has since necessitated further 
surgery.
The second patient developed evidence of a peripancreatic fluid 
collection and at laparotomy was found to have extensive pancreatic 
and peripancreatic necrosis. She was treated by debridement of the 
necrotic tissue on day 40 but further debridement and drainage of pus
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was required on days 70 and 87. She subsequently developed a 
colonic fistula and required transverse colectomy and formation of 
stomas on day 102. After a protracted convalescence she was finally 
discharged on day 284.
Respiratory insufficiency
Twelve patients developed respiratory carpiications, 2 of whcm 
required assisted ventilation for periods of 12 and 13 days 
respectively. In one of these patients this had followed diagnostic 
laparotomy.
The remaining 10 patients developed acute respiratory 
insufficiency with a p02 of less than 60 mrriHg and requiring O2  
therapy by mask for 5 or more consecutive days (mean 8 days). Five of 
these patients had co-existing pleural effusions but none of these 12 
patients developed other local pancreatic carpiications cn serial 
ultrasound examination. Two of these patients had been considered to 
have mild pancreatitis when first seen after their admission and 
accordingly had not been randomised into the formal study.
Other complications
Three patients, 2 with gallstone pancreatitis and one with 
pancreatitis of unknown aetiology, developed septicaemia. The latter 
patient in whom no definite aetiology could be identified had 
gallstones suspected cn biochemical criteria, but not proven. One of 
these patients was considered to have mild pancreatitis when first 
seen and accordingly had not been randomised. He also developed
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severe left ventricular failure during his hospital stay, 
although myocardial infarction was not confirmed cn either 
electrocardiogram or cardiac enzymes.
A total of 39 attacks (24.4%) had a complicated outcome 
resulting in death or a life-threatening complication from which the 
patient recovered. There were no significant differences in the 
median delays between the onset of the attack and admission, in 
patients with uncomplicated, complicated or fatal attacks. There 
appeared to be no important differences in the incidence of 
complicated attacks between patients referred from the 6 
participating hospitals (Table 20). The lowest proportion of 
complicated attacks occurred in the patients where a gallstone or 
alcohol aetiology had been implicated (Table 21). The highest 
incidence of death and complications was found amongst patients with 
pancreatitis secondary to other identified aetiological factors.
Uncomplicated outcome
The remaining patients were considered to have had a mild 
attack of acute pancreatitis. Some manifested a clinically severe, 
although ultimately uncomplicated attack as has been defined above. 
Fifteen patients were recorded as "settling slowly" from their 
attack.
Two patients had recurrent attacks of acute pancreatitis during 
their index admission, one in association with gallstones, the other 
with pancreatitis of unknown aetiology, although she had undergone 
cholecystectomy with carmen bile duct exploration 3 years previously
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TABLE 21.
Outcome and complications in relation to 
the recorded aetiology.
Aetiology of attack
Outcome Gallstones Alcohol
Gallstones
/alcohol Other Unknown
Uncomplicated 45 (76%) 43 (86%) 4 (67%) 6 (46%) 23 (72%)
Complicated 11 (19%) 5 (10%) 1 (17%) 3 (23%) 6 (19%)
Pseudocyst 1 3 - - 3
Abscess 1 - - - 1
Necrosis - 1 - 1 -
Respiratory 7 1 1 2 1
Septicaemia 2 — 1
Fatal 3 (5%) 2 (4%) 1 (17%) 4 (31%) 3 (9%)
and on the current admission had biochemical abnormalities typical of 
a gallstone-associated attack.
Delirium tremens was recorded in 3 patients with alcohol 
associated pancreatitis in the absence of other carpiications. Two 
other women manifested a similar acute confusional state although 
alcohol abuse could not be incriminated with certainty in either 
case. Two patients developed small peripancreatic fluid collections 
(<5cm) on ultrasound examination. In both cases the pancreatitis was 
associated with alcohol abuse and in both cases resolution occurred 
on serial ultrasound scanning. One diabetic cn insulin developed 
ketoacidosis but had an otherwise uncomplicated attack.
Two other patients were admitted with abdominal pain and 
hyperamylasaemia in associated with the presence of cysts, both in 
association with alcohol abuse. One patient had developed a 
pseudocyst following an earlier attack of pancreatitis, the second 
had multiple cysts in the head of his pancreas and was subsequently 
shown on ERCP to have features of chronic pancreatitis. In both 
instances, as the cysts appeared to have preceded the monitored 
episode of acute pancreatitis, they were not considered as 
ccmplicati ons.
The outcome of the attack in relation to the initial and final 
categorisation into trial groups is shown in table 22. A complicated 
outcome was recorded in only 4 patients (4%) considered at 48 hours 
to have a mild attack.
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TABLE 22.
Outcome of the attack in relation to the 
initial and final categorisation of 
patients into trial groupings.
Outcome of attack
Total
Category patients Uncomplicated
Complicated 
Survived Fatal
Total % 
complicated
On admission
Not randomised:
Mild 104 96 7 1 8%
Other exclusions 12 5 3 4 58%
Randomised 44 20 16 8 55%
Einai
Not randomised:
Mild 97 93 4 4%
Other exclusions 12 5 3 4 58%
Randomised 51 23 19 9 55%
Discussion
The estimated catchment populations of the 6 participating 
hospitals ranged frcm 152,418 to 224,295 although the number of 
patients referred from each varied by up to 10-fold. While this may 
be partly explained by a varying incidence of the disease within each 
individual hospital's catchment population, the likely explanation 
was variation in the pattern of referral, some hospitals referring 
only a small proportion of patients. Referral was often dependent 
upon a large number of resident "on-call" medical staff who 
individually may have encountered a suitable patient only 
infrequently. Despite regular reminders and communication with my 
colleagues in the 6 participating hospitals it was clear that this 
system of referral of patients was less than perfect. The referral 
system appeared to work best when emergency patients were admitted to 
one or two wards or areas in a given hospital, as was the case in the 
Royal Infirmary, Stobhill Hospital and Monklands District General 
Hospital.
There was no evidence that only severe cases were being 
referred (Table 20) and thus the study population was considered to 
be representative of acute pancreatitis in this area of the West of 
Scotland.
The patient populations studied in the current trial included 
sate affluent suburban areas and also rural areas although the 
majority of patients derived from the housing schemes and 
industrialised, urban areas of northern and eastern Glasgow. The 
pattern of aetiological factors varied from hospital to hospital,
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that of Monklands District General Hospital most closely 
resembling the Royal Infirmary, where the incidence of 
alcohol-associated attacks recorded was greatest. Elsewhere gallstone 
disease was the aetiological factor most commonly implicated.
Alcohol and gallstone-associated pancreatitis had the lowest 
mortality rates, half that recorded in patients with pancreatitis of 
unknown aetiology. The highest mortality rate was found amongst the 
patients with other identified aetiological factors, almost a third 
of whcm died. It should be noted that these particular patients were 
often old, frail or had significant underlying medical problems.
Pancreatitis secondary to alcohol abuse and attacks of unknown 
aetiology were most often complicated by the development of a 
pseudocyst. Gallstone pancreatitis on the other hand was most often 
complicated by respiratory insufficiency. Such patients were often 
elderly and overweight, factors which may have contributed to both 
the presence of gallstones and the development of hypoxia.
Septicaemia alone appeared a weaker criterion upon which to 
judge an attack as severe but nevertheless 2 of the 3 patients 
developing septicaemia had prolonged admissions associated with a 
clinically severe illness. The other patient had a transient 
septicaemia associated with the presence of jaundice on admission, 
settling quickly thereafter. In all cases the septicaemia was 
associated with a biochemical picture of biliary obstruction and was 
thought to represent a cholangitis.
Recurrent attacks most often occurred in association with 
alcohol abuse. Six patients had recurrent attacks associated with
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gallstones. Three were awaiting surgery and one had declined 
surgery following her initial attack. Fortunately the recurrent 
attacks were usually mild and no deaths occurred, although deaths 
amongst such patients have been noted previously (Chapter 3).
The categorisation of patients into the 3 trial groups on the 
basis of a clinical assessment appeared to be successful, wrongly 
predicting as mild only 4 attacks with an ultimately complicated 
outcome. Most patients with acute pancreatitis recover without 
complication and if the majority of patients with mild pancreatitis 
can be identified accurately soon after admission, they can be 
excluded from clinical trials leaving a study group with smaller 
numbers but a much higher complication rate. This is particularly 
important where therapy is invasive as in the present study where 
patients randomised to the treatment limb undergo peritoneal 
cannulation.
Diagnostic peritoneal lavage is an alternative means of 
predicting the likely outcome early in the course of an attack and 
was used for the majority of the study patients in the recent UK 
trial of formal peritoneal lavage225. It is an invasive test and 
removal of the peritoneal fluid by aspiration and a single lavage may 
itself be therapeutic. It was the aim of the current study protocol 
that the control group should have no peritoneal intervention so that 
any effect of intraperitoneal therapy with aprotinin could be more 
clearly attributed to that particular therapeutic modality.
Multiple factor scoring systems are non-invasive but often 
entail a delay of 48 hours before an answer is obtained. Therapy for
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acute pancreatitis should ideally be commenced as soon as 
possible after diagnosis and therefore the decision to randomise or 
not was based primarily on clinical assessment of the severity. The 
assessment as described here has been shown to provide an acceptable 
compromise, accurately selecting a group of patients at higher risk 
of complication, for investigation by controlled clinical trial. A 
formal analysis of the accuracy of clinical assessment in comparison 
with the standard multiple factor scoring systems is detailed in 
chapter 7.
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CHAPTER 5. EXAMINATION OF PANCREATIC ENZYMES AND ANTIPROTEASES IN 
PERITONEAL EXUDATES AND FLUID SAMPLES - 
EXPERIMENTAL METHODS
Introduction
The aims of this study were to describe and validate the 
biochemical methods used to determine the pancreatic enzyme 
activities, protein and antiprotease contents and the trypsin 
inhibitory capacity of peritoneal exudate and fluid samples following 
intraperitoneal therapy.
Methods
Samples of peritoneal exudate were obtained from rats with 
experimental acute pancreatitis (chapter 9) and from humans with 
acute pancreatitis and other gastrointestinal emergencies (chapter 
10). Additional samples of peritoneal fluid were obtained frcm 
patients with acute pancreatitis randomised to receive 
intraperitoneal antiprotease therapy, following peritoneal lavage 
with a single litre of saline and 8 hours after the initial 
instillation of aprotinin (chapters 4 and 11). Samples of pseudocyst 
fluid were also obtained at the time of cystogastrostaiy or 
percutaneous cyst drainage (chapter 10).
In all cases the samples were centrifuged at 4°C and the 
supernatants separated and deep frozen, within one hour of sampling. 
Aliquots were stored at -20°C until assay. Samples for protein, 
albumin, alpha2macroglobulin, alpha-^antiprotease, amylase and lipase
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measurement were stored for up to 3 months prior to assay, 
those for protease activity were usually assayed within one month.
The following determinations were carried out in the Department 
of Pathological Biochemistry at the Royal Infirmary. Total protein 
and albumin were measured by standard techniques on a Hitachi 704 
Analyser using the biuret and bromcresol green methods respectively. 
Amylase was measured by the Phadebas test (Pharmacia Diagnostics, 
Uppsala, Sweden). Samples for alpha2 macroglobulin and 
alpha^antiprotease assay were diluted with 4% polyethylene glycol 
6000 in 0.9% saline and measured by a conventional rate turbidimetric 
immunoassay on a Baker Encore Centrifugal Analyser, using appropriate 
anti-human antibodies and standards (Atlantic Antibodies, Winnersh, 
Berkshire, UK). The normal ranges in serum (alph^macroglobulin 1.1 - 
3.9g/l, alpha-^antiprotease 1.3 - 3.2g/l) had been established on 
samples from 100 normal controls. The remaining analyses were 
performed personally in the laboratories of the University Department 
of Surgery.
Lipase
Lipase activity was measured utilising the Lipase UV System 
(Boehringer Mannheim, West Germany). Aliquots of 50pl of sample were 
added to 1.25ml of reagent solution, mixed and poured into a cuvette. 
The decrease in turbidity at 365nm over a 5 minute period was 
followed in a spectrophotometer (Pye Unicam, SP6-550 UV/VIS) at 25°C. 
Prior to analysing each batch of samples the absorbance change of the 
lipase standard was determined to permit subsequent calculation of
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the lipase activities. As the lipase activities recorded in 
peritoneal exudate were high the samples were pre-diluted with 0.9% 
saline, as recommended by the manufacturers, to bring the measured 
absorbance change within scale. The between batch coefficient of 
variation for the assay was 5.7% at a mean lipase activity of 
16870u/l.
Tryptic amidase activity
Tryptic amidase activity was measured by Trypsin test kit 
(Boehringer Mannheim, West Germany), a colorimetric method utilising 
a low molecular weight chrcmogenic substrate
benzoylarginine-p-nitroanilide (EAPNA), first described by Erlanger 
Q7and co-workers . BAPNA is a highly sensitive and specific substrate 
for trypsin. Cleavage of an amide bond by trypsin results in the 
liberation of p-nitroaniline and the resultant absorbance change is 
measured at 405nm. Tryptic amidase activity reports free trypsin and 
also trypsin-alpha^acroglobulin complexes, in which trypsin retains 
activity against low molecular weight substrates such as BAPNA. 
Plasmin also hydrolyses BAPNA, at a very much slower rate than 
trypsin, and thrombin oily extremely slowly-^.
Sequential dilutions of trypsin were freshly prepared in 0.9% 
saline to give a range of concentrations between ljig/ml and 50jig/ml 
(Bovine trypsin, ethanol precipitate, T-8003, Sigma Chemical Co., St. 
Louis, USA. The same batch of trypsin, Lot No. 25F-8120, was used for 
all studies reported in this thesis). An aliquot of lOOpl of trypsin 
solution at each trypsin concentration was added to 1.1ml of the
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BAPNA substrate/tris buffer solution which had been 
pne-incubated at 25°C for 5 minutes, rotamixed and then poured into a 
cuvette. A blank was prepared substituting lOOpl of 0.9% saline for 
the trypsin solution. Absorbance was recorded in a spectrophotometer 
(Pye Unicam, SP6-550 UV/VIS) before and after incubation at 25°C for 
one hour. By subtracting the absorbance change in the blank, the net 
absorbance change was calculated for each trypsin concentration, 
permitting construction of a standard curve. Stability of the 
standard trypsin solution (50pg/ml) was examined by assaying tryptic 
amidase activity in 3 samples before and after storage for one month 
at -20°C.
Peritoneal exudate samples were studied in lOOpl aliquots.
Sane samples in which the measured absorbance at the beginning of the 
test was "off-scale" were repeated after dilution of the sample with 
0.9% saline. Stability of the tryptic amidase activity in peritoneal 
exudates was examined in 8 samples assayed before and after storage 
for 6 months at -20°C. The between batch coefficient of variation for 
this assay was 3.3% at a trypsin concentration of 50pg/ml.
Free proteolytic activity
The fibrin plate assay is an established method for studying 
plasminogen activator activity in euglobulin fractions prepared fran 
plasma. The euglobulin fractions are resuspended in buffer and 
applied to a plasminogen-rich fibrin plate, the area of fibrinolysis 
after 18 hours incubation reflecting the amount of enzymatically 
converted substrate and thus quantifying the plasminogen activator
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• • 1 3 .activity . Heating the fibrin plate or utilising a plasminogen-free
fibrinogen in the preparation of the plate prevents this application 
and the plate becomes suitable for the assay of free plasmin or other 
proteolytic enzymes. In the present study the free proteolytic 
activity of peritoneal exudate samples was assessed by examining for 
fibrinolysis on a plasminogen-free fibrin plate as described by Wendt 
and co-workers^^.
Fibrin is a high molecular weight protein substrate resistant 
to attack by alpha2 macroglobulin bound protease. The finding of 
fibrinolysis in the peritoneal exudate samples would, therefore, be 
indicative of the presence of free proteolytic activity rather than 
alpha^acroglobulin bound protease. This assay is not specific for 
trypsin but was used as an indicator of whether activated proteolytic 
enzymes (trypsin being the major pancreatic proteolytic enzyme) had 
overcame the peritoneal antiprotease defences.
The fibrin plates were prepared using 9cm plastic petri dishes 
to which was added a solution of bovine plasminogen-free fibrinogen 
(Poviet BV, Holland supplied by Organon Tecknica, Cambridge, UK) in 
Owren's buffer (Na diethylbarbitone - 11.756g, Na Cl - 14.7g, molar 
HC1 - 43mls, made up to 2 litres with distilled water and adjusted to 
pH 7.35 with HC1). The fibrinogen was clotted by mixing with 25 NIH 
units of bovine thrombin (Fibriquik Thrcmbin Reagent, General 
Diagnostics, USA) in 0.5mls of Owren's buffer and the fibrin plate 
was allowed to clot on a level surface at rocm temperature for one 
hour prior to use. The samples for analysis were applied by automatic 
pipette in 20jil aliquots to the surface of each of the 4 quadrants of
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the plate. Fibrinolytic activity was assessed after an 18 hour 
overnight incubation at 37°C by measuring 2 perpendicular diameters 
of the lysis zone surrounding each sample application and the lysis 
area calculated.
An initial experiment using 20jj1 applications of a freshly 
prepared, bovine trypsin solution (50jjg/ml in lmnol CaCl2  and lirmol 
HCl/litre of distilled water) investigated the effect of varying the 
volume (10 or 20mls) and concentration (between 0.2% and 2%) of 
fibrinogen used in preparation of the fibrin plate.
Using standard fibrin plates (lOmls of 0.2% fibrinogen) the 
areas of lysis resulting from the application of varying 
concentrations of bovine trypsin solution (5pg/ml to 50jjg/ml, 
prepared as above) were determined, permitting construction of a 
standard curve. The sensitivity of the technique was examined by 
assaying concentrations of bovine trypsin solution down to lpg/ml.
The stability of the standard trypsin solution (50jig/ml) was examined 
by measuring the fibrinolysis in 9 samples before and after storage 
for one month at -20°C.
Studies on peritoneal exudates utilised duplicate 20jj1 samples 
with bovine trypsin solution (50jjg/ml, prepared as above) as a 
control. The between batch coefficient of variation for this assay 
was 11% at a trypsin ccncentration of 50jag/ml.
Trypsin binding capacity
The trypsin binding capacities of the peritoneal exudates were 
measured to obtain a functional assessment of the overall
151
antiprotease reserve available for protease binding. This 
technique was first described in 1966 using BAPNA and casein as 
indicators of esterolytic and proteolytic activities respectively.
The trypsin binding capacity was determined by adding increasing 
increments of trypsin to a solution containing 50jil of serum. The 
point at which the added trypsin exceeded the trypsin binding 
capacity of serum was indicated by a marked increase in the 
esterolytic and proteolytic activities, similar to the activities 
obtained for trypsin alone without the addition of serunr^. A 
subsequent report described p-toluene-sulphcny 1-arginine methyl ester 
(TAME) as a suitable indicator of proteolytic activity^. In the 
current study their methodology was modified, utilising the fibrin 
plate assay, as described above, to detect the occurrence of free 
proteolytic activity cnce the antiprotease reserve had been overcame 
by the added trypsin.
Fibrin plates (lOmls of 0.5% fibrinogen) were prepared as 
described above. Increments, usually of 10 or 20pg of freshly 
prepared bovine trypsin solution (lmg/ml in 5irmol CaC^ and 5nmol 
HCl/litre of distilled water), were added to a series of plastic test 
tubes containing lOOjjl of peritoneal exudate to provide a range of 
trypsin concentrations of between 0 and 160pg/100jiil of exudate. The 
volume in each test tube was made up to 1ml by adding tris buffer 
(Trizma - 6.06g, concentrated HC1 - 1.236ml, made up to one litre 
with distilled water and adjusted to pH 7.4 with HC1). The test tubes 
were then rotamixed and incubated at room temperature (21°C) for 15 
minutes. Aliquots of 20ul of the exudate/buffer solution containing
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increasing concentrations of trypsin were applied sequentially by 
automatic pipette to the surface of a fibrin plate. After an 18 hour 
overnight incubation at 37°C the plates were read. The trypsin 
concentration at which lysis first appeared on the fibrin plate was 
considered to represent the point at which the trypsin binding 
capacity of the sample had been exceeded (Fig. 13).
The trypsin binding capacities of the 4 solutions used for 
intraperitoneal therapy (chapter 9) were also determined in a series 
of experiments, substituting lOOpl of each test solution for the 
peritoneal exudate. The 4 solutions examined were as follows 0.9% 
saline, human plasma protein solution+ (predominantly albumin, 45g/l, 
and devoid of antiproteases and other active plasma factors), fresh 
frozen plasma and aprotinin (5000KIU/ml 0.9% saline). The same unit 
of fresh frozen plasma was used for all studies reported in this 
thesis. Aliquots of 20jil of the test solution/buffer solution 
containing increasing concentrations of trypsin, ranging frcm 0 to 
450pg/100pl of test solution, were applied to the surface of a fibrin 
plate, incubated for 18 hours and read as above. Duplicate samples of 
lOOpl of each concentration of trypsin were also added to 1.1ml of 
BAPNA substrate/tris buffer solution, which had been pre-incubated at 
25°C for 5 minutes, and the absorbance changes recorded over one hour 
as detailed earlier.
^Scottish National Blood Transfusion Service Protein Fractionation 
Centre, Edinburgh.
^Glasgow and Vfest of Scotland Blood Transfusion Service, Law 
Hospital, Carluke.
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FIGURE 13.
Example of fibrin plate assay for the trypsin 
binding capacity. Increasing concentrations of 
trypsin/lOOul of sample are applied 
sequentially to the surface of the plate.
Lysis first appears at the 4th application of 
trypsin corresponding to a trypsin binding 
capacity of 40ug trypsin/lOOul. Concentrations 
exceeding the binding capacity are seen to give 
rise to progressively greater lysis areas.
Statistics
The results are expressed as means + s.e.m. Differences between 
paired samples were analysed using the Wilcoxcn rank sum test.
Results
Peritoneal exudate had the characteristics of slightly dilute 
serum and no difficulties were encountered with the assays of 
proteins, antiproteases, amylase and lipase, other than the 
requirement for p re-dilution of the samples prior to enzyme assay, 
because of the high activities recorded.
BAPNA-splitting activity
A standard curve was constructed to permit comparison of the 
absorbance change with the equivalent bovine trypsin concentration in 
jjg/ml (Fig. 14). This produced a linear plot (r = 0.999). BAPNA was 
confirmed to be a highly sensitive substrate detecting trypsin 
concentrations as low as ljjg/ml.
Difficulties were encountered with haemorrhagic peritoneal 
exudate samples obtained from patients with the most severe attacks 
of acute pancreatitis and from rats with experimental acute 
pancreatitis. Despite pre-dilution of the samples the absorbance 
often remained "off scale" at the wavelength of 405nm required for 
the measurement of p-nitroaniline and tryptic amidase activity could 
not, therefore, be assayed in such samples.
Trypsin 50jag/ml prepared in 0.9% saline showed no significant
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FIGURE 14.
Standard plot of BAPNA-splitting activity 
(tryptic amidase) against increasing trypsin 
concentrations. Activity is expressed as the 
change in absorbance units A405nm/hour.
loss of activity after storage for one month at -20°C (1.71 + 0.023 
vs 1.66 + 0.025, p = 0.42). Eight peritoneal exudate samples assayed 
before and after 6 months storage at -20°C showed an average 17% loss 
of activity (0.117 + 0.055 vs 0.097 + 0.038, p = 0.73).
Free proteolytic activity
The technique described by Wendt and co-workers utilised a 2% 
solution of fibrinogen for preparation of the fibrin plates'^. Using 
lOmls of solution instead of 20mls and a lower concentration of 
fibrinogen resulted in a larger areas of lysis, although associated 
with some asymmetry of the circular lysis zones (Table 23).
A 0.2% fibrinogen solution was adopted as the standard for the 
fibrin plates and this increased the sensitivity of the technique, 
trypsin concentrations as low as 2jng/ml being detected, resulting in 
areas of partial thickness lysis of less than 4irm diameter.
Increasing the trypsin concentrations between 5 and 50jjg/ml produced 
a linear relationship with the lysis area and allowed a standard 
curve to be plotted (r = 0.994) (Fig. 15).
Trypsin 50jjg/ml in lmmol CaC^ and lmmol HCl/litre of distilled 
water showed no significant loss of fibrinolytic activity during 
storage for one month at -20°C (mean lysis diameter 18.56 +_ 0.212 vs 
18.17 + 0.486, p = 0.26).
Trypsin binding capacity
Duplicate assays and assays repeated on successive days 
demonstrated the test to be reproducible, providing a measure of the
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TABLE 23.
Effect of varying volume and concentration 
of fibrinogen used in the preparation of 
the fibrin plates on lysis area.
Fibrinogen
concentration Volume
Lysis zone 
. diameters (mm)
Mean
diameter Area (
2% fibrinogen 20mls 10x10,
10x10,
10x10
10x10
10 78.5
2% fibrinogen lOmls 10x10,
10x10,
10x10
10x10
10 78.5
1% fibrinogen lOmls llxll,
12X12,
llxll
12x12
11.5 104
0.5% fibrinogen lOmls 14X15,
15X15,
14x14
16x17
15 177
0.25% fibrinogen lOmls 18x17,
18x17,
18x17
19x19
17.9 251
0.2% fibrinogen lOmls 18x18,
19X18,
19x18
20X18
18.5 269
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FIGURE 15.
Standard plot of fibrin plate lysis area 
against increasing trypsin concentrations.
trypsin binding capacity of the peritoneal exudates within the 
10 - 20pg increments of trypsin/lOOjil of sample studied. The results 
of these assays are detailed in chapter 10.
Examining the solutions used for intraperitoneal therapy, both 
fibrinolytic activity and tryptic amidase activity were found after 
the addition of 5jjg of trypsin to lOOjil of either saline or human 
plasma protein solution (Fig. 16). Adding increasing increments up to 
80jig of trypsin per IOOjjI of fresh frozen plasma produced no 
fibrinolysis after overnight incubation. Fibrinolysis was first 
recorded on the fibrin plate after the addition of lOOjjg of trypsin 
to IOOjjI of human fresh frozen plasma. Monitoring tryptic amidase 
activity, the absorbance change increased progressively on the 
addition of 5jjg and lOjjg increments of trypsin until 20jjg of trypsin 
had been added after which the increase in absorbance change recorded 
tended to level out. The absorbance change again increased sharply 
with the addition of lOOjjg of trypsin indicating that the inhibitory 
capacity had been overcome at this point (Fig. 16).
Aprotinin solution demonstrated the greatest trypsin binding 
capacity and was able to inhibit 400jjg of added trypsin, the binding 
capacity being overcome cn both the fibrin plate assay and by the 
appearance of tryptic amidase activity only after the addition of 
450jug of trypsin to IOOjjI of aprotinin solution (Fig. 16). The 
trypsin binding capacities of the 4 test solutions were, therefore, 
shown to be identical using either the fibrin plate assay or tryptic
amidase activity.
Aprotinin completely inhibited the tryptic amidase activity of
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FIGURE 16.
Trypsin binding capacity of the 4 test 
solutions according to their BAPNA-splitting 
activity on addition of bovine trypsin. 
Activity is expressed as the change in 
absorbance units A405l;ilri/hour. No measurable 
trypsin binding capacity was demonstrated 
for either saline or HPPS (human plasma 
protein solution). The binding capacity of 
FFP (fresh frozen plasma) was exceeded 
after 80ug trypsin/lOOul and for aprotinin 
after the addition of 4 00ug trypsin.
the added trypsin until its binding capacity was overcame, 
unlike fresh frozen plasma where the tryptic amidase activity of 
trypsin was shown to persist, presumably within the 
alpha2 macroglobulin complex, prior to the other antiprotease 
molecules being overwhelmed when fibrinolytic activity became 
evident.
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PART 4.
PREDICTION OF OUTCOME
When you can measure what you are speaking about, and can express it 
in numbers, you know something about it; but when you cannot measure 
it, when you cannot express it in numbers, your knowledge is of a 
meagre and unsatisfactory kind.
(Lord Kelvin, 1824-1907).
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CHAPTER 6. C-REACTIVE PROTEIN, ANTIPROTEASES AND COMPLEMENT FACTORS 
AS OBJECTIVE MARKERS OF SEVERITY IN ACUTE PANCREATITIS
Introduction
Laboratory prediction of severity in acute pancreatitis has 
become accepted since 1974 following Ranson's first description of a 
scoring system utilising 11 objective factors, each with significant 
prognostic value^O. imrie and co-workers subsequently published a 
simplified scoring system, modified for use in UK patients and based
1 cq
on 9 factors .
Multiple factor scoring systems reflect respiratory, renal, 
hepatic, and haematological disturbance in the body and provide seme 
clinically useful information, but may be influenced by the patient's 
pre-admission state and the aetiology of the attack. The greater age 
of the patients and the early, transient liver dysfunction commonly 
associated with gallstone pancreatitis results in such patients 
consistently scoring higher than an alcohol-associated attack of 
equivalent severity. This has lead to modifications being made to 
both major scoring systems; Ranson now describes two different 
scoring systems, one for gallstone and one for non-gallstone 
attacks'^ while the Glasgow system, which has been simplified to 
include only 8 factorsremains applicable to both common 
aetiologies of acute pancreatitis .
Multiple factor scoring systems have been widely used in the 
study of patients with acute pancreatitis, providing stratification 
of the risk of death or major morbidity and comparison of patients
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between different centres. Their complexity, however, probably 
limits their routine use in daily clinical practice. Neither system 
can be applied sequentially to monitor the course of the attack which 
might usefully assess the response to therapy or provide warnirg of a 
developing late complication.
Other possibly useful indicators of severity in acute 
pancreatitis include complement factors^'52,110,199^ 
serum antiproteases alpha^acroglobul in and alpha^antiprotease^' 228. 
The value of C-reactive protein (CRP) in acute pancreatitis was first 
suggested from Leeds in 1984^^ and subsequently by others^.
A comparative study examining the ability of multiple factor 
scoring systems and these individual biochemical factors to predict 
outcome early in the course of the illness has not been reported, 
although a persistently high CRP concentration at the end of the 
first week of the illness appears to identify patients at risk of
developing a late c o m p l i c a t i o n ^ ^ .
The aims of the current study were to examine prospectively the 
value of sequential measurement of five complement factors, the two 
major antiproteases and the non-specific inflammatory marker CRP 
firstly, as early predictors of outcome in acute pancreatitis 
relative to clinical assessment and the multiple factor scoring 
systems^69,290, secondly in monitoring the course of the disease.
Methods
Acute pancreatitis was diagnosed initially in all patients on 
the basis of a serum amylase >1200IU/1 (normal range 70-300HJ/1,
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Phadebas, Pharmacia Diagnostics AB, Uppsala, Sweden) and a 
compatible clinical picture-^.
The patients studied fell into two groups; 30 patients had 
complement factors assayed and 72 patients had antiproteases and CRP 
assayed. The first 50 patients having antiproteases and CRP measured 
were studied consecutively, the remaining 22 patients were selected 
for study from the next 60 patients admitted, having been judged as 
having moderate or severe pancreatitis on the basis of a clinical 
assessment on admission (chapter 4).
Clinical assessment was repeated at 24 and 48 hours, those 
judged to have severe pancreatitis on assessment being considered at 
risk of death or developing a complication (see below).
The details of the patients' age and sex, aetiologies and 
complications are shown in table 24. Complicated attacks of acute 
pancreatitis were defined as resulting in death or a local pancreatic 
corplication; abscess, pseudocyst or necrosis (defined as necrotic 
pancreatic and/or peripancreatic tissue recovered at laparotomy or 
post mortem). Nine additional patients manifested acute respiratory 
insufficiency defined as a p02 <60mmHg, requiring O 2  by mask for 
more than 5 consecutive days (mean 8 days) and were included. Each 
had a prolonged, clinically severe illness with a mean hospital stay 
of 20 days although ultrasound scanning in each failed to demonstrate 
the development of local pancreatic complications.
Multiple factor scoring systems
Laboratory data was collected prospectively frcm all patients
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TABLE 24.
Comparison of age, sex, aetiology and 
outcome from acute pancreatitis in patients 
having measurement of complement factors or 
C-reactive protein and antiproteases.
Complement factors 
(n = 30)
C-reactive protein 
& antiproteases 
(n = 72)
Sex 21 M : 9 F
Mean age (years) 49.3 + 3
Aetiology: gallstones 14 (47%)
alcohol 10 (33%)
other 2 (7 %)
unknown 4 (13%)
gallstones/alcohol -
Mean prognostic factor 
score: Glasgow (8 factors) 2.3 + 0.36
Ranson (11 factors) 2.7 + 0.43
Complicated attacks: 9 (30%)
fulminant pancreatitis 1
necrosis 4
pseudocyst 1
respiratory insufficiency 3
Fatal 2 (7%)
47 M : 25 F
52.2 ± 2.1
24 (33%)
23 (32%)
8 (11%)*
15 (21%)
2 (3%)
2.1 ± 0.22 
2.8 ± 0.28
25 (35%)
5
7
4
9
10 (14%)
familial hyperlipidaemia - 2.
hyperlipidaemia/alcohol - 2, familial hyperlipidaemia - 1, 
viral - 1, trauma - 1, steroids - 1, ERCI* - 1, hypothermia - 1.
to permit scoring of both the Ranson and Glasgow multiple 
factor systems269'290 (Table 27). As the aetiology of the attack was 
not usually apparent on admission the original Ranson scoring system 
has been used throughout.
Experimental methods
Blood samples were taken on the day of admission (day 1) and 
each morning thereafter until day 8 or until discharge if sooner. 
Samples were centrifuged and the supernatants frozen within 60 
minutes of venepuncture.
Complement factors were measured on plasma samples stored at 
-60°C until analysis. C3 and C4 were measured by radial 
immunodiffusion (Behring Diagnostics, Hounslow, Middlesex, UK) and 
factor B by immunodiffusion using an in-house prepared agar plate 
containing anti-human properidin factor B (Atlantic Antibodies, 
Winnersh, Berkshire, UK). Clq and C3d were measured on a Beckman ICS 
nephelcmeter using anti-human Clq (Atlantic Antibodies) and 
anti-human C3d (Dako Ltd., High Wycombe, Buckinghamshire, UK) 
according to the method of Vergani and co-workers .
Antiproteases and CRP were measured cn serum samples stored at 
-20°C prior to analysis. Alpha^acroglobulin and alpha^antiprotease 
were measured by turbidimetric immunoassay (Atlantic Antibodies). CRP 
was measured by a fluorescence polarisation immunoassay (Abbot TDX, 
Abbot Laboratories Ltd., Wokingham, Berkshire, UK).
Normal complement and acute phase protein ranges were 
established on 30 and 100 normal controls respectively.
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Statistics
Results are expressed as means + s.e.m. Statistical analysis 
was performed by the Mann-Whitney U test. The diagnostic performance 
of the various tests and scoring systems have been analysed by 
sensitivity, specificity, predictive value and efficiency-^.
Results
Complement factors
Complement factors C3 and factor B concentrations showed an 
early fall followed by a sustained rise during the course of the 
illness in both mild and complicated attacks, factor B rising above 
the normal range in both groups of patients (Figs. 17,18). The 
individual results showed a wide scatter and no difference emerged 
between mild and complicated attacks. C4 concentrations showed no 
significant changes in either mild or complicated attacks through the 
course of the illness (Fig. 19). Clq levels fell during the attack, 
falling below the normal range in complicated attacks, but these 
differences failed to reach statistical significance (Fig.20). C3d 
levels (a product of C3 activation) were increased in 33% of patients 
at sane time during their illness, thus indicating carpi onent 
activation, but this could not be related to the severity of the 
attack juried clinically or on multiple factor scoring (Fig. 21).
Antiproteases
Alpha2macroglobulin levels fell during the attack with levels
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FIGURE 17.
Sequential changes of complement factor C3 
during the course of acute pancreatitis in 21 
patients with an uncomplicated outcome (mild) 
and 9 with a complicated outcome (comps).
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FIGURE 18.
Sequential changes of complement factor B 
during the course of acute pancreatitis in 21 
patients with an uncomplicated outcome (mild) 
and 9 with a complicated outcome (comps).
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FIGURE 19.
Sequential changes of complement factor C4 
during the course of acute pancreatitis in 21 
patient with an uncomplicated outcome (mild) 
and 9 with a complicated outcome (comps).
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FIGURE 20.
Sequential changes of complement factor Clq 
during the course of acute pancreatitis in 21 
patients with an uncomplicated outcome (mild) 
and 9 with a complicated outcome (comps).
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FIGURE 21.
Sequential changes of complement factor C3d 
during the course of acute pancreatitis in 21 
patients with an uncomplicated outcome (mild) 
and 9 with a complicated outcome (comps).
significantly lower in complicated attacks between days 3 and 8 
(Fig. 22). Alpha^antiprotease levels rose during the attack in both 
mild and complicated attacks with levels significantly higher in 
complicated attacks between days 4 and 8 (Fig. 23).
C-reactive protein
CRP levels provided the best discrimination, with levels 
markedly higher and persisting for longer in those with complicated 
attacks, these differences being highly significant frcm day 2 (the 
morning after admission) to day 8 (Fig. 24). CRP, therefore, was 
shown to be the best of all the factors tested for sequential 
monitoring of acute pancreatitis.
Eight of the 11 patients subsequently developing pancreatic 
necrosis or pseudocyst had a peak CRP concentration of >300mg/l. 
However, the mean CRP concentration did not distinguish these 11 
patients (6 of whan ultimately required surgery) from 9 patients with 
acute respiratory insufficiency, all of whom had a severe illness but 
settled without surgery (Fig. 25). CRP levels did not predict death 
in 3 elderly patients dying of shock on the second day of admission.
The CRP concentration providing the best discrimination 
(combining the highest sensitivity and specificity) was determined 
both for the peak CRP (occurring between the 2nd and 4th day of 
illness) and for the concentration at the end of the first week. The 
best discrimination was found with a peak CRP of ^210mg/l and, at 
the end of the first week of ^120mg/l (Figs. 26,27). Applying these 
levels to the data permitted comparison of the prognostic value of
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FIGURE 22.
Sequential changes of alpha2macroglobulin 
during the course of acute pancreatitis in 47 
patients with an uncomplicated outcome (mild) 
and in 25 with a complicated outcome (comps), 
* p <0.05, ** p <0.01, *** p <0.001.
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Sequential changes of alpha^antiprotease during 
the course of acute pancreatitis in 4 7 patients 
with an uncomplicated outcome (mild) and in 25 
with a complicated outcome (comps), * p <0.05, 
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Sequential changes of C-reactive protein during 
the course of acute pancreatitis in 47 patients 
with an uncomplicated outcome (mild) and in 25 
with a complicated outcome (comps) ,
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FIGURE 25.
Sequential changes of C-reactive protein in 11 
patients developing local pancreatic 
complications (necrosis) and 9 developing acute 
respiratory insufficiency (resp fail).
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Scattergram showing peak C-reactive protein 
concentrations (during day 2 - 4 )  in patients 
with an uncomplicated outcome (mild) and those 
with a complicated or fatal outcome.
C-
RE
AC
TI
VE
 
PR
OT
EI
N 
Cm
g/
L>
450-1
400-
350-
300-
+ +
200-
150-
100-
0 COMPLICATEDMILD
/FATAL
FIGURE 27.
Scattergram showing the C-reactive protein 
concentration on day 7 in patients with an 
uncomplicated outcome (mild) and those with a 
complicated or fatal outcome.
CRP measurement with clinical assessment and the multiple 
factor scoring systems.
Table 25 shows both the peak and seven day CRP concentrations 
to be of similar accuracy to either the Ranson or Glasgow multiple 
factor scoring systems. When the aetiology of the attack was 
considered, CRP measurement appeared to be slightly better than 
either of the multiple factor scoring systems for attacks associated 
with gallstones but slightly less good for alcohol-associated attacks 
(Table 26).
Although the proportion of attacks correctly predicted by 
clinical assessment approached that of the multiple factor scoring 
systems, closer examination of the data reveals that while almost all 
mild attacks were identified correctly, fewer than half the patients 
with complicated attacks were correctly predicted, even at 48 hours.
Discussion
Clinical assessment of the severity and likely outcome of acute 
pancreatitis early in the course of the attack is notoriously 
unreliable. The accuracy of clinical assessment appears to improve 
with time and one study suggested that 83% of severe attacks were 
correctly predicted 48 hours after admission'^. Our own data have 
demonstrated that while all patients subsequently dying were 
correctly identified as having a severe attack at 48 hours, the 
overall accuracy in predicting complicated attacks was poor at 46%. 
Clinical assessment, although an essential component of the overall 
monitoring and management of such patients, remains imprecise,
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TABLE 25.
Comparison of the "peak" and 117th day” 
C-reactive protein concentrations with 
prediction of outcome by clinical 
assessment and multiple factor scoring 
systems.
Predictive Predictive %
Parameter Sensitivity Specificity value +ve value -ve Correct
Peak CRP* 
(>210mg/l)
83% 85% 74% 91% 85%
7th day CRP 
(>120mg/l)
90% 85% 75% 94% 87%
Glasgow score 
(8 factors)
76% 83% 70% 87% 81%
Ranson score 
(11 factors)
88% 79% 69% 93% 82%
Clinical assessment 
(on admission)
37.5% 96% 82% 75% 76%
Clinical assessment 46% 98% 92% 78% 80%
(at 48 hours)
KEY:
Peak *= highest concentration on 2nd, 3rd or 4th day.
Sensitivity « % of all complicated attacks predicted correctly by test. 
Specificity * % of all mild attacks predicted correctly by test.
PV +ve *= % complicated attacks among all predicted severe by test.
PV -ve = % mild attacks among all predicted mild by test.
% Correct «= % correctly classified.
TABLE 26.
Comparison of C-reactive protein 
concentration and multiple factor scoring 
systems in gallstone and alcohol-associated 
attacks.
Predictive Predictive %
Parameter Sensitivity Specificity value +ve value -ve Correct
Gallstone
Peak CRP (>2l0mg/l) 100% 79% 81% 92% 87.5%
7 Day CRP (>120rog/l) 100% 100% 100% 100% 100%
Glasgow score 80% 71% 67% 83% 75%
Ranson score 90% 71% 69% 91% 79%
C/A on admission* 33% 86% 60% 67% 65%
C/A at 4 8 hours 44.5% 93% 80% 72% 74%
Peak CRP (>210mg/l) 100% 87% 75% 100% 90%
7 Day CRP (>120mg/l) 67% 86% 100% 88% 82%
Glasgow score 67% 100% 100% 92% 93%
Ranson score 83% 96% 83% 96% 93%
C/A on admission 20% 100% 100% 84.5% 85%
C/A at 48 hours 20% 100% 100% 84.5% 85%
C/A - clinical assessment. 
KEY as for table 24.
subjective and non-reproducible and the search continues for an 
ideal marker of severity in this condition.
Complement factors showed no relationship to the severity of an 
attack and their measurement was therefore discontinued after 30 
patients had been analysed. Other workers have found complement 
levels, particularly of C3, to be of value in the prediction of 
outcome in acute pancreatitis20'52'110'299. Whicher and co-workers 
found, as in the current study, a wide scatter of results and no 
apparent relationship between the presence or absence of complement 
activation (as indicated by an elevated C3d concentration) and 
severity of the attack2^9.
The most premising of the complement factors studied was Clq.
This is the first component of the classical complement pathway and
its apparent consumption in acute pancreatitis is difficult to
explain. Complement activation in acute pancreatitis is thought to
occur by a direct attack on C3 by trypsin2^2 or, as Foulis and
co-workers have suggested, by the alternative complement pathway220.
Neither should lead to consumption of the early factors of the
classical complement pathway. CRP binds at sites of injury within the
body and once ccmplexed is a potent activator of the classical
974camplement pathway beginning with Clq^ . The fall m  Clq which 
occurs in the more severe cases may, therefore, be associated with 
this mechanism.
Sequential measurement of the antiproteases appeared more 
premising, particularly alpl^macroglobulin which showed useful 
discrimination between mild and complicated attacks.
166
Alpha2 macroglobulin is most probably the key intravascular 
antiprotease. It binds irreversibly with activated proteolytic 
enzymes leading to a conformational change within the antiprotease 
molecule and its rapid uptake by the macrophages of the 
reticulo-endothelial system. Alpha2macroglobulin does not act as an 
acute phase reactant since its synthesis does not increase in 
response to injury. The low levels of alpha2 macroglobulin seen in the 
most severe attacks of acute pancreatitis suggest its ccnsurrpticn and 
may reflect the amount of proteolytic enzyme activation occurring. A 
proportion of the measured alpha2 macroglobulin in serum is in a 
ccmplexed form and unavailable for protease binding204. The 
importance of low levels of this antiprotease is as yet unclear, but 
may have clinical relevance.
Alpha^antiprotease acts as an acute phase reactant, levels 
rising severalfold during the illness. The net effect of this is that 
the overall capacity of serum to bind trypsin and other activated 
proteolytic enzymes increases during the course of the a t t a c k . The 
binding between alpha^antiprotease and trypsin is reversible, this 
complex appearing to dissociate, the trypsin being taken up by
o /r  /
alpha2 macroglobulin prior to its clearance from the body 0 . 
Therefore, although the total trypsin binding capacity of serum may 
increase, the fall in alph^raacroglobulin may be a rate limiting step 
to the clearance of proteases frcm the circulation. Clearance of 
trypsin-alpha2macroglobulin complexes by the reticulo-endothelial 
system may also be depressed in severe acute pancreatitis^0-1- and as 
these complexes retain proteolytic activity100'148'302, this might be
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pathogenic in man.
A recent controlled clinical trial has studied the therapeutic 
benefit of administration of fresh frozen plasm in patients with 
acute pancreatitis. This was able to maintain alph^macroglobulin 
levels in treated patients but produced no clear evidence of a 
beneficial effect on outcome, although too few patients with severe 
illness had been included to confirm this statistically^®®.
In the current study the CRP concentration provided the best 
discrimination of all the factors investigated. CRP is a protein of 
uncertain role in the body. It acts as a non-specific inflammatory 
marker and monitoring has been shown to be of clinical value in a
0 7 4
number of conditions . CRP is usually present in low concentrations 
in the bloodstream. It is synthesised in hepatocytes, elevated serum 
levels being detected about 8 hours after injury and reaching a peak 
seme 24-48 hours later. The delay until peak levels are attained 
probably accounts for its failure to detect early death in 3 patients 
in this study.
Buchler and co-workers, on the basis of a rather limited study
of 35 patients, have suggested that a CRP concentration of >100mg/l
52correctly predicts pancreatic necrosis in 95% of cases , these 
patients having necrosis confirmed at subsequent laparotomy. In the 
current study this level would result in 57 (79%) of the 72 patients 
reported here having "pancreatic necrosis" predicted. While a cut-off 
level of 210mg/l in the current study (more than twice that described 
by Buchler's group) identifies a group of patients with severe 
pancreatitis, it was clearly not specific for the presence of
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pancreatic necrosis. While a number of the patients in the 
severe group may have had unsuspected pancreatic necrosis manifesting 
only as acute respiratory insufficiency, the clinical improvement 
which occurred without recourse to surgery suggests that Buchler1 s 
group may be operating unnecessarily in seme patients.
The assay for CRP is quick and simple and the current study has 
demonstrated that measurement of CRP is at least as accurate as 
either of the multiple factor scoring systems and probably better for 
gallstone related attacks, which presently account for over 50% of 
patients in the UK. In practice a peak CRP of 300mg/l and/or 
persistent elevation at the end of the first week, as was originally 
shown by the Leeds group , provides useful warning of the 
development of a local pancreatic complication. Such a test would 
clearly be of clinical value in selecting patients for investigation 
by expensive imaging techniques such as contrast-enhanced CT 
scanning, to select those patients who might usefully be monitored in 
an intensive care unit or those in whom parenteral nutrition may be 
indicated if the attack appears to be slow in settling. The 
complexity of the multiple factor scoring systems has probably 
limited their routine use and measurement of a single factor, such as 
CRP, appears more likely to be adopted into daily clinical practice.
169
CHAPTER 7. COMPARATIVE STUDY OF PREDICTION OF SEVERITY IN ACUTE 
PANCREATITIS BY CLINICAL ASSESSMENT, MULTIPLE FACTOR 
SCORING SYSTEMS AND DIAGNOSTIC PERITONEAL LAVAGE.
Introduction
While the majority of attacks of acute pancreatitis are mild 
and resolve quickly following admission to hospital, seme 20% of 
attacks give rise to complications which may be fatal, necessitate 
surgery or merely prolong the hospital stay. Sane of these patients 
will be admitted with an overtly severe illness but others may appear 
to have a mild attack on admission only to deteriorate later despite 
full supportive therapy. A further group may appear to have a mild 
attack which appears to settle but are subsequently found, perhaps 
after discharge, to have developed a carpiication such as a 
pancreatic abscess or pseudocyst.
Attempts have been made to identify these patients early in the 
course of their illness, the hope being that earlier, more aggressive 
treatment of this subgroup might reduce the mortality rate. The aim 
of the current study was to evaluate clinical assessment and the 
objective severity scoring systems in the 160 patients documented in 
the current trial, to determine their value in identifying such 
patients.
Methods
Clinical assessment
The results of the initial clinical assessment were recorded in
<
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the patient's proforma and this assessment was repeated on the next 
two mornings (approximately 24 and 48 hours after admission) (chapter 
4). This assessment was purely subjective and was made without 
reference to the biochemistry or other available laboratory results.
The assessment of an attack as severe took into account the 
presence or absence of shock, the adequacy of the peripheral 
perfusion and urine output, the presence of respiratory distress and 
on the degree of abdominal tenderness, distension and ileus. Patients 
were also considered to have severe acute pancreatitis if they 
developed body wall staining. In addition to the overall clinical 
assessment the presence or absence of each of these individual 
factors was recorded in every patient at their initial assessment.
Multiple factor scoring systems
Biochemical, haematological and the appropriate clinical data
were recorded prospectively on all the patients studied to permit
2fiQ 290scoring of the Glasgow , Ranson , modified Ranson (for gallstone-
2R7 24associated attacks) and Bank and Wise scoring systems . The
details of the prognostic factors comprising each of the systems are
detailed in tables 27 and 28. The equivalent SI. and local units used
for scoring the Ranson scoring systems are detailed below table 27.
The enzyme units used for LDH and SGOT in the Ranson scoring systems
were approximately equivalent to LDH = 600U/1 and AST = 100U/1 used
for the original Glasgow classification159 (Imrie CW, personal
communication) although the most recent modification of this scoring
system, as used here, raised the AST/ALT cut-off to >200 U/l^59.
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TABLE 27.
Objective prognostic factors comprising the 
Ranson and Glasgow multiple factor scoring 
systems.
Ranson 'Modified Ranson Glasgow
On admission: On admission: Within 48 hours:
Age >55 years 
WCC >16000/mm3 
LDH >350 IU/1 
SGOT >250 SFU% 
Glucose >200mg%
Within 48 hours:
Hct fall >10%
BUN rise >5mg%
Calcium <8mg%
p02 <60mmHg
Base deficit >4mEq/l
Fluid >6000ml
sequestration
Age >70 years 
WCC >18000/mm3 
LDH >400 IU/1 
SGOT >250 SFU% 
Glucose >220mg%
Within 48 hours:
Hct fall >10%
BUN rise >2mg% 
Calcium <8mg%
Base deficit >5mEq/l 
Fluid >4000ml
sequestration
Albumin <32 g/1 
WCC >15000/mm 
LDH >600 U/l 
AST/ALT >200 U/l 
Glucose >10mmol/l 
Urea >16mmol/l 
Calcium <2mmol/l 
p02 <60mmHg
Any scoring system >3 factors positive = severe disease.
Key and conversion to equivalent SI. or local units:
"Modified Ranson, only for gallstone associated attacks; WCC *= white 
cell count; LDH = lactate dehydrogenase, 350 IU/1 equivalent t;o 600 U/l, 
400 IU/1 equivalent to 700 U/l; SGOT = AST, 250 SFU equivalent to 
120 U/l; Glucose 200mg% equivalent to 10mrool/l, 220mg% equivalent to 
llmmol/1; Hct = haematocrit; BUN =• blood urea nitrogen, 5mg% equivalent 
to 0.9mmol/l, 2mg% equivalent to 0.4mmol/l; Calcium 8mg% equivalent 
to 2mmol/l.
TABLE 28.
Prognostic signs comprising the clinical 
criteria of Bank and frise.
System Prognostic signs
Cardiac Shock, tachycardia >130/min, arrhythmia, ECG changes.
Pulmonary Dyspnoea, rales, p02 <60mmHg, ARDS.
Renal Urine output <50ml/hour, rising BUN and/or creatinine.
Metabolic Low or falling calcium, pH, albumin.
Haematological Falling haematocrit, DIC (low platelets, 
split products).
Neurological Irritability, confusion, localising signs
Haemorrhagic
disease
On signs or peritoneal tap.
Tense distension Severe ileus, fluid ++.
> 1 factor positive = severe (potentially lethal) disease.
KEY:
ARDS = adult respiratory distress syndrome; DIC «= disseminated 
intravascular coagulation.
The time at which the laboratory results routinely became 
available to the ward or when clinical criteria were first considered 
positive was recorded to permit calculation of the delay from 
admission to the prediction of severity being made.
Diagnostic peritoneal lavage
Of the 25 patients randomised to receive intraperitoneal 
therapy with aprotinin, one refused to consent to peritoneal 
cannulation. Two other patients were excluded because of atypical 
findings on peritoneal aspiration. One was discovered to have a 
haemoperitoneum and at laparotomy was found to have had a pancreatic 
transection secondary to trauma. The other patient had foul smelling 
haemorrhagic peritoneal exudate and at laparotomy was found to have 
extensive small bowel infarction due to mesenteric venous thrombosis.
Diagnostic peritoneal lavage was performed in one additional 
patient who presented over 72 hours after the onset of pain and who 
was, therefore, excluded from the formal trial. Thus 23 patients 
underwent diagnostic peritoneal lavage and were available for 
analysis.
After peritoneal cannulation the colour and volume of any 
peritoneal exudate and the return fluid following a single litre 
saline lavage were recorded, the colour having been compared against 
a standard colour chart226(Fig. 11). Severe pancreatitis was 
predicted if at least 20mls of exudate was present on aspiration, if 
the exudate was dark coloured (6 or more on the colour chart), or if 
the return fluid was darker than mid-straw colour (4 or more on the
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colour chart)226,234  ^<piie delay from admission to the prediction of 
severity was recorded.
Outcome of attacks
Complicated attacks of acute pancreatitis were defined as those 
causing death or a major complication (chapter 4).
Patients
The aetiology of the attacks was determined as outlined in 
chapter 4. Of the 160 attacks documented, 2 were excluded from 
consideration here because of an alternative diagnosis made on 
diagnostic peritoneal lavage. One further patient was excluded as 
death was considered more likely to be due to rupture of an abdominal 
aortic aneurysm, although this was not confirmed as permission for 
post mortem was not granted by the family.
Clinical assessment and the objective severity scoring systems 
have been analysed in 157 patients overall. Twelve of these patients 
had a fatal outcome recorded and a further 26 had a complicated 
clinical outcome but survived. In the remaining 119 patients the 
attack ran a mild, uncomplicated course.
Statistical analysis
Statistical analysis was conducted by Fisher's exact test, Chi
square test and the Mann-Whitney U test. The diagnostic performance
119of the scoring systems have been analysed as in chapter 6
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Results
Clinical assessment
Clinical assessment at 24 and 48 hours provided the highest 
overall accuracy of all the methods tested (Table 29). On the initial 
clinical assessment only two of the patients with an uncomplicated 
outcome had been incorrectly predicted to have a severe attack, and 
by 24 and 48 hours none of the patients with an uncomplicated outccme 
were wrongly predicted as severe.
On admission only 13 of the 38 patients with a fatal or 
complicated outcome were correctly identified by clinical assessment, 
rising to 18 patients at 24 hours and, therefore, the sensitivity of 
clinical assessment was low. Of the 20 patients with a complicated 
outccme incorrectly predicted at 24 hours, 10 had been predicted as 
moderate and 10 as having a mild attack. The complications recorded 
in these patients comprised respiratory insufficiency in 10, 
pseudocysts in 5, abscesses in 2, pancreatic necrosis in 2 and 
septicaemia in one. Amongst these 20 patients, gallstones were the 
commonest underlying aetiological factor accounting for 8 attacks.
Clinical assessment on admission failed to predict a 
complicated outccme in 4 patients who subsequently died although by 
24 and 48 hours only one of the patients dying had been incorrectly 
identified.
Table 30 details the incidence and discriminatory value of the 
individual clinical factors recorded on admission, many being 
recorded only infrequently amongst the patients with an ultimately 
complicated or fatal outcome.
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TABLE 29.
Analysis of clinical assessment, multiple 
factor scoring systems and diagnostic 
peritoneal lavage in the prediction of 
outcome from acute pancreatitis.
Sensitivity Specificity
Predictive 
value +ve
Predictive 
value -ve
%
Correct
Clinical
assessment:
On admission 34% 98% 87% 83% 83%
At 24 hours 47% 100% 100% 85.5% 87%
At 48 hours 44% 100% 100% 85.5% 87%
Glasgow 71% 88% 66% 90.5% 84%
Ranson 87% 70.5% 48.5% 94% 74.5%
Modified Ranson* 81.5% 79% 55% 93% 80%
Bank & Wise 100% 12% 26.5% 100% 33%
Diagnostic 67% 62.5% 77% 50% 65%
peritoneal lavage
KEY:
modified for attacks associated with gallstones 4- standard Ranson score 
for other aetiological factors.
Sensitivity «= % of all complicated attacks predicted correctly by test. 
Specificity «= % of all mild attacks predicted correctly by test.
PV +ve *» % complicated attacks among all predicted severe by test.
PV -ve *= % mild attacks among all predicted mild by test.
% Correct *= % correctly classified.
TABLE 30.
Comparison of the value of individual 
clinical factors recorded at the initial 
assessment in predicting the outcome from 
acute pancreatitis.
Clinical parameter
Fatal or
complicated
outcome
Uncomp1icated 
outcome P value*
Pulse rate >i20/min 2 0 NS
Systolic BP <100mmHg 3 1 P <0.05
Temperature >38°C 3 1 P <0.05
Respiratory rate >30/min 3 1 P <0.05
Peripheral shutdown 14 1 P <0.001
Clammy skin 18 9 P <0.001
Peritonism/ 
abdominal distension
13 4 P <0.001
Absent bowel sounds 8 2 P <0.001
Body wall staining 1 0 NS
Chi square or Fisher's exact test as appropriate.
Glasgow scoring system
Fourteen patients with an uncomplicated outcome were wrongly 
predicted as having a severe attack, gallstones being the underlying 
aetiological factor in 11 (79%) of these attacks. Amongst the 11 
cases with a complicated outcome incorrectly predicted as mild were 4 
patients developing a pseudocyst, 4 developing respiratory 
insufficiency, 2 developing septicaemia and one a pancreatic abscess. 
All 12 patients with a fatal outcome were correctly predicted before 
death.
Original Ranson system
Thirty-five patients with an uncomplicated outcome were wrongly 
predicted as having a severe attack, gallstones accounting for 24 
(69%) of these attacks. Only 5 patients with a complicated outcome 
were wrongly predicted as mild, the attacks being complicated by a 
pseudocyst in 2 patients, respiratory insufficiency in 2, septicaemia 
in one and an abscess in one. All 12 patients with a fatal outcome 
were correctly predicted before death.
Modified Ranson system
When the modified Ranson scoring system is substituted for 
those attacks associated with gallstones, the overall accuracy of the 
system improved (Table 29). Twenty-five attacks with an uncomplicated 
outcome were wrongly predicted as severe, including 14 attacks 
associated with gallstones. Seven patients with a complicated outcome
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were wrongly predicted as mild, respiratory insufficiency developing 
in 4 attacks, pseudocysts in 2 attacks and septicaemia in one. All 12 
fatal attacks were correctly predicted before death.
Bank and Wise system
This performed poorly in the patients studied. Although all 
with a complicated outcome were correctly predicted as severe, so too 
were 105 of the 119 patients with an uncomplicated outcome. This 
resulted in poor specificity and low overall accuracy (Table 29).
Diagnostic peritoneal lavage
Three of the 8 patients with an uncomplicated outcome were 
wrongly predicted as severe. These attacks were all associated with 
alcohol abuse and had been judged as severe based on the presence of 
28mls of haemorrhagic free fluid in one patient, and on the presence 
of dark straw coloured return fluid (colour chart nos. 4 and 5 
respectively) after a single litre saline peritoneal lavage in the 
other 2 patients.
Five of the 15 patients with a fatal or complicated outcome 
were wrongly predicted as mild. One of these patients dying of 
pancreatitis secondary to hypothermia, had no free fluid on 
peritoneal cannulation. Of the others predicted as having mild 
pancreatitis, 3 developed respiratory insufficiency and one a 
pseudocyst, the aetiologies underlying the attacks being attributed 
to gallstones (2), unknown (1) and hyperlipidaemia (1).
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Comparison between alcohol and gallstones
Table 31 compares multiple factor scoring systems and 
diagnostic peritoneal lavage in attacks associated with either 
alcohol or gallstones. The original Ranson system performed best for 
attacks associated with alcohol abuse whereas either the Glasgow or 
modified Ranson systems appeared best for gallstone-associated 
attacks. Multiple factor scoring systems performed better overall for 
attacks associated with alcohol abuse. Diagnostic peritoneal lavage 
appeared to perform less well for alcohol-associated attacks although 
this may partly reflect the smaller number of patients studied.
Delay to prediction.
The overall delay to the prediction of severity by the multiple 
factor scoring systems was always greater than for diagnostic 
peritoneal lavage, although for patients who ultimately died, these 
differences were not significant. The analysis of the delays in 
prediction have been detailed in table 32. The differences between 
the Glasgow and Ranson scoring systems were minor, 14 and 13 patients 
respectively had their prediction of severity delayed over 48 hours 
post-admission.
The Bank and Wise system provided an answer sooner than either 
the Glasgow or Ranson scoring systems, both in attacks associated 
with a complicated or fatal outcome, but in attacks with an 
uncomplicated outcome there were no significant differences. Only 9 
patients had their prediction of severity delayed beyond 48 hours.
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TABLE 31.
Comparison of multiple factor scoring 
systems and diagnostic peritoneal lavage 
for prediction of outcome in gallstone and 
alcohol-associated attacks of acute 
pancreatitis.
Sensitivity Specificity
Predictive 
value +ve
Predictive 
value -ve
%
Correct
Gallstone
Glasgow 64% 78% 47% 88% 75%
Ranson 86% 52% 35% 92% 60%
Modified Ranson 71% 70% 42% 89% 70%
Diagnostic 
peritoneal lavage
50% 100% 100% 60% 71.5%
Glasgow 57% 98% 80% 93% 92%
Ranson 86% 98% 86% 98% 96%
Diagnostic 
peritoneal lavage
100% 25% 62.5% 100% 67%
KEY as for table 29.
TABLE 32.
Delay from admission to prediction of 
severity by multiple factor scoring systems 
and by diagnostic peritoneal lavage.
Delay to prediction (hours) by outcome of attack
Mild
attacks
Complicated
attacks
Fatal
attacks
All
attacks
Glasgow 22 (2-60) 28 (6-56) 26 (9-72) 24 (2-72)'
Ranson 24 (0-60) 27.5 (2-56) 22.5 (1-72) 24 (0-72)'
Modified Ranson 26.5 (0-60) 28.5 (6-56) 22.5 (1-72) 27 (0-72)'
Bank and Wise 24 (0-60) 12 (0-48) 7.5 (0-56) 20 (0-60)*
Diagnostic 
peritoneal lavage
5 (3-8) 8.5 (4-31) 17 (9-27) 8.5 (3-31)*
KEY:
Values are medians (range); * no significant difference between Glasgow, 
Ranson and modified Ranson; * significantly different from modified 
Ranson and diagnostic peritoneal lavage (p <0.01); * significantly 
different from Ranson and Bank and Wise (p <0.01), and from Glasgow 
and modified Ranson (p <0.001).
Discussion
A problem faced during any attempt to compare predictive 
systems is how to define the outcome of an attack (Table 33). Many of 
the endpoints quoted are vague or ill-defined, and, for example, the 
length of ICU or hospital stay may depend on many factors including 
the policy of the individual consultant, the availability of such 
beds and the demand for such beds from other patients.
Clinical assessment of the severity and likely outcome of an 
attack of acute pancreatitis early in the course of an attack is 
notoriously unreliable. The accuracy of clinical assessment in 
identifying attacks with a complicated outcome has been reported to 
improve with time and one study has suggested that 83% of such 
attacks were correctly predicted 48 hours after admission22**. The 
data reported here do not support this. While clinical assessment 
appeared to provide the most accurate overall prediction of outcome, 
the sensitivity remains low and even at 48 hours is only 44%, thus 
clinical assessment performs poorly in its most important function, 
that of predicting complicated and potentially fatal attacks. 
Individual clinical parameters, although showing a significant 
difference between mild and complicated attacks, were each present in 
too few patients to be of overall value.
Of the multiple factor scoring systems the Glasgow scoring 
system was most accurate overall, although its sensitivity was lower 
than for either of the Ranson scoring systems. The Ranson scoring 
systems appeared to be better in identifying attacks with a 
complicated outcome but at the cost of a lower specificity. The
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TABLE 33.
Comparison of the definitions for severe 
attacks of acute pancreatitis used in the 
description and analysis of different 
scoring systems.
Authors Year Mild attack Severe attack
Ranson et al. 1974
Ranson and 1977
Pasternack
Imrie et al. 1978 
Osborne et al. 1981
No serious illness
Recovered without 
major life- 
threatening 
complications
Not stated
Symptoms settled 
on conservative 
treatment
Seriously ill 
Death
Requiring >7 days 
in ICU 
Death
Not stated
Symptoms and signs 
failed to settle
McMahon et al. 1980 Not stated Hospital stay >14 days 
Severe complication: 
renal/respiratory 
failure
pancreatic abscess 
Death
Mayer and 
McMahon
1985 Not stated Hospital stay >14 days 
Pseudocyst or abscess 
Death
Corfield 
et al.
1985 Not stated Death
Complication: abscess 
pseudocyst, necrosis 
septicaemia, cholangitis, 
renal failure, diabetes, 
venous thromboembolism, 
myocardial infarction,
GI haemorrhage, .pulmonary 
complications and hypoxia 
and/pr X-ray changes.
modification of the Ranson scoring system for gallstones improved the 
overall accuracy while reducing the sensitivity. Although applied 
retrospectively here, the delay from admission until gallstones are 
positively identified might diminish its value in clinical practice. 
The original Ranson scoring system appeared to be the method of 
choice for attacks associated with alcohol.
There was little to chose between the Glasgow and Ranson 
scoring systems as regards the delay to prediction. The Ranson system 
predicted deaths earlier although this difference did not reach 
statistical significance.
The Bank and Wise scoring system was the most extreme example 
of losing specificity as sensitivity was increased. It correctly 
identified all the patients with a carpiicated outcome but with a 
very low specificity, all except 14 patients having severe disease 
predicted. In this patient population at least, the Bank and Wise 
scoring system appeared worthless.
Diagnostic peritoneal lavage permitted the prediction of 
severity significantly earlier than the multiple factor scoring 
systems. Its ability to predict patients with a complicated outcome 
and its overall accuracy appeared to be poorer than either the 
Glasgow or Ranson scoring systems, although as it was applied in 
relatively few patients in the current study, a direct comparison 
cannot be made. It nevertheless appeared less successful in 
predicting attacks complicated by respiratory insufficiency, although 
correctly predicting 4 of the 5 patients developing local pancreatic 
carpiications, a fact perhaps recognised by its originators. In the
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original analysis of the technique renal and respiratory failure were 
included amongst the ccmplications226 but have been excluded in the 
most recent report (Table 33 )22 .^
One valuable aspect of diagnostic peritoneal lavage was 
confirmed here by the early identification of 2 patients with 
abdominal pain and hyperamylasaemia due to causes other than acute 
pancreatitis. Both patients would have had their diagnosis and 
institution of the correct therapy delayed had diagnostic peritoneal 
lavage not been performed.
Multiple factor scoring systems are considered to be worth 
recording as an objective measure of the severity of an attack. They 
may be of particular value in comparing groups of patients within 
clinical trials and in seme instances may provide useful warning of a 
complicated outcome. Prediction of outcome, particularly by the 
Ranson scoring systems, depends on the measurement of a large number 
of factors and the result may be delayed for 48 hours or more, thus 
limiting its value in clinical practice.
180
CHAPTER 8. A COMPARATIVE STUDY OF PREDICTION OF OUTCOME IN ACUTE 
PANCREATITIS BY APACHE II - A SEVERITY OF DISEASE 
CLASSIFICATION SYSTEM.
Introduction
The original APACHE illness grading system (acute physiology 
and chronic health evaluation) was developed on the premise that the 
severity of an acute disease could be measured by quantifying the 
degree of abnormality of multiple physiological variables - the acute
"I '70
physiology score . The original APACHE system provided weightings
(frcm 0 - normal to 4 - most abnormal) for 34 potential physiological
and laboratory measurements, each being determined frcm the most
abnormal recording made during that particular 24 hour period. The
sum of all the measurements recorded represented the patient's total
physiology score - the acute physiology score. The higher the score
1 78the sicker the patient . To this was added an assessment of the 
patients pre-admission health status (A - fit to D - severely 
compromised health) to give the overall APACHE classification.
The original APACHE system was complex and difficult to use and
i on
a much simplified modification the APACHE II was reported in 1985 .
APACHE II utilised only 12 routine physiological and laboratory 
measurements with an additional weighting for age and pre-admission 
health status. An increasing APACHE II score was found to correlate 
with the subsequent risk of hospital death in 5815 intensive care 
admissions'^. Furthermore, it was suggested that APACHE II wculd 
provide prognostic stratification of patients and might assist
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investigators in catiparing new or differing forms of treatment180.
To date the APACHE II system has been assessed exclusively in 
intensive care patients and reports of its application to the study 
of patients with acute pancreatitis have not been published.
The aims of the current study were to evaluate prospectively 
the APACHE II severity of disease classification in patients with 
acute pancreatitis and compare it with the other illness-specific 
multiple factor scoring systems.
Methods
All 160 patients documented in the current trial had the 
appropriate laboratory and physiological data recorded prospectively 
each day to permit subsequent calculation of their daily APACHE II 
scores (Fig. 28). The only difference between the calculation here 
and the published table was in the use of SI. units for serum 
creatinine. The conversion used throughout between SI. and 
traditional units was lpnol/1 = O.Olmg/lOOmls.
The 7 laboratory variables and 5 physiological variables were 
added separately to provide sub-totals and then the overall APACHE II 
score was calculated by adding the weightings for age and chronic 
health state.
The aetiology and outcome of the attacks were as defined in 
chapter 4. Thus 160 patients were studied with 3 exclusions. A fatal 
outcome was recorded in 12 patients and a complicated outcome in 
another 26 patients who survived. An uncomplicated outcome was 
recorded in the remaining 119 patients.
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P H Y S I O L O G I C  V A R I A B L E
HIGHABNOR«ALRANGE LOW ABNORMAL RANGE
+ 4 + 3 4-2 + 1 0 + 1 + 2 + 3 + 4
TEMPERATURE — rectal (*C) O*41 • o39*-40.9* O38 5-.38.9- O36*-38 4- O34-35 9- O32- 33 9- O30--31.9" <3S29.9-
MEAN ARTERIAL PRESSURE -  mm Hg U130-159 0110-129 7o9 o9 U50-69 O< 49
HEART RATE 
(ventricular response)
O
*180
O
140-179
O
110-139
O
70-109
O
55-69
O
40-54 O<39
RESPIRATORY RATE -  
(non-ventllated or ventilated) o*50
O
35-49
O
25-34
O
12-24
O
10-11
O
6-9 0<5
OXYGENATION: A-aDO, or PaO, (mm Hg)
a. FIO, * 0.5 record A-aOO,
b. FIO, <0.5 record only PaO,
o
*500 O350-499
O
200-349
O 
<200 
0  p5, > 70' OPO, 61-70 O PO, 55-60 O PO,< 55
ARTERIAL pH 7.6-9e9 7.59.59 O7.33-7.49 O7.25-7.32 O7.15-7.24 77< 7.15
SERUM SODIUM (mMol/L) O160-179 15^ 159 O150-154 13o9*9 0120-129 O111 119 O<110
SERUM POTASSIUM (mMoUL) "  <3* J 6§9 O5.5-59 O3.5-54 O3-3 4 O2.5-29 0<2 5
SERUM CREATININE (mg/100 ml)
(Double po*nt score for acute renal failure) O*3.5
O
2-3.4
O
1.5-1.9
O
0.6-1.4
O
<0.6
HEMATOCRIT (%> 50-^ 9 9 O46-49.9 "O30-45 9 O20-29.9 O<20
WHITE BLOOD COUNT (total/mm3) (in 1.000s) A 20^ 9.9 O15-19 9 O3-14.9 O1-2.9 O<1
GLASGOW COMA SCORE (GCS): 
Score = 15 minus actual GCS
fflTotal ACUTE PHYSIOLOGY SCORE (APS): 
Sum of the 12 individual variable points
Serum HCO, (venous-mMol/L)
(Not preferred, use if no ABGs) O'*52
o41-51.9 O32-40.9 O22-31.9
O
18-21.9
O15-17.9 O<15
11 AGE POINTS:
Assign points to age 
as follows:
AGE(yrs) Points
<44 0
45-54 2
55-64 3
65-74 5
*75 6
SI CHRONIC HEALTH POINTS
If the patient has a history of severe organ system in­
sufficiency or is immuno-compromised assign points 
as follows:
a. for nonoperative or emergency postoperative 
patients — 5 points
or
b. for elective postoperative patients — 2 points 
DEFINITIONS
Organ Insufficiency or immuno-compromised state 
must have been evident prior to this hospital admis­
sion and conform to the following criteria:
LIVER: Biopsy proven cirrhosis and documented portal 
hypertension; episodes of past upper Gl bleeding at­
tributed to portal hypertension; or prior episodes of 
hepatic failure/encephalopathy/coma.
CARDIOVASCULAR: New York Heart Association 
Class IV.
RESPIRATORY: Chronic restrictive, obstructive, or 
vascular disease resulting in severe exercise restric­
tion, i.e., unable to climb stairs or perform household 
duties; or documented chronic hypoxia, hypercapnia. 
secondary polycythemia, severe pulmonary hyperten­
sion (>40mmHg). or respirator dependency.
RENAL: Receiving chronic dialysis. 
IMMUNO-COMPROMISED.'The patient has received 
therapy that suppresses resistance to infection, e.g.. 
immuno-suppression, chemotherapy, radiation, long 
term or recent high dose steroids, or has a disease 
that is sufficiently advanced to suppress resistance to 
infection, e.g., leukemia, lymphoma. AIDS.
APACHE II SCORE
Sum of E  + HO + IS
E  APS points
(B) Age points.............. .........
[C] Chronic Health points
Total APACHE II____  ____
FIGURE 28.
The APACHE II severity of disease 
classification system (Knaus WA et al., Crit 
Care Med 1985;13:818-29). Reproduced by 
permission of the editor and publishers, 
Williams & Wilkins (1985).
In the comparison with the multiple factor scoring systems the 
original Ranson system290 (Table 27) was used throughout as the 
diagnosis of gallstones was not usually available on admission.
Statistical analysis
Statistical analysis was conducted by the Mann-Whitney U test, 
Chi square test and Fisher's exact test. The diagnostic performance 
of the scoring systems have been analysed as described in chapter 
6119.
Results
Examining the component parts of the APACHE II score, the 
laboratory data score, the physiology data score, the combined 
laboratory/physiology score and the total score, while all provide 
useful separation between the groups of patients it was the total 
score which best separated the 3 groups throughout the 7 day period.
Admission APACHE II
The differences between the 3 groups of patients were 
significant on the day of admission to hospital, the "cn admission" 
values often being the most abnormal values recorded. A scattergram 
showing the distribution of the day 1 values is shown in Figure 29. 
The "cut-off" value providing the best discrimination was calculated 
by taking the highest product of the sensitivity and specificity and 
was found for an APACHE II score of >5. This score provided a high 
sensitivity of 95% with a positive predictive value of 40%, 64% of
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FIGURE 29.
Scattergram shows the distribution of the 
on admission APACHE II scores in relation to 
the outcome from acute pancreatitis.
)
attacks overall being graded correctly (Table 34). Raising the 
cut-off to > 7  resulted in a slightly greater overall accuracy with 
seme loss of sensitivity.
When the 14 individual components of the "on admission" APACHE 
II score were examined potassium, p02, heart rate, respiratory rate 
and age were all found to separate the uncomplicated attacks from 
complicated or fatal attacks. Sodium, the Glasgow ccma scale and the 
chronic health evaluation were each found to be abnormal in very few 
patients (Table 35).
Peak APACHE II
A rather better discrimination between uncomplicated, 
complicated and fatal attacks was provided if the peak
APACHE II score (during the first 3 days) was used (Fig. 30). A 
score of > 9  provided a sensitivity of 82% with 76% of attacks being 
predicted correctly, rising to 83% if the cut-off was raised to >12 
(Table 34). Table 34 compares the admission and peak APACHE II scores 
with the other illness-specific prognostic scoring systems. Table 36 
details the comparison of the scoring systems for attacks associated 
with the 2 major aetiologies, gallstones and alcohol respectively.
No deaths occurred in the patients with a peak APACHE II score 
of <10 and of these 95 patients, only 6 (6%) developed a 
complication (Fig. 31). As the peak APACHE II score increased so too 
did the incidence of death and complication.
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TABLE 34.
Analysis of "admission" and "peak" APACHE II 
scores and comparison with multiple factor 
scoring systems and diagnostic peritoneal 
lavage in the prediction of outcome from 
acute pancreatitis.
Predictive Predictive %
Sensitivity Specificity value +ve value -ve Correct
On admission:
APACHE II (>5) 95% 54% 40% 97% 64%
APACHE II (>7) 68% 67% 40% 87% 67.5%
Peak:
APACHE II (>9) 82% 74% 50% 93% 76%
APACHE II (>12) 53% 92% 69% 86% 83%
Glasgow 71% 88% 66% 90.5% 84%
Ranson 87% 70.5% 48.5% 94% 74 . 5%
Diagnostic 67% 62.5% 77% 50% 65%
peritoneal lavage
KEY:
Peak APACHE II score «= highest score in day 1 - 3.
Sensitivity «= % of all complicated attacks predicted correctly by test. 
Specificity «= % of all mild attacks predicted correctly by test.
PV +ve * % complicated attacks among all predicted severe by test.
PV -ve *= % mild attacks among all predicted mild by test.
% Correct^ % correctly classified.
TABLE 35.
Examination of the value of the 14 
individual parameters comprising the 
admission APACHE II score in discriminating 
complicated from uncomplicated attacks.
Parameter
Complicated/ 
uncomplicated 
attack
Number of 
patients - 
scoring 1
Weighting 
2 3
score i 
4
distribution
5 6 value
Sodium complicated 2 2 NS
uncomplicated 1 1
Potasium complicated 9 7 1 1 p <0.05
uncomplicated 9 8 1
Creatinine complicated 9 5 1 2 1 NS
uncomplicated 12 11 1
Arterial pH complicated 3 2 1 NS
uncomplicated 7 4 2 1
Arterial p02 complicated 17 7 3 7 p <0.02
uncomplicated 27 17 6 4
Haematocrit complicated 7 4 3 NS
uncomplicated 24 18 6
White cell complicated 9 4 5 NS
count uncomplicated 23 15 8
Temperature complicated 17 16 1 NS
uncomplicated 39 39
Heart rate complicated 25 19 6 p <0.02
uncomplicated 50 43 7
Mean blood complicated 26 19 5 2 NS
pressure uncomplicated 63 49 13 1
Respiratory complicated 15 12 3 p <0.001
rate uncomplicated 11 10 1
Glasgow complicated 2 1 . 1 NS
coma scale uncomplicated 3 2 1
Age complicated 31 .5 10 11 5 p <0.01
uncomplicated 64 11 20 20 13
Chronic
health complicated 1 1 NS
evaluation uncomplicated 2 2
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FIGURE 30.
Scattergram shows the distribution of the peak 
APACHE II scores (day 1 - 3 )  in relation to 
the outcome from acute pancreatitis.
TABLE 36.
Comparison of the peak APACHE II score with 
multiple factor scoring systems and 
diagnostic peritoneal lavage for gallstone 
and alcohol-associated attacks of acute 
pancreatitis.
Sensitivity Specificity
Predictive 
value +ve
Predictive 
value -ve
%
Correct
Gallstone
Peak
APACHE II (>9) 93% 66% 45% 97% 72%
Glasgow 64% 78% 47% 88% 75%
Ranson 86% 52% 35% 92% 60%
Diagnostic 
peritoneal lavage
50% 100% 100% 60% 71.5%
Alcohol
Peak
APACHE II (>9) 57% 88% 44% 92% 83%
Glasgow 57% 98% 80% 93% 92%
Ranson 86% 98% 86% 98% 96%
Diagnostic 
peritoneal lavage
100% 25% 62.5% 100% 67%
KEY: as for table 34 .
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FIGURE 31.
Incidence of death and morbidity from acute 
pancreatitis in relation to the peak APACHE II 
score recorded.
Monitoring the course of illness
Figure 32 shows the daily mean APACHE II scores plotted for 
each of the 3 groups of patients: fatal attacks, complicated attacks 
and uncomplicated attacks. There were highly significant differences 
throughout the 7 days studied between those patients with a mild,
uncomplicated attack and both those patients with a complicated
|
attack and those with a fatal attack.
Patients with an uncomplicated attack of pancreatitis showed a 
steady fall each day in their mean laboratory, physiology and total 
APACHE II scores with resolution of the attack. Patients with a 
complicated outcome who survived showed a higher but similar overall 
pattern except for a transient elevation of the laboratory and total 
APACHE II scores on the third day. Their physiology score was also 
slower in falling.
A different pattern was seen amongst the 12 patients with a 
fatal outcome. They showed an early rise in both the laboratory and 
total scores, peaking on the third day before falling. This group 
also showed persistent elevation of their physiology score presumably 
reflecting the continuing disease activity. The worsening scores 
recorded in the 7 patients dying within the first week of their 
illness are shown in figure 33. Thus monitoring the APACHE II score 
during the first 7 days may provide an objective measure of the 
degree of illness and appears to reflect improvement or deterioration 
in the patients' clinical condition.
No differences emerged between the mean APACHE II scores over 
the first 7 days in patients with attacks complicated by respiratory
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FIGURE 3 2♦
Mean daily APACHE II scores by outcome in 119 
patients with an uncomplicated course (mild), 
2 6 patients with a complicated course (comp) 
and in 12 patients with a fatal outcome 
(death). The differences between fatal and 
uncomplicated and between complicated and 
uncomplicated were highly significant each 
day, p <0.001.
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FIGURE 33.
Shows the rising pattern of the APACHE II 
scores in the 7 patients who died from acute 
pancreatitis during the first week of their 
illness.
insufficiency or by local pancreatic complications such as 
necrosis or pseudocyst.
Discussion
APACHE II has been shown to provide useful discrimination 
between mild, complicated and fatal attacks of acute pancreatitis 
within a few hours of admission to hospital. The laboratory tests 
required are simple and routine and are readily available "out of 
hours" which is not generally the case for the calcium or the enzyme 
assays required for the Ranson and Glasgow multiple factor scoring 
systems.
On admission neither the overall accuracy nor the predictive
value of APACHE II were particularly high but appeared to ccmpare
favcurably with diagnostic peritoneal lavage in this study.
Diagnostic peritoneal lavage was not performed in all patients in the
current study and thus is not strictly comparable but in previous
70studies has correctly predicted the outcome in between 82% and 90% 
996of cases . Although providing an early prediction of outcome 
diagnostic peritoneal lavage remains an invasive test with a small 
risk of visceral injury and has not found widespread acceptance 
outwith clinical trials.
APACHE II was superior to clinical assessment on admission 
which, although shown to have a higher overall accuracy in the 
previous chapter, failed to identify 2/3rds of the attacks with a 
ccmplicated or fatal outcome. Furthermore, APACHE II as it depends on 
the measurement of laboratory and physiological parameters is
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objective and reproducible.
When the peak APACHE II scores were considered, its diagnostic 
accuracy improved to levels equivalent to the illness-specific 
multiple factor scoring systems, although this would then incur a 
similar delay. Vflien gallstone and alcohol-associated attacks were 
examined separately it can be seen that the APACHE II score performed 
as well as the established multiple factor scoring systems for 
attacks associated with gallstones. The Ranson scoring system 
performed particularly well for attacks associated with alcohol abuse 
and APACHE II performed slightly less well in such cases.
Thus the APACHE II scoring system may prove to be a useful 
addition to the management and study of these patients. It may 
provide an indication of the severity and possible outcome of an 
attack soon after admission to hospital, permitting early, 
non-invasive selection of patients for study in clinical trial. The 
peak APACHE II score provided a more accurate prognostication of 
outccme similar to that of the standard multiple factor scoring 
systems and was able to grade patients by their percentage risk of 
major morbidity or death.
While the standard illness-specific scoring systems provide a 
single "one-off" prognostication, usually within the first 48 hcurs 
of the attack, but sometimes delayed 60 hours or more, the APACHE II 
score can be repeated daily to monitor the course of the attack. 
Patients dying within the first 4 days of admission showed a rising 
score reflecting their deteriorating organ function, whereas patients 
with an uncomplicated or complicated outcome demonstrated a falling
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trend during the first 7 days of their illness with resolution 
of the systemic manifestations of their attack. The APACHE II score 
appeared to reflect continuing disease activity and may, therefore, 
be a useful means of monitoring the course of the illness and any 
response to therapy.
There were no differences in the mean APACHE II scores whether 
the attack was carplicated by respiratory insufficiency or local 
pancreatic complications such--,as necrosis or pseudocyst. The design 
of the study did not allow for the continued monitoring of patients 
who went on to develop a late carpiication, to look for signs of 
secondary deterioration. This aspect might be examined in future 
studies.
Several components of the overall APACHE II score contributed 
to the total in oily a few patients and other parameters failed to 
provide significant discrimination between the patient groups (Table 
35). Other potential drawbacks of the APACHE II score when used to 
monitor the disease course included scoring patients who were 
clinically well during the latter half of their attack for a lew 
normal heart rate or for an abnormal bicarbonate (used if pC^ was not 
available). Perhaps the system might be improved by placing less 
weight on low normal values in an otherwise well patient. 
Nevertheless, it is an attractive concept to have a single scoring 
system applicable to all illnesses, although this will inevitably be 
associated with less accuracy than scoring systems designed for one 
particular condition.
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PART 5.
INTRAPERITOQEAL ANTIPROTEASE THERAPY
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CHAPTER 9. STUDY OF FREE PROTEOLYTIC ACTIVITY IN PANCREATITIS EXUDATE 
AND THE EFFICACY OF INTRAPERITONEAL ANTIPROTEASE THERAPY 
IN EXPERIMENTAL ACUTE PANCREATITIS IN RATS
Introduction
Peritoneal proteolytic enzyme activity has previously been 
investigated in dogs with pancreatitis induced by the closed duodenal 
loop technique and by retrograde injection of bile into the 
pancreatic duct^^'^^, overwhelming of the peritoneal antiprotease 
defences being associated with the onset of shock, and subsequent 
death of the animals.
Rats have in recent years became the most frequently used 
animal for studies of experimental acute pancreatitis but the 
exudates associated with the most ccmmonly used taurocholate-induced 
pancreatitis model have not previously been examined for protease 
activity and adequacy of their antiprotease defences.
Formal peritoneal lavage has been shown to prolong the survival
of rats with taurocholate-induced pancreatitis, addition of the
antiprotease aprotinin to the lavage fluid in one series of
1 97experiments providing no additional benefit . Therapy with 
intraperitoneal aprotinin alone was not associated with an 
improvement in survival, nor reduction in the degree of pancreatic 
damage in another study*^.
The aim of the current study was to investigate proteolytic 
enzyme activation and the adequacy of the peritoneal antiprotease 
defences in the exudates associated with taurocholate-induced
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pancreatitis in the rat and secondly, to determine whether a 
novel treatment comprising removal of the exudate followed by 
instillation of an antiprotease solution, might be therapeutic.
Pilot studies
Preliminary studies were performed to investigate the severity 
and reproducibility of the bile salt model of acute pancreatitis 
originally described by Lankisch and co-workers'1-^ and later by 
others . Both groups described a "free hand" retrograde injection, of 
0.6ml and 0.2ml of sodium taurocholate solution respectively, into 
the bile-pancreatic duct of the rat. Using a "free hand" injection 
technique it is difficult to standardise both the rate of infusion 
and the pressures generated and thus the degree of pancreatic ductal 
rupture and pancreatic injury. This might be expected to produce 
variability in the severity of the pancreatic lesion induced and thus 
a lack of reproducibility which could be important, particularly if 
only small numbers of animals were to be studied. Pilot studies were 
therefore conducted, to determine the mortality rate and the pattern 
of the survival time associated with acute pancreatitis induced by a 
controlled retrograde infusion of sodium taurocholate.
A further modification of the technique was also studied 
entailing the slow retrograde infusion of a combined sodium 
taurocholate/enterokinase solution (Leese T, personal communication).
Methods
Male Wistar rats weighing 170-200g were used throughout. The
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animals were fasted overnight prior to the induction of 
pancreatitis but were permitted free access to water. The body weight 
of the rats was determined just prior to use to permit calculation of 
the anaesthetic dose and volumes of subsequent intraperitoneal 
therapy. Anaesthesia was induced by intraperitoneal injection of 
pentobarbitone sodium (Sagatal, May and Baker, Dagenham, UK) 6ng/100g 
body weight.
Cannulation of the pancreatic duct
The abdcmen was opened through a midline laparotomy and the 
duodenal loop with the head of pancreas was delivered out of the 
wound. A puncture was made in the antimesenteric border of the 
duodenum, just distal to the entry point of the canmon 
bile-pancreatic duct on the mesenteric border. Prior to introducing a 
cannula into the duodenum the cannula was primed with the appropriate 
bile salt solution. The tip of a size 23g x 22rrm teflon cannula 
(Wallace Y-Can, H G Wallace Ltd., Essex, UK) was then passed into the 
duodenal lumen and manipulated into the bile-pancreatic duct via the 
ampulla. The cannula was secured in place in the duct by an 
encircling 3/0 silk ligature placed around the bile-pancreatic duct 
in the head of the gland, just proximal to its entry into the 
duodenal wall. A neurosurgical aneurysm clip was then placed across 
the caution hepatic duct at the liver hilum, above the highest 
pancreatic ductal branch, to prevent retrograde injection of the bile 
salt solution into the liver bile duct radicles (Fig. 34).
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Infusion Pump
FIGURE 34.
Diagrammatic representation of the method of 
inducing experimental pancreatitis showing 
transduodenal placement of a cannula in the rat 
bile-pancreatic duct. A neurosurgical clip is 
applied across the proximal bile duct, at the 
liver hilum, prior to commencement of the bile 
salt infusion.
Induction of acute pancreatitis
The cannula in the bile-pancreatic duct was connected by 
standard extension tubing to a 5ml capacity glass syringe mounted in 
a syringe driver (Braun-Melsungen, West Germany). The infusion of the 
bile salt solution was timed and at the required volume the syringe 
driver was stepped. Calibration of the pump for a delivered volume of 
200pl at an infusion rate of lOOpl/minute resulted in a coefficient 
of variation of 0.9%.
After infusion of the bile salt solution the aneurysm clip at 
the liver hilum was removed. The ligature encircling the cannula in 
the distal bile-pancreatic duct was released and the cannula removed 
carpietely. Finally the puncture wound in the duodenal wall was 
repaired with a pursestring suture of 6/0 Ethilon. The appearance of 
the pancreas during the induction of pancreatitis is shown in figures 
35-37.
Placement of peritoneal cannula
The pancreas was returned to the abdcmen and a peritoneal 
dialysis cannula was placed in the peritoneal cavity. The dialysis 
cannula was fashioned frcm an intravenous infusion extension set 
comprising a three-way tap, a 10cm length of plastic tubing and a 
luer lock (Connecta, Viggo AB, Helsingborg, Sweden). This was 
selected because the plastic tubing was rigid and did not collapse on 
applying suction when aspirating fluid. The luer lock was excised and 
several side holes cut in the distal 5cm of the tubing thus 
fashioning a peritoneal dialysis cannula.
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FIGURE 35.
Induction of pancreatitis. Cannula secured in 
bile-pancreatic duct with an encircling silk 
ligature. Appearance of pancreas soon after 
commencement of infusion showing oedema and 
haemorrhage around the main pancreatic duct.
FIGURE 36.
Appearance of the pancreas at the end of the 
infusion, showing marked oedema, swelling and 
haemorrhage in the head of the gland.
-Ml
FIGURE 37.
Appearance of gland after removal of cannula 
showing swelling, oedema and haemorrhage of 
head, body and tail of gland extending to 
splenic hilum. Note pursestring suture of 
the puncture site in the duodenal wall.
The tip of a haemostat was passed from within the peritoneal 
cavity through the peritoneum, muscle and skin to emerge high cn the 
animal's back, just to the right of the midline. Withdrawing the 
haemostat the cannula was pulled into the peritoneal cavity and the 
three-way tap was secured to the skin of the animal's back with a 
single silk suture. The open end of the cannula with side holes was 
placed adjacent to the pancreas, to lie in the most dependent portion 
of the peritoneal cavity with the animal upright. Finally the 
laparotomy wound was closed in layers.
Pilot studies
To determine the most suitable model for study a series of 
experiments were run utilising different concentrations of sodium 
taurocholate (BDH Chemicals Ltd., Poole, UK) in solution with 0.9% 
saline solution, prepared imnediately before use. In one series of 
experiments porcine enterokinase (Sigma Chemical Co, St Louis, USA) 
was added to the test solution to a concentration of 0.2%.
The test infusions and the infusion rates studied are detailed 
as follows
sodium taurocholate 3%, 0.6ml infused at 200pl/minute
sodium taurocholate 5%, 0.2ml infused at lOOpl/minute
sodium taurocholate 5%, 0.6ml infused at 200pl/minute
sodium taurocholate 5%, 2ml/kg infused at 50pl/minute
sodium taurocholate 3.5% with enterokinase 0.2%, 2ml/kg body weight
infused at 50pl/minute.
These animals did not have a peritoneal cannula placed and
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received no additional therapy postoperatively. The survival
times were recorded and any animals remaining alive at 72 hours were
sacrificed.
Experiment - intraperitoneal therapy
All rats had standard induction of pancreatitis with sodium 
taurocholate 5%, 0.6ml, freshly prepared and infused at 200pl/minute. 
Each animal had a peritoneal dialysis cannula placed prior to closure 
of the laparotomy wound. Only after successful completion of the 
procedure were the animals randomly allocated to one of the 4 
treatment groups or to the control group, the randomisation ensuring 
5 groups each of 10 rats.
Therapy (see below) was carried out on all rats exactly one 
hour after the induction of pancreatitis, the animals at this stage 
remained sedated or were only just beginning to recover from the 
earlier pentobarbitone injection.
In rats from the 4 treatment groups (randomised to receive 
intraperitoneal therapy) the peritoneal cannula was aspirated with a 
5ml syringe and the volume and colour of the exudate was recorded 
(Figs. 38,39), the colour being compared against a standard colour 
chart226. In each case a 1ml aliquot of the fluid was centrifuged at 
4°C and the supernatant stored at -20°C for subsequent analysis.
The peritoneal cavity was then washed out by a single 
peritoneal lavage with 0.9% saline solution (1.5ml/100g body weight). 
This was chosen to correspond to an approximate volume of lOOOmls in 
a 70kg man, as suggested for diagnostic peritoneal lavage of patients
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FIGURE 38.
Aspiration of free peritoneal exudate via the 
peritoneal dialysis cannula, one hour after the 
induction of experimental pancreatitis.
1 2
free fluid
FIGURE 39.
Shows Leeds colour chart for identification of 
severity of acute pancreatitis with samples of 
peritoneal fluid from a rat with experimental 
pancreatitis, from left to right: peritoneal 
fluid after saline lavage, free exudate one 
hour after induction of pancreatitis and free 
exudate obtained at post mortem.
with acute pancreatitis226. After circulating the fluid by gently 
squeezing the animal's abdcmen the fluid was then aspirated and the 
volume and colour recorded as before. An antiprotease or similar 
inactive solution was then instilled into the peritoneal cavity 
(1.5ml/100g body weight) and finally the peritoneal cannula was 
withdrawn leaving the fluid in situ (Fig. 40). The net fluid balance 
was calculated by subtracting the total volume of fluid aspirated 
from the total volume of fluid instilled and the balance recorded.
Active antiprotease or inactive solutions were studied as 
follows:- aprotinin (5000 KlU/ml in 0.9% saline solution) or 0.9% 
saline solution, human fresh frozen plasma (whole plasma containing 
clotting factors and the natural antiproteases) or human plasma 
protein solution (a colloid solution, predominantly of albumin at a 
concentration of 45g/l, devoid of active antiproteases and other 
active plasma factors).
The control rats received a single subcutaneous injection of 
0.9% saline solution (1.5ml/100g body weight) exactly one hour after 
the induction of pancreatitis. The peritoneal cannula was then 
withdrawn without removing any free ascitic fluid frcm the peritoneal 
cavity (Fig. 41).
Animals frcm all groups were kept in cages of 4 with free 
access to water. Food pellets were reintroduced 24 hours 
postoperatively. The animals were examined every hour and the time of 
death recorded. Animals surviving to 72 hours' were sacrificed. A post 
mortem was performed on all animals immediately after death. The 
volume and colour of any peritoneal exudate was recorded as described
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TREATMENT GROUPS
1 Aspirate Free Peritoneal Fluid
2 Peritoneal Washout:
Instill Saline (1.5ml/ 100gm) 
Aspirate Saline
3 Instill Test Fluid (1.5ml/100gm)
4 Remove Cannula
FIGURE 40.
Experimental protocol in rats randomised to 
receive intraperitoneal therapy at one hour.
CONTROL GROUP
1 Subcutanous Saline 
(1.5ml/100gm)
2 Remove Cannula
FIGURE 41.
Experimental protocol in rats randomised to 
the control group.
above (Fig. 39), and a 1ml aliquot of fluid was centrifuged at 
4°C and the supernatant stored at -20°C for subsequent analysis.
The extent of the pancreatitis in the head and tail of the 
gland was graded macrosccpically on a scale 1 to 4, corresponding to 
a normal appearance, mild inflammation/ thickening, severe 
inflammation/thickening or necrosis respectively (Fig. 42). The 
extent of fat necrosis in the peritoneal cavity was recorded as none, 
localised to the pancreas, regional or generalised. The pancreas was 
excised and the pancreatic weight recorded. The pancreas was then 
fixed in formalin, processed, sectioned and stained with haematoxylin 
and eosin for histological examination.
Biochemical analyses
The trypsin binding capacities of the 4 test solutions were 
determined in chapter 5. The peritoneal fluid samples obtained from 
the rats in the 4 treatment groups at one hour post-induction of 
pancreatitis and from all rats at autopsy were examined for evidence 
of free proteolytic activity as described in chapter 5. The 
peritoneal fluid specimens were thawed at roan temperature and 20ul 
samples of each specimen were applied to a 0.2% plasminogen-free 
fibrin plate. Free proteolytic activity was judged to be present if a 
zone of lysis appeared on the plate following overnight incubation at 
37°C.
Statistics
Statistical analysis of the survival times was conducted by the
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FIGURE 42.
Pancreas excised at post mortem showing 
extensive necrosis of gland (grade 4).
Leg rank test. Simultaneous comparisons between all 5 groups 
were made with the Kruskal Wallis test and comparisons between 2 
groups, by the Mann-Whitney U test.
Results 
Pilot study
Table 37 shows the survival times associated with induction of 
pancreatitis by retrograde infusion of various concentrations of 
sodium taurocholate. Infusion of 5% sodium taurocholate, 0.6ml at 
200jjl/minute was the only method to produce a consistently high 
mortality. Animals surviving 48 hours remained well and were 
sacrificed at 72 hours.
Trypsin binding capacity
Trypsin binding capacities determined on the 4 test solutions 
demonstrated both 0.9% saline solution and human plasma protein 
solution to have no appreciable trypsin binding capacity. Human fresh 
frozen plasma was able to bind 80}jg of trypsin/lOOpl, lysis appearing 
after the addition of lOOpg of trypsin/lOOpl. Aprotinin solution was 
able to bind over 400jjg of trypsin before lysis appeared after the 
addition of 450pg of trypsin/lOOul and thus had the highest trypsin 
binding capacity of the 4 test solutions.
Experiment
The mean body weights of the rats frcm all 5 groups were 
comparable (Table 38). The mean volumes of exudate recovered frcm the
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TABLE 37.
Pilot study investigating the mortality 
associated with different methods of 
inducing pancreatitis: varying the 
concentration, volume and rate of 
retrograde bile infusion.
Survival
Bile salt(concentration) Volume Rate No. <24hrs 24-48hrs >48hrs
Na taurocholate (3%) 0.6ml 200pl/min 2 - 2
Na taurocholate (5%) 0.2ml lOOpl/min 8 1* 7
Na taurocholate (5%) 0.6ml 200pl/min 18 15 3
Na taurocholate (5%) 2ml/kg 50pl/min 2 - 2
Na taurocholate (3.5%)/ 
Enterokinase (0.2%)
2ml/kg 50pl/min 6 3 3
leakage from repaired duodenal puncture wound at post mortem.
TABLE 38.
Comparability of peritoneal exudate 
characteristics, fluid balance and 
morphological parameters in the control 
group and in the 4 groups receiving 
intraperitoneal therapy.
Intraperitoneal therapy groups
Plasma Fresh
Control protein frozen
Parameter group Saline solution plasma Aprotinin
Body weight (Gm) 186+7 187+7 184+6 186+8 185+7
Exudate Vol.(mis) - 1.3+0.4 1.7+0.4 1.55+0.3 1.5+0.5
at 1 hour
Colour - 6.5 6.5 6.5 6.5
Net fluid balance 2.8+0.1 1.8+0.7 1.2+0.5 1.4±0.5 1.7+0.6
post-therapy (mis)
Exudate Vol.(mis) 6.7±2.7 5.3+2.2 6.9±3 3.25+2.5 6.55+2.5
at post
mortem Colour 6.8±1 6.15+0.9 6.3+0.75 6.2+0.9 6.25+1
Macroscopic Head 3.9+0.3 3.8+0.4 4 3.7+0.6 3.9+0.3
score
Tail 3.35+0.4 3.3+0.3 3.35+0.55 3.25+0.75 3.3+0.6
Pancreatic weight 119±38 117+32 110+18 131+32 124±21
(mg)
•
P
value
NS.
NS.
NS.
p<0.01
NS.
NS.
NS.
NS
NS.
Results expressed as means + s.e.m. 
Kruskal Wallis test.
rats in the 4 treatment groups one hour post induction of 
pancreatitis ranged between 1.3 and 1.7mls and were not significantly 
different and the mean fluid colour scores were identical (Table 38). 
Following peritoneal lavage and instillation of the test solution, 
the mean net fluid gains amongst rats in the 4 treatment groups were 
similar. The control group had a significantly higher net fluid gain 
(p <0.01), having had no peritoneal exudate removed (Table 38).
At post mortem the mean volumes of exudate were highest in the 
human plasma protein solution, control and aprotinin groups and was 
lowest in the group treated by human fresh frozen plasma although 
these differences were not significant (Table 38). The volume of 
exudate was lowest in the rats surviving to sacrifice at 72 hours.
The exudate recovered at post mortem tended to be darker in the 
control rats but these differences were not significant.
Morphological aspects
Macroscopic assessment of the degree of pancreatitis at post 
mortem uniformly recorded necrosis in the head of the gland amongst 
the early deaths, those rats surviving to sacrifice at 72 hours 
showing severe pancreatic inflammation and thickening. The 
appearances of the body and tail of the glands was more variable, 
seme showing necrosis mainly in the central portion of the gland 
around the main duct with more normal looking pancreas peripherally, 
other glands showed complete necrosis. No trend was apparent between 
the macroscopic appearances and the treatment administered. The mean 
scores are shown in Table 38 and no significant differences emerged
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between the groups.
Fat necrosis was generalised in all animals and did not 
distinguish the groups or whether death occurred early or late.
The pancreatic weight was slightly greater in the 2 groups of 
rats receiving antiprotease solutions but these differences just 
failed to reach statistical significance (Table 38). Histology 
confirmed acute pancreatitis in all rats.
Survival time
The 4 groups of rats receiving intraperitoneal therapy had 
significant prolongation of their median survival times compared to 
controls (Fig. 43). When the intraperitoneal therapy groups were 
compared individually with the control group only the group treated 
with human fresh frozen plasma had a significantly longer median 
survival (Table 39). Therapy with human fresh frozen plasma 
significantly prolonged survival when compared with human plasma 
protein solution (Fig. 44). Therapy with aprotinin appeared no better 
than therapy with saline alone (Fig. 45) although when compared with 
the control group the improvement in survival of the aprotinin group 
just failed to reach statistical significance (Table 39).
Free proteolytic activity
Exudates aspirated one hour post-induction of pancreatitis 
demonstrated free proteolytic activity in between 4 and 5 of the rats 
in each treatment group (mean lysis area 359 + 82mm , equivalent to 
63jjg free bovine trypsin/ml) (Table 40). The median survival time
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FIGURE 43.
Life table showing improved survival time 
amongst the 40 rats having intraperitoneal 
therapy (treated) compared to the 10 controls 
(control).
TABLE 39.
Comparison of survival times in the 4 
treatment groups and in the control group 
following the induction of pancreatitis.
p value
No. Median survival Interquartile compared to
(hours) range (hours) control group
Control 10 9.5 8.8-13.4
Saline 10 20.3 7.9 - 51.4 0.236
Plasma protein 10 17.5 14.9-22.5 0.116
solution
Fresh frozen 10 24.8 1 8 . 8 - 7 2  0.01*
plasma
Aprotinin 10 19.8 14.0-23.3 0.065
significant, log rank test.
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Life table showing improvement of survival time 
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Life table showing survival time of the 10 rats 
treated with intraperitoneal aprotinin 
(trasylol) compared to the 10 treated with 
intraperitoneal saline (saline).
TABLE 40.
Incidence and extent of free proteolytic 
activity in peritoneal exudates in the 5 
groups of rats at one hour post-induction 
of pancreatitis and at post mortem.
Intraperitoneal therapy groups
Exudate
tested
Control
group Saline
Plasma
protein
solution
Fresh
frozen
plasma Aprotinin
One hour (no. ) ~ 5/10 5/10 4/10 4/10
Mean lysis 
area (mm2)
- 378+166 384+160 176+76 659+205
Post
mortem (no.) 6/10 2/10 1/10 1/10 1/10
Mean lysis 
area (mm2)
273+145 44+8 trace trace trace
(No.) = number in each group of 10 showing activity.
Mean lysis area - area of zone of fibrinolysis (indicating free 
proteolytic activity).
amongst the rats with free proteolytic activity at one hour 
(20.5 hours) was not significantly different from the rats who had no 
free proteolytic activity demonstrated (median survival time 21.5 
hours).
At post mortem the fluid frcm 6 of the 10 control rats showed 
free proteolytic activity (mean lysis area 273 + 145mm^, equivalent - 
to 50pg free bovine trypsin/ml) (Table 40). Two of the rats in the 
saline treated group showed residual proteolytic activity at post 
mortem (equivalent to lOjig free bovine trypsin/ml), only one rat in 
each of the 3 other treatment groups showing a trace of activity.
Discussion
When the efficacy of a given therapy is judged on the basis of 
it prolonging the survival time, then the assessment of such a 
benefit is dependent only upon the proportion of untreated animals 
having a fatal outcome. This dictates that the experimental model 
should have a high mortality, close to 100% in the control group. 
Furthermore, the study of small numbers of animals within each 
treatment limb necessitates that the pancreatic injury be standard 
and reproducible. These goals appear to have been achieved here, the 
pilot study showing that the retrograde intraductal infusion of 5% 
sodium taurocholate at a constant rate by syringe pump produces a 
severe pancreatitis with a 83% mortality within 24 hours.
Such a mortality is unknown in the context of human acute 
pancreatitis, a mortality rate of 10% being more representative. 
Furthermore, only a proportion of the patients dying of acute
201
pancreatitis die within the first few days of their illness. 
Extensive necrosis is the usual result of taurocholate-induced 
pancreatitis whereas in man this degree of pancreatic damage may 
occur in fewer than 5% of attacks. However, in seeking to influence 
the course of the disease it does seem valid to examine therapy in 
the most severe cases, as it is these patients which present major 
problems in management, the majority of the remainder settling on 
simple supportive therapy.
Of the various methods of inducing acute pancreatitis 
experimentally, retrograde infusion of bile salt appears an 
appropriate choice having certain similarities with the theory of 
initiation of pancreatitis in man by reflux of bile. Although an 
invasive method, it reliably produces a rapidly evolving pancreatitis 
with similar macroscopic and histological features to man, including 
the production of fat necrosis and a haemorrhagic peritoneal 
exudate^.
There is evidence of proteolytic enzyme activation in the 
peritoneal fluid with just under half the rats having exudate sampled 
at one hour demonstrating fibrinolysis representing free proteolytic 
activity and indicating overwhelming of the peritoneal antiprotease 
defences. Taurocholate-induced pancreatitis in rats thus appears 
similar to the pancreatitis induced in dogs by retrograde injection 
of bile where the highest enzyme levels in peritoneal exudate were 
found one hour after the induction of pancreatitis, associated with 
saturation of the antiprotease molecules and the presence of free 
proteolytic (caseinolytic) activity^63.
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The free proteolytic activity demonstrated in the present study 
does not reflect activity due to the presence of protease- 
alpha2macroglobulin canplexes as these are unable to attack large 
substrate molecules such as fibrin. The presence of trypsin might be 
confirmed by demonstrating tryptic amidase (BAPNA splitting activity) 
but attempts to examine for this were unsuccessful due to the 
haemorrhagic coloration of the exudates, both at one hour and at the 
time of post mortem.
Although serial sampling of the exudate for analysis was not 
performed, free proteolytic activity presumably was present at one 
hoar and persisted until death in the majority of the control rats 
but was diminished at post mortem in the rats which had received 
intraperitoneal therapy. The rats receiving intraperitoneal therapy 
had prolongation of their median survival time suggesting that 
removal of the peritoneal exudate was beneficial. Among these rats 
the median survival time was the same whether the peritoneal exudate 
removed at one hour possessed free proteolytic activity or not.
In the control rats not receiving intraperitoneal therapy the 
median survival time did not vary whether free proteolytic activity 
was present at post mortem or not, although free proteolytic activity 
was not found in the animal surviving longest at 72 hours. This 
suggests that factors other than the presence of free proteolytic 
activity may determine the timing of death from taurocholate-induced 
pancreatitis.
Both human fresh frozen plasma and particularly aprotinin were 
found to possess significant trypsin inhibitory activity, the binding
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capacity of fresh frozen plasma being similar to that reported 
p r e v i o u s l y ^ 07 # Human plasma protein solution and saline were 
confirmed to have no measurable trypsin binding capacity.
Instillation of human fresh frozen plasma appeared to be the most 
effective of the intraperitoneal therapies tested when each of the 
treatment groups were compared in turn with the control group, the 
improvement associated with aprotinin therapy just failing to reach 
statistical significance. These data suggest that the instillation of 
a solution possessing antiprotease activity may be superior to one 
possessing no such activity.
Although human fresh frozen plasma was not significantly better 
than aprotinin, the trend towards a longer median survival in 
association with fresh frozen plasma may suggest that the nature of 
the antiprotease solution, rather than its overall capacity to bind 
trypsin, might be the more important factor.
Canplexation of protease with aprotinin, as with 
alphas antiprotease leads to inhibition of the enzyme and such 
complexes possess no residual proteolytic activity. The mode of 
clearance of aprotinin-protease and alpha^antiprotease-protease 
complexes from the peritoneal cavity is unknown but as in the 
bloodstream may involve transfer of the protease molecules to 
alpha2 macroglobulin, and hence to the peritoneal macrophages where 
the ccrrplex may be taken up and broken down. Thus it may be that the 
concentration of alpl^macroglobulin, as appears to be the case in 
the bloodstream, may be the rate-limiting step in the clearance of 
proteases from the peritoneal cavity. Provision, therefore, of
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exogenous alpha2 macroglobulin in fresh frozen plasma may boost the 
clearance of activated proteases frcm the peritoneal cavity although 
it is also recognised that the persistent proteolytic activity 
associated with such carpiexes may in itself be pathogenic.
The numbers of rats studied in the present study were too small 
to permit confident conclusions as to the superiority of fresh frozen 
plasma over aprotinin. Nevertheless the study has demonstrated that 
this form of intraperitoneal treatment is therapeutic and that the 
addition of antiproteases to the peritoneal cavity may confer 
additional benefit. An investigation of this approach to the 
treatment of acute pancreatitis in man would seem to be justified.
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CHAPTER 10. EXAMINATION OF PANCREATIC ENZYMES AND ANTIPROTEASES IN 
PERITONEAL EXUDATES AND PSEUDOCYST FLUID
Introduction
Peritoneal effusions are thought to resemble slightly diluted 
plasma with respect to their protein composition . The peritoneal 
exudate complicating acute pancreatitis comprises proteins, including 
the major antiproteases alpt^macroglobulin and alpha^antiprotease, 
active enzymes such as amylase and lipase, zymogens and activated 
proteolytic enzymes such as trypsin, chymotrypsin and elastase bound 
to antiproteases, and also includes prostaglandins, complement 
breakdown products and k i n i n s " ^ *202,204  ^T^e colour and
biochemical characteristics of the peritoneal exudate, including its 
albumin, total protein and aspartate aminotransferase content, have
all been shown to reflect the severity of an attack of acute
. . 997 977 pancreatitis ' .
The peritoneal fluid associated with an attack of acute 
pancreatitis has been considered to arise frcm an exudaticn of 
enzyme-rich fluid frcm the pancreas. This fluid presumably excites a 
peritonitis leading to a migration of white blood cells and an 
out-pouring of fluid containing plasma proteins and antiproteases 
frcm the peritoneum, thus diluting and ccmplexing any potentially 
dangerous proteolytic enzymes.
The toxic factor or factors in peritoneal fluid have not been 
fully characterised but may include pancreatic enzymes, complement 
breakdown products, kinins or other small vasoactive peptide
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molecules or even prostaglandins. Sane workers consider that 
saturation of the peritoneal antiprotease defences may be a central 
event mediating this toxicity, at least in experimental
Ofi 1— ^pancreatitis . Alpt^macroglobulin appears to be the key 
protective antiprotease in this situation, preferentially binding 
activated proteases. The onset of shock in these experimental models 
appears to occur following saturation of alph^macroglobulin, which 
is rapidly followed by activation of the trypsinogen and saturation 
of the remaining alpha-^antiprotease.
Activated proteolytic enzymes have been demonstrated in the 
peritoneal exudate in man in complex with alpl^macroglobulin and 
alpha-^antiprotease and high degrees of complexation of 
alpha^acroglobulin, up to 100%, have been demonstrated, suggesting 
this mechanism may also be important in man^'^^. Free tryptic 
activity, which would indicate overwhelming of the peritoneal 
antiprotease defences, was not observed in 12 exudates studied by 
Geokas and colleagues-^. One study has reported free proteolytic 
activity to be present in 6 of 13 exudates sampled at the time of 
surgery-^, but no clinical details were presented as to whether 
these patients were shocked or not.
The aim of the present study was to investigate further the 
extent of proteolytic enzyme activation and adequacy of the 
peritoneal antiprotease reserve in human acute pancreatitis. It is 
not clear whether antiproteases are normally present in peritoneal 
fluid and, if so, what the normal concentrations are. In health only 
a trace of fluid exists in the peritoneal cavity, insufficient for
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sampling and analysis, and therefore a series of patients with 
a reactive effusion secondary to intestinal obstruction have been 
studied to permit comparison.
The release of active proteolytic enzymes in duodenal contents 
following perforation of a duodenal ulcer might in sane ways mimic 
the enzyme- release occurring in acute pancreatitis and samples of 
peritoneal exudates frcm a group of these patients have also been 
studied.
Finally cyst fluid frcm a series of patients with pseudocysts 
were also studied. Pseudocysts often communicate with the pancreatic 
duct and the fluid might represent pancreatic juice or possibly 
resemble the "pancreatic" component of pancreatitis exudate 
associated with an acute attack of pancreatitis.
Methods
Peritoneal exudate was obtained at diagnostic paracentesis frcm 
21 patients with acute pancreatitis as described in chapter 4. 
Patients were admitted a median of 9 hours frcm the onset of their 
symptoms and peritoneal cannulation was performed at a median time of 
8 hours after admission to hospital (range 4-31 hours). The 21 
patients studied have been divided into two groups, 10 patients who 
died and 11 who survived their illness. The clinical details of the 
patients in the 2 groups are shown in table 41.
Free peritoneal fluid was obtained at the time of laparotomy in 
7 patients with a perforated peptic ulcer (duodenal - 6, gastric - 1) 
and frcm 8 patients with various forms of mechanical intestinal
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TABLE 41.
Comparison of age, sex, aetiology and 
complications in relation to the outcome 
from acute pancreatitis.
Acute pancreatitis
Fatal attacks Survivors
(n = 10) (n = 11)
Sex 8 M : 2 F
Age 55.4 + 4.‘
Aetiology: gallstones 4 (40%)
alcohol 2 (20%)
other
unknown 3 (30%)
gallstones/alcohol 1 (10%)
Mean prognostic factor 
score: Glasgow (8 factors) 4.5 ± 0.5
Ranson (11 factors) 7.2 + 0.8
Complications:
fulminant pancreatitis 3
necrosis 5
abscess 1
pseudocyst -
respiratory insufficiency 1 
none
9 M : 2 F
52.2 ± 4.8
5 (45%)
5 (45%)
1 (9%)
2.6 ± 0.43
3.7 + 0.77
obstruction. Samples of fluid were also collected frcm one 
patient with hyperamylasaemia due to extensive mesenteric infarction 
resulting frcm mesenteric venous thrombosis. Twelve patients with a 
pancreatic pseudocyst had their cyst fluid sampled, 10 at the time of 
cystogastrostcmy and at percutaneous cyst drainage in two.
In all cases samples were centrifuged at 4°C and the 
supernatants separated and deep frozen, usually within one hour of 
sampling. Samples were stored at -20°C until assay.
Biochemical investigations
The following determinations were performed as described in 
chapter 5. Fluid total protein, albumin, alpl^macroglobulin and 
alphajantiprotease concentrations and amylase, lipase and tryptic 
amidase activities were assayed. Free proteolytic activity and the 
trypsin binding capacity were determined using the plasminogen-free 
fibrin plate technique. Eleven of the patients with acute 
pancreatitis also had serum alph^macroglobulin and 
alpha-^antiprotease concentrations assayed in blood samples taken at 
the time of their peritoneal cannulation.
Statistical analysis
Results are expressed as means + s.e.m. Differences between 
groups have been compared using the Mann-Whitney U test and by 
regression analysis.
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Results
The results are detailed fully in Appendices 2 and 3.
Plasma proteins
The total protein and albumin concentrations were similar in 
all 3 exudates and were approximately l/3rd lower than normal serum 
levels. Total protein concentrations tended to be lower amongst the 
pancreatitis patients with a fatal outcome compared to the survivors 
(38.4 + 2g/l vs 44.4 + 2.3g/l) although just failing to reach 
statistical significance. The mean total protein concentration was 
significantly lower in pseudocyst fluid (Fig. 46) as was the mean 
albumin concentration (Table 42).
Antiproteases
The alpha2 macroglobulin concentrations in the exudates were 
typically below the lower limit of normal for serum (1.1 - 3.9g/l).
In the 10 patients dying of acute pancreatitis the mean 
alpha2 macroglobulin concentration was significantly lower than for 
the 11 survivors (0.51 + 0.05g/l vs 0.7 +_ 0.06g/l, p <0.05). The 
mean peritoneal alpt^macroglobulin concentrations were significantly 
higher in patients with perforated ulcer and lower in pseudocyst 
fluid (Fig. 47).
Alpha^antiprotease concentrations in exudate were typically 
within or just belcw the lower limit of normal for serum (1.3 - 
3.2g/l). The mean peritoneal alpha^antiprotease concentrations were 
slightly higher in patients with intestinal obstruction and lower in
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FIGURE 46.
Total protein concentrations in the 3 
peritoneal exudate samples and in pseudocyst 
fluid. Mean concentration in pseudocyst fluid 
compared to pancreatitis exudate, *** p <0.001.
TABLE 42.
Comparison of pancreatic enzymes, total 
protein, antiproteases and trypsin binding 
capacity in exudates from patients with 
pancreatitis, perforated ulcer and 
intestinal obstruction and in pseudocyst 
fluid.
Pancreatitis Perforated Intestinal
Dead Survived peptic ulcer obstruction Pseudocysts
Parameter (n = 10) (n = 11) (n = 7) (n = 8) (n = 12)
Amylase 39021 27556 6056** 84*** 153578
(IU/1) ±11511 ±6273 ±2787 ±24 ±60505
Tryptic amidase 0.141 0.267 0.133 0.005*** 0.469
(A/hr)* ±0.073 ±0.063 ±0.061 ±0.003 ±0.245
Total protein 38.4 44 .4 41 43.9 18***
(g/D ±2 ±2.3 ±4.5 ±1 ±5.1
Albumin 23.1 29 24.9 25.4 9.4**
(g/D ±1 ±2.2 ±2.9 ±0.96 ±2.9
Alphaz- 0.51 0.7 0.9* 0.68 0.27**
macroglobulin ±0.05 ±0.06 ±0.12 ±0.14 ±0. 07
(g/i)
Alpha, - 1.62 1.77 1.31 1.91 1.23
antiprotease ±0.2 ±0.16 ±0.09 ±0.11 ±0.28
(g/i)
Trypsin binding 62 72 35.7* 115*** 11.3***
capacity ±11 ±8.5 ±10.2 ±7.3 ±4.6
(pg trypsin/lOOpg)
* Units of absorbance change A405fn/hr.
Means + s.e.m, «= p <0.05 •* —, ■= p <0. 01, *** - p <0. 001.
a2
M 
CO
NC
EN
TR
AT
IO
N 
CG
/L
)
2-1
1.5-
1-
5-
k-
«►+
I
r  I
i
ACUTE PANCREATITIS
FATAL SURVIVED
PERFORATED
ULCER
*
INTESTINAL
OBSTRUCTION
PSEUDOCYST
**
FIGURE 47.
Alpha2macroglobulin concentrations in the 3 
peritoneal exudate samples and in pseudocyst 
fluid. Mean concentration in fatal pancreatitis 
exudate compared to survivors, * (p <0.05) and 
in perforated ulcer exudate and pseudocyst 
fluid compared to pancreatitis exudate, * and 
** (p <0.01) respectively.
patients with perforated ulcers and pseudocysts, which showed a 
wide range of concentrations of alpha^antiprotease, but these 
differences were not significant (Fig. 48).
There were only minor differences in the concentrations of 
peritoneal antiproteases whether the attack was due to alcohol or 
- gallstones (Table 43).
Serum levels of alpt^macroglobulin were within the normal 
range in all but 2 of the 11 patients studied and were always 
significantly higher than the corresponding concentraticns in exudate 
(1.68 + 0.18g/l vs 0.64 + 0.06 g/1, p <0.001). Serum levels of 
alpha^antiprotease were all within the normal range and again were 
always significantly higher than in exudate (2.68 + 0.23g/l vs 1.62 + 
0.14g/l, p <0.01).
Pancreatic enzymes
Patients with acute pancreatitis had very high fluid amylase 
activities exceeded only by pseudocyst fluid, although this 
difference was not significant (Fig. 49). Amylase activities tended 
to be higher in pancreatitis patients who subsequently died compared 
with the survivors, but the mean values were not significantly 
different. Amylase activities were elevated in all tut one of the 
patients with a perforated ulcer, but in none of the patients with 
intestinal obstruction. In both conditions the mean amylase 
activities were significantly lower than in the exudates frcm 
patients with pancreatitis (Table 42).
Tryptic amidase activity, indicating trypsinogen activation,
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Alpha^ntiprotease concentrations in the 3 
peritoneal exudate samples and in pseudocyst 
fluid. No significant differences compared to 
mean concentration in pancreatitis exudate.
TABLE 43.
Comparison of pancreatic enzymes, protein, 
antiproteases and trypsin binding capacity 
of exudates from patients with pancreatitis 
associated with alcohol and gallstones.
Acute pancreatitis
Alcohol Gallstones
Parameter (n = 7) (n = 9) p value
Amylase (IU/1) 32984 ± 7297 20636 ± 4553 p = 0.29
Lipase (U/l) 34643 + 3526 19156 + 4807 p = 0.567
Tryptic amidase (A/hr)* 0.309 ± 0.046 0.199 ± 0.094 p = 0.37
Total protein (g/1) 44.4 ± 3.4 39.6 ± 2.4 p = 0.23
Alpha2macroglobulin (g/1) 0.74 ± 0.06 0.57 + 0.09 p = 0.055
Alpha^ntiprotease (g/1) 1.53 ± 0.16 1.79 ± 0.2 p = 0.37
Trypsin binding 61.4 + 12.5 75 ± 8.2 p ■ 0.43
capacity
(pg trypsin/lOOjil)
Units of absorbance change A405fw/hour.
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Amylase concentrations in the 3 peritoneal 
exudate samples and in pseudocyst fluid. Mean 
concentration in perforated ulcer and 
intestinal obstruction exudates compared to 
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was demonstrated in all the patients with acute pancreatitis in 
whom it could be measured, equivalent to free bovine trypsin 
concentrations of up to 18pg/ml (Fig. 50). Of the 10 patients with 
pancreatitis who ultimately died, the typical dark, haemorrhagic 
coloration of the peritoneal fluid in 6 of the patients interfered 
with the assay and tryptic amidase could not be determined in these . 
patients.
None of the pancreatitis exudate samples demonstrated 
fibrinolytic activity that would suggest the presence of free 
proteolytic activity, and thus that the antiprotease defences had 
been overwhelmed.
Patients with pancreatitis secondary to alcohol abuse tended to 
have higher amylase, lipase and tryptic amidase activities in exudate 
than patients with a gallstone aetiology, although these differences 
failed to reach statistical significance (Table 43).
Four of the 6 patients with peritonitis due to perforation of a 
duodenal ulcer showed tryptic amidase activity. One other patient 
with perforation of a gastric ulcer showed a trace of amidase 
activity. Two of the 8 patients with intestinal obstruction showed a 
trace of tryptic amidase activity but in neither condition was 
fibrinolytic activity found to indicate free proteolytic activity.
Tryptic amidase activity could not be assayed on the single 
patient with extensive mesenteric infarction due to dark, 
haemorrhagic coloration of the peritoneal exudate. He was the only 
patient with peritoneal exudate demonstrating free proteolytic 
activity, equivalent to 270jig/ml of free bovine trypsin.
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FIGURE 50.
Tryptic amidase activities in the 3 peritoneal 
exudate samples and in pseudocyst fluid. Mean 
activity in intestinal obstruction exudate 
compared to pancreatitis exudate, *** p <0.001.
In pseudocyst fluids, 7 of the 11 patients in whan it could be 
measured showed tryptic amidase activity. Five of these patients 
demonstrated fibrinolytic activity and one other patient a trace of 
activity on the fibrin plate, indicating the presence of free 
proteolytic activity equivalent to free bovine trypsin activities 
ranging fran 13.5jjg/ml to 67pg/ml.
Trypsin binding capacity
No significant difference was found in the trypsin binding 
capacity amongst patients with acute pancreatitis who died compared 
to those who survived, although 3 patients (tying early, including 2 
who died within 24 hours of sampling, had very lew binding capacities 
indicating almost complete saturation of their antiprotease reserve 
(Fig. 51). There were only minor differences between patients with an 
alcohol and gallstone aetiology (Table 43).
The trypsin binding capacity of the pancreatitis exudate was 
found to correlate significantly with the alpha^antiprotease 
concentration (r = 0.764, p <0.001) but not with alpha2 macroglobulin 
concentrat ion (F ig. 52).
Exudates frcm patients with perforated peptic ulcers shewed a 
significantly lower mean trypsin binding capacity and those with 
intestinal obstruction a significantly higher mean trypsin binding 
capacity than those with acute pancreatitis (Table 42).
Eleven of the 12 pseudocyst fluids studied shewed a markedly 
decreased trypsin binding capacity indicating complete or almost 
complete overwhelming of their antiprotease defences.
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(a) Correlation of trypsin binding capacity and 
alpha^antiprotease concentration.
(b) Correlation of trypsin binding capacity and 
alpha2xnacroglobulin concentration.
Discussion
Unfortunately the tryptic amidase activity could not be
measured in 7 of the patients with acute pancreatitis, including 6
with an ultimately fatal outccme. There was measurable tryptic
amidase activity in all the remaining patients indicating that
trypsinogen activation had occurred, in agreement with the findings
of o t h e r s ^ ' . The presence of tryptic amidase activity in the
absence of demonstrable free proteolytic activity has previously been
confirmed to be due to the presence of trypsin-alpha2 macroglobulin 
1complexes .
Similar levels of tryptic amidase activity were found in the 
patients with a perforated peptic ulcer, the trypsin in these cases 
arising from the escape of duodenal contents, where trypsinogen had 
been activated in the duodenum by enterokinase.
Two of the patients with intestinal obstruction also showed low 
grade tryptic amidase activity; one of these had a strangulated 
external hernia, although the bowel was viable. It is possible that 
trypsin may have migrated across the corpronised bowel wall in this 
case although the explanation in the other case is unclear. Bieth and 
co-workers also noted low grade BAPNA splitting activity in ascitic 
fluids from conditions such as ovarian carcinana, cardiac failure and 
cirrhosis, the cause of which was unexplained .
Peritoneal exudates were all shown to have a lower total 
protein concentration than serum, with reduced levels of albumin (mw. 
68,000), alpha2macroglobulin (mw. 725,000) and alpha^antiprotease 
(mw. 55,000). Concentrations of alpha^antiprotease in exudate were
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around the lower limit of the normal serum values suggesting 
the concentrations of these plasma protein molecules in peritoneal 
exudate may be determined by their molecular size, with large 
molecules such as alph^macroglobulin less able to pass into the 
exudate.
In the 11 patients with acute pancreatitis for whom data were 
available, concentrations of the major antiproteases in exudate were 
always lower than the corresponding serum values. Previous studies on 
pancreatitis exudate have produced conflicting results; 
alpha^antiprotease concentrations in exudate have been reported to be 
higher-^, l o w e r  ^ 4  and markedly l o w e r t h a n  serum levels, although 
all found reduced alpha2 macroglobulin levels in exudate.
The assay of the trypsin binding capacity provides an overall 
assessment of the free antiprotease reserve available for binding. 
Alpha^antiprotease is a much smaller molecule than 
alpha^macroglobulin and on a molar basis is able to complex many more 
molecules of protease than alpt^macroglobulin. Alpha-^antiprotease 
accounts for 90% of the measured trypsin binding capacity in 
seruirr^^, and that it accounts for the major part of the trypsin 
binding capacity of peritoneal exudate is confirmed here by the 
significant positive correlation between the two. Alpl^macroglobulin 
accounts for most of the remaining trypsin binding capacity in serum 
but its relative contribution in exudate is not known. The additional 
contribution of the other antiproteases including inter-alpha-trypsin 
inhibitor, antichymotrypsin, and pancreatic secretory trypsin 
inhibitor must also be considered, but are thought to be relatively
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unimportant in vivo.
The mean trypsin binding capacity of exudates from patients 
with intestinal obstruction was 115pg trypsin bounc^/lOOpl of sample 
and was thus similar to the trypsin binding capacity of normal human 
s e r u m ® I n  comparison the trypsin binding capacities were 
significantly reduced in the exudates from patients with acute 
pancreatitis and perforated peptic ulcer. Apart fran the higher 
alpha-^macroglobulin concentration in perforated ulcer exudates, the 
levels of alpha2 macroglobulin and alpha-^antiprotease were broadly 
similar amongst all 3 exudates. The reduced trypsin binding capacity 
reflects then a degree of saturation of the antiproteases in the 
exudates from patients with pancreatitis and perforated ulcer and is 
supported by the finding of tryptic amidase activity in these 
patients, indicating the presence of trypsin-alpha^acroglobulin 
complexes.
No significant differences were found between fatal and 
recoverable attacks of pancreatitis in terms of their mean trypsin 
binding capacity although 3 patients did have markedly reduced 
levels. All 3 were shocked at the time of sampling and 2 died of 
fulminant pancreatitis within 24 hours. The low trypsin binding 
capacities in these patients indicates incipient saturation of the 
peritoneal antiprotease defences. As alpha^acroglobulin binds 
trypsin more readily and has been shown to become ccmplexed first , 
marked reduction of the total trypsin binding capacity suggests that 
actual or incipient saturation of alpl^macroglobulin is likely, 
which in dogs precedes the development of shock and death of the
216
animal. Thus complete saturation of the antiprotease defences 
in pancreatitis exudate has not been confirmed to occur in this study 
but, from the data, it appears possible that it may occur in a few 
instances, were proteolytic enzyme release or zymogen activation to 
continue.
A low trypsin binding capacity was also demonstrated in 3 
exudates from patients with a perforated ulcer. This situation is 
not, therefore, unique to acute pancreatitis and may cast seme doubt 
on the overall importance of this phenomenon as an explanation for 
the systemic toxicity in acute pancreatitis. The low trypsin binding 
capacity in these cases may be explained on the basis of the sudden 
escape of proteolytic enzymes into the peritoneal cavity associated 
with the ulcer perforation. The resulting peritonitis and secondary 
influx of fluid and antiproteases will, over a period of time, dilute 
and complex the activated proteolytic enzymes, but in the early 
stages, the antiproteases are likely to show high degrees of 
saturation. These patients all had the typical features of 
peritonitis but did not manifest shock, as judged by their heart rate 
and blood pressure. Thus the trypsin binding capacity may frequently 
be low or overwhelmed soon after the actual perforation but, in this 
situation, its clinical relevance is uncertain.
Free proteolytic activity in peritoneal exudate was found in 
only one patient in the present study. He had extensive mesenteric 
infarction due to venous thrombosis and was shocked, anuric and in 
extremis when seen. He was resuscitated and taken to theatre where he 
underwent an extensive bowel resection but died soon afterwards.
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Marked free proteolytic activity unchecked within the 
peritoneal cavity was confirmed in this one patient to be associated 
with profound systemic toxicity. Whether the peritoneal proteolytic 
activity was responsible for his shocked state, a contributing factor 
or an unrelated phenomenon is not known.
Data frcm the pseudocyst fluids are interesting to compare. In 
comparison with the peritoneal exudates pseudocyst fluids had a lower 
protein content but higher enzyme activities. Antiprotease levels 
were usually lower and in the majority there was complete or almost 
complete saturation of the antiproteases as indicated by the reduced 
or absent trypsin binding capacity. Two of the patients showing free 
proteolytic activity had no demonstrable tryptic amidase activity and 
one must postulate that another proteolytic enzyme from the pancreas 
was responsible for the fibrinolysis in each case.
Free proteolysis is then a common finding in pancreatic
pseudocysts but confined within the fibrous wall of the cyst appears
to pose no threat. There are occasional reports of shock and death in
184such patients in association with acute rupture of a pseudocyst 
and it may be postulated that this could occur due to the sudden 
appearance of a large amount of free proteolytic activity within the 
peritoneal cavity. This scenario does not seem to hold for cases of 
pancreatic ascites. The leak from the cyst or from the pancreatic 
duct is often small and, although it can give rise to extremely high 
enzyme levels within the ascitic fluid, the chronic escape of enzymes 
rather than the sudden catastrophic leak described above does not 
appear to be associated with any acute, systemic effects.
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None of the patients with pancreatitis showed free proteolytic 
activity in their peritoneal exudate and this is in agreement with 
the work of others employing a different assay for free trypsin-^. 
The results, however, contrast with those of Wendt and co-workers, 
despite free proteolytic activity having been sought in the current 
study using the same plasminogen-free fibrin plate technique as they 
had employed'^. In their study they stated that 6 out of 13 samples 
of exudate taken at the time of surgery demonstrated free proteolytic 
activity equivalent to 20.9 + 16.8jjg trypsin/ml^.
It would be unusual to operate early in the course of an attack 
of acute pancreatitis and the exudates reported in their study may 
not be comparable to those reported here, or those in an earlier 
study where the exudates were also sampled by peritoneal cannulation
1 n/r
soon after admission to hospital-1 . Wendt and co-workers provided no 
other details about their patients and, in particular, when the 
samples were collected in relation to the onset of the attack and 
whether the samples were truly of free peritoneal exudate, loculated 
peripancreatic collections or even of acute pseudocysts was not 
clear. The current study has shown that free proteolytic activity 
occurs in 50% of pseudocysts, a strikingly similar incidence to that 
reported in their study where 6 of 13 "exudates" showed free
0*7 fZ
proteolytic activity .
The peritoneal antiprotease defences appeared to be adequate in 
the majority of patients with acute pancreatitis for the degree of 
proteolytic en2yme release occurring, there being no evidence, at the 
time of sanpling, of free proteolytic activity. The antiprotease
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defences appeared close to being overcane at the time of 
sampling in cnly 3 patients. The pancreatitis induced by retrograde 
infusion of bile to dogs is associated with extensive destruction of 
the gland and a massive early release of pancreatic enzymes 
systemically and intraperitoneally, quickly overwhelming the 
peritoneal antiprotease defences'^. Such a severe, rapidly evolving 
lesion is presumably a rare occurrence in man, a slower release of 
enzymes providing time for a protective response by the accumulation 
of antiproteases within the peritoneal cavity.
No protease-antiprotease imbalance was demonstrated early in 
the attack when the exudate is thought to be most toxic. It should be 
noted, however, that sampling was delayed a median of 17 hours from 
the onset of symptoms in the current study compared with the one hour 
delay reported in experimental pancreatitis. Continued release of 
enzymes, or activation of zymogens, perhaps by the action of trypsin-
onp
alpl^macroglobulin complexes , might lead to overvhelming of the 
antiprotease defences later during the course of the attack giving 
rise to shock. Equally, the continued presence of irritant fluid in 
the peritoneal cavity may lead to continued outpouring of fluid and 
antiproteases from the peritoneal capillaries which, presumably in 
most patients, keeps pace with the rate of proteolytic enzyme 
activation occurring.
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CHAPTER 11. EFFECT OF INTRAPERITONEAL ANTIPROTEASE THERAPY WITH 
APROTININ ON PERITONEAL FLUID CHARACTERISTICS AND 
BIOCHEMISTRY
Introduction
Examination of peritoneal exudates from patients with acute 
pancreatitis have demonstrated high levels of the pancreatic enzymes 
with evidence of trypsin activation. The aim of the current study was 
to examine the effect of intraperitoneal antiprotease therapy on the 
peritoneal enzyme activities and protein concentrations in patients 
randomised to receive this treatment modality.
Methods
Peritoneal cannulation was performed as detailed in chapter 4. 
Aliquots of any free fluid obtained on aspiration were retained as 
were samples drained following lavage with a single litre of saline 
and samples drained 8 hours after the first instillation of 
aprotinin. Thus a maximum of 3 fluid samples were available for each 
patient.
The volume of the fluid drained on each occasion was recorded 
and the colour of the fluid was compared against a standard colour 
chart^^. In all cases the samples were centrifuged at 4°C within one 
hour of sampling, the supernatants were separated and stored at -20°C 
until analysis. Total protein and albumin content, amylase, lipase 
and tryptic amidase activities were measured and the presence of free 
proteolytic activity was sought as detailed in chapter 5.
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Of the 25 patients randomised to receive intraperitoneal 
therapy with aprotinin, one refused to consent to treatment and 2 
others were found on peritoneal cannulation to have free fluid which 
was not characteristic of acute pancreatitis, both of whan 
subsequently underwent surgery. The remaining 22 patients had 
sequential study of their peritoneal fluid biochemistry.
The patients were studied in two groups based on the presence 
or absence of free peritoneal fluid at the initial cannulation. Ten 
patients had free fluid present in amounts ranging from 6 to 200 mis 
(median 45 mis). Of the remaining 12 patients, 4 had small quantities 
of free peritoneal fluid of less than 1ml on aspiration, insufficient 
for analysis, and have been studied with the patients who had no free 
fluid on aspiration. Table 44 details the characteristics of the 
patients in the 2 groups. Alcohol was the carmonest aetiological 
factor amongst the patients with free peritoneal fluid present.
Significantly more fluid was recovered following saline lavage 
in the patients with free peritoneal fluid, but 8 hours after the 
instillation of aprotinin there was no significant difference in the 
mean volume of fluid returned from each group (Table 44).
Statistical analysis
Results have been expressed as means + s.e.m. Statistical 
analysis was conducted by the Mann-Whitney U test and Wilcoxon rank 
sum test.
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TABLE 44.
Comparison of age, sex, aetiology, delay to 
cannulation and volumes of fluid recovered 
during intraperitoneal therapy in the 
patients with and without free peritoneal 
fluid.
Parameter Free fluid No free fluid
Sex 9M : IF 7M : 5F
Mean age (yrs) 51.8 + 4 . 5  55.3+4.5
Aetiology: alcohol 5 1
gallstones 3 5
unknown 2 4
other - 2
Median delay onset*
to cannulation (hrs) 25 (12-47) 16.5 (8-61)
Volume returned after
saline lavage (mis) 740 + 70 461 + 84
Volume returned 8 hrs
after instillation 480 + 70 320 + 64
of aprotinin (mis)
p value
NS
NS
NS 
p <0.05 
NS
median (range).
Results
Peritoneal fluid colour
Free peritoneal fluid ranged in colour frcm straw coloured (No. 
3 on chart) to dark haemorrhagic (No. 8). In all but 2 patients in 
whom the colour was unchanged, the colour score of the fluid, 
according to the standard colour chart, decreased following lavage 
with a single litre of saline (4.5 + 0.6 vs 5.9 + 0.5, p <0.02)
(Fig. 53). Despite recovering most of the instilled saline after the 
single peritoneal lavage and the instillation of a further litre of 
saline with aprotinin, the returned fluid was darker 8 hours later in 
15 of the 22 patients (Fig. 53), although this difference was not 
significant.
Protein content
Figure 54 shows the total protein concentration to have fallen 
after a single litre saline lavage, the concentration rising again in 
the returned fluid in both groups of patients 8 hours after the 
instillation of aprotinin. Albumin levels demonstrated a similar 
pattern (not shown).
Pancreatic enzymes
Figures 55 and 56 show similar patterns for the amylase and 
lipase activities respectively.
Of the 10 patients with free peritoneal fluid, tryptic amidase 
activity could be measured in 8 of them. In the other 2 patients the 
dark, haemorrhagic coloration of the fluid prevented its measurement.
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FIGURE 53.
Mean colour scores in free peritoneal fluid, 
following saline lavage and 8 hours after the 
instillation of aprotinin solution, in 
patients with and without free fluid at the 
initial cannulation. Differences between 
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significant (NS).
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FIGURE 54.
Mean total protein concentrations in free 
peritoneal fluid, following saline lavage and 
8 hours after the instillation of aprotinin 
solution in patients with and without free 
fluid at the initial cannulation. Differences 
between saline return and aprotinin return,
* p <0.05.
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FIGURE 55.
Mean amylase concentrations in free peritoneal 
fluid, following saline lavage and 8 hours 
after the instillation of aprotinin solution in 
patients with and without free fluid at the 
initial cannulation. Differences between saline 
return and aprotinin return, * (p <0.05) and 
NS (not significant) respectively.
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FIGURE 56.
Mean lipase concentrations in free peritoneal 
fluid, following saline lavage and 8 hours 
after the instillation of aprotinin solution in 
patients with and without free fluid at the 
initial cannulation. Differences between saline 
return and aprotinin return, ** (p <0.01) and 
* (p <0.05) respectively.
No patients were found to have free proteolytic activity on the 
fibrin plate assay.
Patients with no free peritoneal fluid had low levels of 
tryptic amidase activity detected following a single litre saline 
lavage. Unlike for amylase and lipase which both demonstrated an 
increased activity in the fluid returned 8 hours after the 
instillation of aprotinin, tryptic amidase activity fell 
significantly further in both groups (Fig. 57).
Free proteolytic activity was not found on the fibrin plate 
assay in the return fluids of any patient following saline lavage or 
8 hours after instillation of aprotinin.
Discussion
The results of this study have confirmed high pancreatic enzyme 
activities in the peritoneal exudate associated with acute 
pancreatitis. The demonstration of tryptic amidase activity in the 
fluid confirms trypsin activation and the absence of free proteolytic 
activity indicates this is due to the presence of trypsin- 
alpha2macroglobulin complexes.
The levels of protein and enzymes in peritoneal fluid were 
reduced approximately 10-fold following the aspiration of free fluid 
and a single litre saline lavage. Despite draining off a median of 
670 mis from the litre of saline lavage fluid and diluting this 
further by instilling a another litre of saline with aprotinin, the 
concentrations of amylase, lipase, albumin and total protein had all 
risen significantly in the returned fluid 8 hours later, even in the
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Mean tryptic amidase activities in free 
peritoneal fluid, following saline lavage and 
8 hours after the instillation of aprotinin 
solution in patients with and without free 
fluid at the initial cannulation. Differences 
between saline return and aprotinin return,t * 
p <0.05.
cases where there had been no free fluid at the initial peritoneal 
cannulation.
Three explanations can be suggested for this finding. Firstly, 
if blood enzyme levels were higher than levels in peritoneal fluid, 
enzymes might diffuse down the concentration gradient and thus 
equilibrate with the serum levels. Against this is the fact that 
peritoneal enzyme levels tend to be higher, only 3 patients having 
serum levels documented to be higher than the final peritoneal fluid 
levels 8 hours after the instillation of aprotinin. Although the 
dynamic changes in amylase and lipase activities were not monitored 
during the initial 8 hours of intraperitoneal therapy and serum 
levels could have been transiently higher than peritoneal fluid 
levels at sane point in a greater number of the patients, the amount 
of enzyme required to cross the peritoneum to raise the 
concentration, of in excess of a litre of peritoneal fluid would be 
considerable and unlikely to have occurred in practice.
If selective reabsorbtion of water occurred from the peritoneal 
fluid, then the relative concentration of the enzymes would increase. 
A median of 670 mis of the single litre saline lavage was drained 
off, leaving at least 230mls of fluid in situ with a mean amylase 
concentratice of 4216IU/1. Addition of one litre of saline with 
aprotinin to this would give an approximate amylase concent rat ion of 
970IU/1. As the mean amylase concentration in the return fluid after 
8 hours was 9054IU/1, selective water reabsorbtion would need to 
account for a 10-fold increase in the enzyme concentration and on the 
basis of the volume of fluid drained 8 hours after the instillation
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of aprotinin, this explanation seems unlikely.
The most plausible explanation would appear to be continued 
enzyme release frcm the pancreas into the peritoneal cavity during 
the initial 8 hour period during which the aprotinin solution was in 
situ.
This pattern of an increasing protein concentration and enzyme
activity in peritoneal fluid, during the 8 hours of the initial
aprotinin instillation, was not observed for the tryptic amidase
activity. Trypsin release from the pancreas or activation of
trypsinogen within the peritoneal exudate may have ceased
spontaneously or as a result of the action of aprotinin.
Alternatively aprotinin may be inhibiting the tryptic amidase
activity of any trypsin-alph^macroglobulin complexes present in the
exudate thus preventing its detection by the assay. Aprotinin,
because of its relatively large molecular size, is considered to be a
poor inhibitor of the trypsin-alpl^macroglobulin complex due to 
148 164steric hindrance ' ,  nevertheless, others consider its high
concentration and massive molar excess may be sufficient to inhibit
• • 191much of the residual tryptic amidase activity .
The results of this study support the continued release of 
enzymes from the pancreas, at least during the first 8 hours of 
intraperitoneal therapy. The instillation of aprotinin (5 x 10 KIU) 
following peritoneal aspiration and a single litre saline lavage 
markedly reduces tryptic amidase activity in the peritoneal cavity 
during the 8 hour period of the instillation.
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CHAPTER 12. INFLUENCE OF INTRAPERITONEAL ANTIPROTEASE THERAPY WITH
APROTININ ON THE OUTCOME FROM ACUTE PANCREATITIS: INTERIM 
REPORT OF A RANDOMISED, CONTROLLED CLINICAL TRIAL
Introduction
The aims of this study were to compare and contrast the 
patients randomised to receive standard therapy with those randomised 
to receive additional intraperitoneal antiprotease therapy with 
aprotinin. The patients were analysed firstly, to determine whether 
the groups were similar with respect to their presentation, clinical 
characteristics and severity of illness, and secondly to determine if 
therapy resulted in any differences in outcome as judged by the 
incidence of death and major complication.
The effect of intraperitoneal therapy with aprotinin and any 
complications attributable to its use were also investigated based on 
clinical criteria and on the examination of various laboratory and 
physiological criteria, including the APACHE II illness scoring 
system.
Methods
Of the 160 patients with acute pancreatitis assessed and 
documented on admission to hospital, 51 (32%) satisfied the inclusion 
and exclusion criteria detailed in chapter 4 and were randomised, 26 
to receive standard therapy alone (controls) and 25 to receive 
additional intraperitoneal therapy with aprotinin.
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Exclusions
Two patients were found on peritoneal cannulation to have frank 
blood (No. 21) and foul smelling, dark, haemorrhagic fluid (No. 129) 
respectively on aspiration. Both were submitted to urgent laparotomy 
and were treated for a traumatic transection of the body of the 
pancreas and mesenteric infarction due to mesenteric venous 
thrombosis respectively and have been excluded. One patient (No. 131) 
randomised to receive intraperitoneal aprotinin declined to consent 
to peritoneal cannulation and has been excluded frcm further 
consideration. Twenty-two patients, therefore, underwent 
intraperitoneal therapy and were compared with the 26 control 
patients.
Determination of outcome
Death or the development of a major complication, as defined in 
chapter 4, were the primary endpoints by which the effectiveness of 
therapy was judged. In addition the patient's clinical condition, 
analgesic requirements, and the physiological and laboratory response 
to illness were recorded daily to look particularly at any short-term 
benefit of intraperitoneal therapy with aprotinin which might not be 
reflected in the eventual outcome.
Statistical analysis
Statistical analysis was conducted by Mann-Whitney U test, 
Fisher's exact test and by the Chi square test.
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Ccmparability of groups
Table 45 compares various clinical, biochemical, aetiological 
and prognostic factors in the 2 groups of patients. A greater number 
of the patients in the control group were female, were slightly older 
and had gallstones found more frequently, although these differences 
were not significant. There was a greater incidence of hypoxia on 
admission in the treatment group (not significant), but overall the 
groups appeared to be well matched.
Results
Intraperitoneal therapy
Therapy with intraperitoneal aprotinin was associated with no 
adverse effects although in 5 patients there was a problem 
establishing cannula flow. In 2 of these patients the cannulas had to 
be repositioned after instillation of a litre of saline. In 2 other 
patients only a small amount of the first instillation of aprotinin 
was returned after 8 hours. In the final patient the cannula flew was 
slow and was attributed to a plug of fibrin, partially blocking the 
cannula tip and discovered on removal of the cannula after the second 
instillation of aprotinin.
A scanty growth of organisms was cultured from the peritoneal 
exudate in two patients and frcm the saline lavage return fluid in 
one instance. One of these patients subsequently developed a 
pancreatic abscess but unfortunately bacteriology samples were not 
sent when the abscess was drained 4 months later. No adverse effects 
were noted in the other 2 patients. Culture of the peritoneal cannula
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tip revealed skin contaminants, usually S. albus, in 8 patients but 
in no instance were any adverse effects apparent.
Death and major complications
Four of the 22 patients (18%) who received intraperitoneal 
antiprotease therapy with aprotinin died compared to 5 of the 26 
control patients (19%) (Table 46). Three (60%) of the control 
patients died within the first week of their illness, all within 4 
days of admission. These early deaths were due to fulminant acute 
pancreatitis with shock, one in addition showing evidence of 
disseminated intravascular coagulation. The other two patients died 
later (on day 19 and day 38) as a result of pancreatic necrosis and 
sepsis.
Only one of the patients receiving intraperitoneal aprotinin 
died during the first week due to cardiac failure and hypothermia.
The remaining deaths occurred in the second or subsequent week of the 
illness. One had fulminant acute pancreatitis due to pancreatic 
necrosis and died on day 9. The others died late (on day 50 and day 
64) as a result of pancreatic necrosis and sepsis. Two of these 3 
patients underwent surgical treatment prior to their death.
The median time to death in the control patients was 4 days 
compared to 29.5 days in the treatment group, although this 
difference was not significant. Of the remaining patients 9 (35%) of 
the controls developed a major complication compared with 10 (45%) of 
the patients receiving intraperitoneal aprotinin (Table 46).
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TABLE 46.
Outcome: death, major complications and 
clinical outcome amongst patients receiving 
intraperitoneal aprotinin or standard 
therapy.
Intraperitoneal 
aprotinin 
(n = 22)
Control 
(n = 26)
Death 4 (18%)
Fulminant pancreatitis 1
Pancreatic necrosis/sepsis 2 
Other - hypothermia 1
5 (19%)
3
2
Major complication 10 (45%)
Local complications:
pseudocyst 4
necrosis -
abscess 1
Systemic complications:
respiratory insufficy 5 
septicaemia -
9 (35%)
p value
NS
NS
Uncomplicated 
"Slow settling" 
Settled quickly
8 (36%) 
5 
3
12 (46%) 
6 
6
NS
Clinical course
Five (23%) of the therapy group and 6 (23%) of the control 
group with an ultimately uncomplicated outcome were considered to be 
"slow settling" while 3 (14%) of the therapy group and 6 (23%) of the 
control group settled quickly following admission (Table 46). The 
median hospital stay was 11.5 days in the control group and 14 days 
in the group receiving intraperitoneal aprotinin, although this 
difference was not significant (Fig. 58). Table 47 compares various 
clinical features amongst the 2 groups of patients, no significant 
differences being found.
Clinical parameters
The initial clinical assessment performed soon after admission 
was repeated 24 and 48 hours later. The results of these assessments 
are shown in figure 59. The pancreatitis was graded as severe on 
admission in 7 of the patients receiving intraperitoneal aprotinin, 
falling to 4 at 48 hours. Only 4 of the control patients were graded 
severe on admission rising to 7 at 48 hours (excluding 2 other 
patients who had already died).
The degree of abdominal tenderness assessed unblinded each day 
was slightly more marked on admission in the intraperitoneal therapy 
group and was less than in controls on the 3rd and subsequent days, 
none of these differences reaching statistical significance (Fig.
60).
Eleven of the control patients became shocked (pulse >130/min, 
systolic BP <100mmHg) at seme time during the first 3 days of their
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FIGURE 58.
Duration of hospital stay (log scale) in 
patients receiving intraperitoneal aprotinin 
or standard therapy (control).
TABLE 47.
Comparison of treatment amongst patients 
receiving intraperitoneal aprotinin or 
standard therapy.
Intraperitoneal 
aprotinin Control
Parameter (n = 22) (n = 26) p value
Nasogastric tube:
number
duration (days)*
22
3
(100%)
(0-13)
22
3
(85%)
(0-23)
NS
NS
Ileus:
number
duration (days)*
14
1.5
(64%)
(0-9)
16
1
(62%)
(0-12)
NS
NS
Intravenous fluids: 
duration (days)* 6.5 (3-43) 7 (1-57) NS
Re-start oral fluids (day) * 4 (1-24) 4 (1-12) NS
Recommence diet (day)* 6 (4-25) 8 (5-48) NS
TPN employed: number 3 (14%) 4 (15%) NS
Oxygen therapy: 
number
duration (days)* 
ventilated
18
4.5
2
(82%)
(0-42)
(9%)
21
4
6
(81%)
(0-20)
(23%)
NS
NS
NS
Median (range).
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FIGURE 59.
Results of clinical examination at initial 
assessment, and 24 and 48 hours later, in 
patients receiving intraperitoneal aprotinin 
or standard therapy (control).
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FIGURE 60.
Assessment of degree of abdominal tenderness in 
patients receiving intraperitoneal aprotinin 
or standard therapy (control).
illness compared with only 6 of the treated group although this 
difference was not significant. Aprotinin therapy appeared to have 
had little effect on the maximum or minimum mean blood pressures or 
heart rates (Fig. 61).
Patients receiving additional fluid as intraperitoneal 
aprotinin had a higher positive fluid balance, persisting throughout 
the first 7 days. This was most marked in the first 2 days and was 
partly compensated for by a lower positive balance during the 3rd and 
4th days following admission (Fig. 62).
Subjective improvement in their pain following peritoneal 
washout and instillation of aprotinin was reported by 16 patients 
(73%). Four reported no improvement and 2 did not know. Any 
improvement was short-lived, their pain usually having returned 
within a few hours and their mean cumulative intramuscular analgesic 
requirement was identical to the control group (Fig. 63).
Laboratory studies: Renal function
The mean serum urea was slightly higher in the control patients 
from admission until day 4 (Table 48). The mean serum creatinine 
remained elevated at the upper limit of normal throughout the first 
week of the illness in the aprotinin treated group while falling 
steadily after the 2nd day in the control patients (Table 48). These 
differences did not reach statistical significance.
Pancreatic effects
The uncorrected serum calcium showed a similar falling pattern
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(a) Maximum.and minimum mean blood pressure in 
patients receiving intraperitoneal aprotinin 
or standard therapy (control).
(b) Maximum and minimum heart rate in patients 
receiving intraperitoneal aprotinin or 
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receiving intraperitoneal aprotinin or 
standard therapy (control) *** p <0.001.
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TABLE 48.
Daily serum biochemical values in patients 
receiving intraperitoneal aprotinin therapy 
or standard therapy.
Parameter Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Urea (T) 6.39 
±0.75
6.35
±0.98
6.19
±1.1
6.8
±1.4
7.09
±1.4
6.02
±1.3
6.09
±1.6
(C) 7.74 
±1.2
8.3
±1-1
7.32
±1.1
6.1
±1
5.94
±1
5.26
±0.8
6.74 
±1. 3
Creatinine (T) 112
±9
110
±13
111
±12
111
±15
105
±16
100
±15
103
±20
(C) 107 
±9
116
±12
100
±8
89
±11
79
±5
78
±4
76
±7
Calcium (T) 2.22 
±0. 04
2*
±0. 04
1.95 
±0. 06
2 . 01 
±0. 07
2
±0.05
2.07 
±0. 08
2.1 
±0. 04
(C) 2.3 
±0.05
2.15 
±0.04
1.97
±0.06
2.02 
±0. 05
2.06
±0.06
2.16 
±0. 04
1.97 
±0. 06
Glucose (T) 8.7 
±0.7
8.2
±0.8
7.2
±0.5
7.1
±0.7
6.4
±0.5
7.7
±1
9 . 9 
±1.8
(C) 9.7 
±0.9
8.5
±0.5
6.9
±0.5
7.1
±0.4
7.7
±0.7
6.6
±0.5
7.3
±0.5
Amylase (T) 5110 
±940
2099
±293
1401
±304
838
±293
405
±113
401
±88
310
±66
(C) 5241 
±966
3268
±625
1617
±360
710
±145
344
±56
308
±40
251
±51
po2 (T) 65.8* 
±3.4
87.3
±7.2
74.7
±6.3
77
±4.4
88.4
±9.5
93.3
±9.8
84 .8 
±8.2
(C) 76.8 
±3.2
75
±2.9
77.9
±5.1
89
±5
74.2
±4.1
80. 6 
±5.5
78.3
±8.6
Fio2/po2 (T) 2.6* 
±0.2
2.92
±0.18
4.1*
±0.45
3.36
±0.43
3.12
±0.39
2.67
±0.32
2.98
±0.56
(C) 2.07 
±0.1
3.12
±0.38
2.87
±0.3
3.09 
±0 ..29
3.1
±0.37
3.37 
±0.4 5
3.1
±0.37
KEY:
Means ± s.e.m.
* p <0.05, otherwise no significant differences found
(C) Standard therapy
(T) Intraperitoneal
aprotinin
in both groups but with significantly lower levels in the treated 
group on day 2 (Table 48). Randan blood glucose was elevated in both 
groups on admission showing an identical pattern thereafter (Table 
48).
Serum amylase levels fell rapidly in both groups, approaching 
the upper limit of normal by day 5 (Fig. 64) (Table 48). The mean 
serum amylase had fallen further by day 2 in the treatment group but 
this difference failed to reach statistical significance.
Respiratory effects
The p02 was significantly lower on admission in the treatment 
group but thereafter showed a similar pattern in both groups (Table 
48). As many patients received oxygen therapy the adequacy of 
oxygenation may be better expressed by the ratio of the inspired 
oxygen concentration (FiC^) to the pC^. The maximum ratio was 
calculated daily to reflect the poorest gas exchange and was found to 
be significantly higher in those patients receiving intraperitoneal 
aprotinin during days 1 and 3, although no consistent pattern emerged 
(Table 48).
Liver function
Aspartate and alanine aminotransferases were elevated initially 
in both groups of patients. Levels fell steadily fran day 1 in the 
control patients whereas the aprotinin treated group showed a 
transient elevation on day 2 followed by a similar fall (Table 49). 
Alkaline phosphatase showed an identical falling pattern in both
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Mean daily serum amylase in patients receiving
intraperitoneal aprotinin or standard therapy
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TABLE 49.
Daily serum liver function tests in patients 
receiving intraperitoneal aprotinin therapy 
or standard therapy.
Parameter Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Aspartate (T) 160 256
amino­ ±51 ±163
transferase
(C) 190 112
±4 0 ±23
Alanine (T) 117 141
amino­ ±42 ±56
transferase
(C) 170 118
±47 ±25
Alkaline (T) 372 223
phosphatase ±71 ±24
(C) 384 284
±56 ±32
Lactate (T) 567 799
dehydrogenase ±72 ±207
(C) 578 637
±49 ±104
Bilirubin (T) 23.9 26.6
±3.8 ±4.6
(C) 18.5 28.9
±2.7 ±5
150 55 60 56
±70 ±7 ±8 ±10
66 61 45 46
±9 ±12 ±5 ±7
114 64 56 51
±40 ±21 ±13 ±10
68 57 55 43
±13 ±10 ±8 ±6
232 227 252 277
±22 ±24 ±3 0 ±3 6
241 235 264 272
±24 ±24 ±24 ±29
764 736 812* 764*
±117 ±102 ±68 ±106
575 611 511 511
±60 ±85 ±68 ±4 6
34.5 31.5 36 32.7
±7.7 ±9.7 ±12.8 ±14 .3
31.5 23 27.9 20.8
±6.7 ±3.1 ±5 ±3.4
KEY:
Means + s.e.m.
* p <0.05, otherwise no significant differences found.
(C) Standard therapy
(T) Intraperitoneal
aprotinin
Day 7
81’
±24
37
±5
50
±8
39
±5
319 
±55
320 
±35
903
±223
605
±77
39.5
±20
26
±8.4
groups (Table 49). Lactate dehydrogenase tended to rise through the 
course of the illness in the aprotinin treated group while remaining 
fairly constant at the upper limit of normal in the control group. 
These differences were statistically significant cn days 5 and 6 
(Table 49). Bilirubin showed a transient elevation in the control 
group whereas levels in the aprotinin treated group continued to rise 
to the end of the first week.
Plasma proteins
Serum albumin showed an identical falling pattern in both 
groups (Table 50). C-reactive protein showed marked elevation in both 
groups of patients, peaking around the 3rd day and no significant 
differences were found (Fig. 65)(Table 50). Levels of 
alpha2 macroglobulin fell in both groups of patients, reaching a 
trough around the 3rd and 4th days and rising slowly again thereafter 
(Fig. 66). Alpha-^antiprotease showed a similar rising pattern in both 
groups of patients, peaking between days 4 and 5 (Fig. 67)(Table 50).
Haematology
The mean haematocrit showed an identical falling pattern in 
both groups (Table 50). The white cell count showed high initial 
values, falling to within the normal range in both groups by day 6.
APACHE II illness scoring system
The overall APACHE II score was slightly higher in the 
aprotinin treated group of patients cn admission and, with the
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TABLE 50.
Daily values of plasma proteins, haematocrit 
and white cell count in patients receiving 
intraperitoneal aprotinin therapy or 
standard therapy.
Parameter Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Albumin (T) 39.9
±1.2
37.5
±0.96
34.5
±1
34.6
±1.1
33.9
±1
32.8
±1.3
32.5
±1.2
(C) 40.5
±1.3
38.4
±1
34.7
±0.9
33.7
±1
34.5
±1.5
34 .5
±1
30
±1.6
C-reactive
protein
(T) 56
±15
156
±21
231
±19
232
±22
186
±18
153
±17
158
±20
(C) 58
±14
169
±16
217
±20
198
±18
176
±23
145
±18
133
±21
Alpha2macro
-globulin
(T) 1.72
±0.12
1.39
±0.12
1.28 
±0.11
1.26
±0.11
1.4
±0.12
1.39 
±0.13
1.38 
±0.14
(C) 1.64
±0.1
1.47
±0.08
1.29
±0.09
1.3 
±0. 09
1.33 
±0.11
1.31 
±0. 09
1.35
±0.1
Alpha^nti
-protease
(T) 2.48 
±0.15
2.95 
±0.16
3.86
±0.22
4.52
±0.28
4.4
±0.31
4.49
±0.32
4 .53 
±0.3
(C) 2.38
±0.14
3.1 
±0.13
3.77
±0.16
4 . 17 
±0.19
4 .33 
±0.21
4 .17 
±0.24
4 .12 
±0.25
Haematocrit (T) 45.6
±0.9
42.4
±0.7
40
±1.1
38.3
±1.3
36
±1.1
37 . 6 
±1.3
38.3
±1.4
(C) 44.5
±1.5
43.1
±1.3
39.3
±1.2
36.4
±1.1
36.3
±1.5
36.7
±0.9
35.4
±1.7
White cell 
count
(T) 17.1
±2.2
14.5
±1
13.8
±1.2
11.5
±1.4
11.5
±1.3
9.6
±1.1
10.4
±1.2
(C) 16.6
±1.5
16.1
±1.6
15.4
±1.7
12.3
±1.1
10.7
±1.1
10.1
±1
12.6
±1.6
KEY:
Means ± s.e.m.
No significant differences found
(C) Standard therapy
(T) Intraperitoneal
aprotinin
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FIGURE 65.
Mean daily C-reactive protein concentration in
patients receiving intraperitoneal aprotinin
or standard therapy (control).
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Mean daily alpha2macroglobulin concentration in
patients receiving intraperitoneal aprotinin
or standard therapy (control).
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Mean daily alpha^antiprotease concentration in
patients receiving intraperitoneal aprotinin
or standard therapy (control).
exception of day 2, remained slightly higher throughout the first 
week, although these differences were not statistically significant 
(Fig. 68).
Discussion
The 2 exclusions and one refusal to participate in the study 
have resulted in a slight imbalance in the numbers between the 2 
groups but nevertheless the groups appeared to be reasonably well 
matched. This finding of 2 patients with alternative diagnoses serves 
to emphasise the potential value of diagnostic peritoneal aspiration 
in patients with abdominal pain and hyperamyl as aemia 
suspected of having severe acute pancreatitis, a finding 
noted previously by others ' .
Intraperitoneal antiprotease therapy with aprotinin, although 
having been shown to markedly reduce intraperitoneal tryptic amidase 
activity, had no appreciable effect on outcome as judged by the 
overall mortality rate and incidence of major complications in this 
interim report. There were, nevertheless, a number of features which 
might be interpreted as suggesting seme therapeutic benefit.
Early death from fulminant pancreatitis occurred more often 
amongst the control patients and shock was observed more frequently 
in these patients. This may indicate an effect attributable to 
intraperitoneal therapy with aprotinin, although none of these 
differences reached statistical significance. This possible effect 
cannot be attributed directly to the drug and may merely reflect the 
greater positive fluid balance early in the course of the illness in
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Mean daily APACHE II score in patients 
receiving intraperitoneal aprotinin or standard 
therapy (control).
the patients undergoing intraperitoneal therapy. Ranson considered 
that the shock in acute pancreatitis often reflects a fluid
• O O 7
deficit and simply by providing more fluid (by the intraperitoneal 
rcute) over the first 48 hairs might have diminished the incidence of 
shock.
A greater proportion of the patients receiving intraperitoneal 
therapy were assessed clinically as severe on admission (7 vs 4). By 
24 hours 7 patients in each group were considered severe and by 48 
hours this applied to only 4 of the treatment group whereas 7 of the 
control patients were still considered severe, excluding another 2 
patients who had already died. This difference was not statistically 
significant and, although subjective and unblinded, suggested a trend 
towards a worsening clinical condition in a number of the control 
patients compared with the apparent improvement in the group treated 
with intraperitoneal aprotinin.
Against there being any important early differences between the 
groups was the failure to detect important variations in the APACHE 
II scores, or in other objective physiological parameters such as the 
mean heart rate and mean blood pressure, although it is recognised 
that significant changes in only a few patients may have been 
obscured by the lack of change in the majority.
Overall 14 (64%) of the intraperitoneal therapy group and 14 
(54%) of the control group had a fatal or complicated clinical course 
suggesting that the treatment was associated with no major advantage 
in terms of these clinically important endpoints. Thus the initial 
results of this study are in agreement with the negative results of
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the two recent studies investigating formal cycled peritoneal 
lavage333'233. Earlier studies in a predominantly2^  or exclusively 
alcoholic patient population33  ^had suggested an early beneficial 
effect but too few such patients had been randomised in the current 
study to permit a separate analysis.
Relief of pain has been claimed to be a beneficial effect "of 
peritoneal lavage in acute pancreatitis, particularly in the earlier 
anecdotal reports. There has been only one previous attempt to 
quantify the patient's degree of pain during treatment, based on a 12 
hourly assessment by the attending nurse, grading the pain as absent 
- 0 to severe - 2. In this rather subjective assessment no difference 
emerged between the patients undergoing formal cycled peritoneal 
lavage and the control group333. The majority of patients undergoing 
a single peritoneal lavage and instillation of aprotinin in the 
current study claimed, when questioned, to have had relief of their 
pain, but this appeared to be short-lived and was not reflected in 
the more objective assessment of a diminution in their intramuscular 
analgesic requirement throughout the remainder of their illness.
Peritoneal washout appeared to produce a slightly greater fall 
in the mean serum amylase by day 2 in the patients undergoing 
intraperitoneal therapy, although this difference failed to reach 
statistical significance. Mayer and co-workers found that in dogs 
with experimental pancreatitis drainage of the peritoneal exudate did 
not lead to reduced serum enzyme levels23^  nor ^id peritoneal lavage 
in man235 although, in another study in man, peritoneal lavage led to 
the serum amylase falling more rapidly333. The small effect on the
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serum amylase levels postulated to have occurred in the current study 
does not appear to reflect greater haemodiluticn in the therapy group 
as the haematocrit and serum albumin levels were similar in both 
groups of patients throughout the first 7 days of their illness.
Minor differences between the groups emerged for the 
transaminases and lactate dehydrogenase. The highest lactate 
dehydrogenase levels were found in the illest patients in the 
treatment group towards the end of the first week by which time 3 of 
the corresponding patients in the control group had already died. 
Serum creatinine levels appeared to behave differently in the therapy 
group although the differences failed to reach statistical 
significance. The possible reasons for this remain unclear.
None of the specific protein markers were able to distinguish 
the two groups of patients. In particular serum levels of 
alpha2 macroglobulin did not appear to be influenced by 
intraperitoneal administration of an antiprotease solution nor was 
the acute phase response to illness, as reflected by the elevation in 
C-reactive protein and alpha^antiprotease concentrations, diminished 
by therapy. Similarly, although APACHE II had earlier appeared to be 
a premising marker of the course of illness, no important differences 
were apparent in the analysis of patients receiving intraperitoneal 
therapy compared to those receiving standard therapy alone.
In conclusion, this interim report has demonstrated that 
intraperitoneal antiprotease therapy with aprotinin appears to have 
had no important effect cn the incidence of death or major 
complications amongst the patients in the treatment group. There was
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a suggestion of a trend towards earlier clinical improvement 
and a possible reduction in the incidence of shock and fulminant 
acute pancreatitis amongst the treated patients. These effects may be 
clinically important and will be examined further when a greater 
number of patients have been randomised.
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CHAPTER 13. CONCLUSIONS
Incidence and mortality
The apparent incidence of acute pancreatitis, as reflected by 
the number of discharges recorded, has increased dramatically over 
the past 25 years. This is largely thought to reflect an increase in 
the diagnostic rate, particularly of mild cases vtfio are less likely 
to die and thus accounting for the contemporaneous fall in the case 
mortality rate. It is likely that the true incidence of acute 
pancreatitis is increasing also, particularly amongst elderly females 
and young adult males, but the extent of this is unknown highlighting 
the lack of accurate data on the true incidence and mortality trends 
across the country.
Within Glasgow Royal Infirmary the number of patients with 
acute pancreatitis recorded each year has remained relatively stable 
over the 11 year period reviewed but, in conjunction with the 23% 
fall in the catchment population, probably indicates a true increase 
in the local incidence of the disease. As patients with acute 
pancreatitis had been sought and documented prospectively for 3 years 
prior to the study period, this was thought likely to rule out any 
major effect of increased investigative zeal on the diagnostic rate.
The small fall observed in overall mortality may be accounted 
for by a reduction in the number of patients first diagnosed at post 
mortem and is largely explained by the fall in the hospital's post 
mortem rate. Mortality amongst those diagnosed in life remained 
unchanged at 9% throughout the period of the study. This would appear
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to confirm the contention that improvements in therapy over this 
period may have failed to influence outcome.
Closer examination of the data suggests that, at least for 
gallstone-associated attacks, improvements in therapy may have 
contributed to the 47% reduction in number of deaths. A reduction in 
the number of fatal recurrent attacks has contributed to this fall, 
perhaps reflecting the current policy of early cholecystectomy for 
gallstone-associated pancreatitis, performed during the initial 
admission. Surgical eradication of gallstones also appears to have 
been more successful during the latter half of the study and, 
finally, the incidence of gallstone-associated pancreatitis itself, 
may be decreasing amongst the local population.
The study has also confirmed the persistent early mortality 
associated with acute pancreatitis, almost half the patients dying 
within 7 days of admission. Surgery rarely, if ever, has a role in 
the treatment of this phase of the illness and if this early 
mortality is to be improved upon then we need to be able to identify 
these cases more accurately and more rapidly. Early ERCP and 
endoscopic sphincterotomy may well become the treatment of choice for 
gallstone-associated pancreatitis in the future^ but in other forms 
of severe acute pancreatitis an effective, specific therapy is 
required.
Prediction of severity
Measurement of 5 different complement factors provided no 
useful discrimination between uncomplicated and complicated attacks.
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As markers of severity the antiproteases provided useful 
discrimination, particularly during the second half of the first week 
of the illness. Alph^macrogloblin demonstrated a falling pattern in 
severe attacks, presumably indicating its consunption. Its serum 
levels are normally stable during illness and the magnitude of its 
fall may reflect the degree of protease ccmplexation and uptake by 
the reticulo-endothelial system, and hence the degree of proteolytic 
enzyme activation.
The increase in alpha^antiprotease, which accounts for the bulk
of the serum antitrypsin activity, appears to more than adequately
compensate for the reduction in alpi^macroglobulin. The serum
antitrypsin defences are boosted in acute pancreatitis, a more than
300% increase in the trypsin binding capacity having been reported
during the course of the illness, although this increase appeared to
133be delayed m  the severe cases . Whether a reduced 
alpha2 macroglobulin concentration in serum is of importance in acute 
pancreatitis is not clear. Levels of alpt^macroglobulin were 
restored by the infusion of fresh frozen plasma in one recent study 
but was not associated with evidence of any beneficial effect within 
the treated group‘d .  Overwhelming of the serum antiprotease defences 
in acute pancreatitis has not been reported in man.
C-reactive protein provided a better prediction of outcome 
although its elevation is not specific to acute pancreatitis, rather 
it acts as an acute phase reactant, levels rising in response to any 
insult or injury. The non-specific nature of its elevation should 
mean that it truly reflects the severity of inflammation or illness
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and is uninfluenced by other factors such as the age of the patient 
or the underlying aetiology of the attack which are drawbacks of the 
current scoring systems.
The peak levels of C-reactive protein provided the best 
discrimination but may not be attained until the 3rd or 4th day and 
thus .C-reactive protein has no advantage over multiple factor scoring 
systems in terms of speed. C-reactive protein can be measured 
repeatedly thus permitting sequential monitoring of an attack. 
Persistently high levels were found in complicated attacks and in 
those developing a late complication. Furthermore, measurement of a 
single factor is much simpler than the currently used systems and 
more likely to be adopted into daily clinical practice.
Clinical assessment provided the highest overall accuracy
although, even at 48 hours post-admission, failed to accurately
identify patients with severe disease likely to have a complicated
outcome. In this respect the present data is at variance with that
reported by McMahon and colleagues and highlights the lack of
objectivity of clinical assessment, particularly with respect to what
00 ficonstitutes a complicated attack . The illest patients are often 
identifiable on clinical assessment as are those with an obviously 
mild attack, the problem being the identificaticn of severe attacks 
amongst patients with clinical features lying between these two 
extremes.
Examination of several individual clinical parameters 
demonstrated that while they usually provided significant 
discrimination between uncomplicated and complicated attacks, they
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were typically recorded in only a small proportion of patients
developing a complicated attack.
Both the Ranson and Glasgow scoring systems performed well with
little to choose between them, although the Ranson system appeared
superior for alcohol-associated attacks. Diagnostic peritoneal lavage
performed less well, although as pointed out earlier, not all
patients were assessed by this technique. In the original description
72% of severe attacks had been correctly predicted (sensitivity) and
95% of mild attacks (specificity) with 90% of attacks overall
correctly predicted . In a subsequent 3 centre analysis of patients
entered into the recent UK trial of therapeutic peritoneal lavage,
65% of complicated attacks were correctly predicted, 90% of mild
attacks and overall 82% of attacks were correctly predicted^.
Diagnostic peritoneal lavage is probably as accurate as the
multiple factor scoring systems and may be better for alcohol- 
70associated attacks . Multiple factor scoring systems are not widely
utilised outwith clinical studies and remain complex to apply.
Diagnostic peritoneal lavage has the advantage of speed but may be
70less accurate for gallstones . It is invasive and despite the 
advantage of occasionally detecting an erroneous diagnosis earlier in 
the course of an attack, many clinicians remain reluctant to apply 
it.
The APACHE II score has some advantages, not least the fact 
that it is objective, uses easily available data and provides 
reasonable accuracy soon after admission. The accuracy of the peak 
APACHE II score (within the first 3 days) was equivalent to the
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multiple factor scoring systems but then has no clear advantage in 
terms of delay to prediction. APACHE II can be measured daily and 
used to follow the ccurse of the illness which may prove to be its 
most valuable role, overccming sane of the drawbacks of the standard 
scoring systems. The APACHE II remains complicated to apply and from 
the analysis of the individual factors on admission, not all 
contribute to the overall score in this illness. The preliminary 
results nevertheless seem encouraging and worthy of further 
investigation.
All the laboratory based methods for prediction of severity
examined here were indirect, often dependent upon secondary changes
within other systems, and were typically slow in providing a
prediction of outcome. A more direct assessment of the degree of
proteolytic enzyme activation may more closely reflect the extent of
the pancreatic injury* Phospholipase A 2  is produced by activation of
its zymogen by trypsin. It has no natural inhibitors in the body and
levels may more accurately reflect the degree of trypsin activation.
In a recent study phospholipase A 2  levels were found to correlate
984with outcome, the highest levels being found m  fatal attacks^0 .
C-reactive protein was also assessed, appearing to provide similar
discrimination between the groups, but a comparative analysis of
984these 2 factors was not provided 0  .
Trypsin-alpha-^antiprotease complexes can be detected in serum 
and may reflect the amount of trypsin activation occurring42'43. The 
method is carpiicated, however, and remains purely a research 
technique.
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A development which premises to be of great inportance in this
field of understanding is the recent description of an assey for the
trypsinogen activation peptide released when trypsinogen is activated 
■ 1 IQ
to trypsin . This peptide can be detected in blood and in urine and 
directly reflects the amount of trypsinogen activation occurring. 
Increased levels have been detected an admission and early in an 
attack of pancreatitis in patients with a severe outcome139. Such an 
assay may allcw us to monitor both the timing and extent of 
trypsinogen activation and may even provide guidance as to the need 
for antiprotease therapy.
Protease-antiprotease balance.
Free proteolytic activity, indicating overwhelming of the 
antiprotease defences, is frequently detected in exudates socn after 
the induction of experimental pancreatitis by the retrograde 
intraductal injection of bile . Later in the course of pancreatitis 
induced by the closed duodenal loop method, saturation of the 
peritoneal antiproteases has been shown to be associated with the 
development of irreversible shock and death. The activation of 
zymogens and the complement and kinin systems with release of 
vasoactive peptides including kinins and histamine, which may cross 
the peritoneum into the circulation to exert a systemic effect, are 
thought to mediate this toxic effect.
The experimental study in rats confirmed the previous reports 
of frequent, early overwhelming of antiprotease defences associated 
with retrograde intraductal injection models of pancreatitis. The
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improved survival amongst rats receiving intraperitoneal therapy 
appeared to confirm that the exudate was toxic and that its removal 
was beneficial. Survival was prolonged both when free proteolytic 
activity had been demonstrated in the exudate and when absent.
The addition of fresh frozen plasma after removal of the 
exudate proved the most effective therapy, possibly by the 
replenishment of active, natural antiproteases. Other active factors 
are present in fresh frozen plasma including clotting factors and 
fibronectin which conceivably could have played a role, although 
unlikely. Alpha2 macroglobulin is considered likely to be the key 
constituent of fresh frozen plasma and further studies might confirm 
this by examining the effectiveness of the various components of 
fresh frozen plasma which can be separated by fractionation 
techniques.
The trypsin binding capacities of peritoneal exudates were 
reduced in acute pancreatitis in man, indicating a degree of 
saturation of their antiproteases. The antiprotease defences seemed 
adequate in the majority of patients, appearing to be critically 
reduced in only 3 cases. Thus similar changes as reported in 
experimental pancreatitis, although less marked, were observed in 
human acute pancreatitis.
If overwhelming of the antiprotease defences is important to 
the toxicity of exudate in human pancreatitis, it wculd appear to be 
a rare phenomenon occurring in only a small proportion of patients. 
This contrasts with the results of a similar study where 6 of 13 
exudates, sampled at the time of surgery, demonstrated free
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proteolytic activity indicating overwhelming of the antiprotease 
defences3^ .
No data is available on whether human exudate is toxic in the 
absence of overwhelming of its antiproteases. Alpha2macroglobulin, 
due to its large size, appears less able than alpha^antiprotease to 
enter the peritoneal exudate. Alpha2macroglobulin appears, however, 
to be the key protective antiprotease and when saturated kinin 
release and complement activation can proceed, despite only limited
1 q  2n
saturation of alpha^antiprotease ' . The binding capacity or degree
of saturation of alpha2macroglobulin in exudate may then be more 
iirportant than assessment of the total trypsin binding capacity and 
should be examined in future studies. Nothing is known of the dynamic 
changes in protease-antiprotease balance in exudates during human 
acute pancreatitis and serial investigation of these parameters would 
be of interest in any subsequent studies.
The results reported here suggest that intraperitoneal 
antiprotease therapy may be only rarely be indicated in human acute 
pancreatitis for overwhelming of the antiprotease defences. High 
degrees of alpha2macroglobulin ccmplexation in exudate appear to be 
more carmen204 and antiprotease therapy with aprotinin might also be 
expected to benefit these patients, aprotinin having been shewn in 
vivo and in vitro to be protective against trypsin mediated kinin 
release and caiplement activation19'203'205. Whether intraperitoneal 
antiprotease therapy might benefit the remaining patients is 
doubtful, given the failure of recent studies to shew benefit from 
removing the exudate ty formal peritoneal lavage ' , despite
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previous reports of successful t h e r a p y .
The preliminary report of the clinical study comparing standard 
therapy alone or with additional intraperitoneal antiprotease therapy 
with aprotinin confirmed the protocol to be workable and the 
treatment regime acceptable to the patients and clinicians involved. 
Diagnostic peritoneal lavage was performed on the small group 
randomised to receive intraperitoneal antiprotease therapy without 
morbidity, and with the additional bonus of detecting two cases with 
alternative diagnoses requiring early surgery.
Clinical assessment proved an effective method for selecting an 
"at risk" group of patients with a high incidence of death and 
morbidity and thus suitable for study, early in the course of an 
attack.
Evidence was presented that the pancreas appears to continue to 
exude enzymes into the peritoneal cavity during the early phase of an 
attack. Intraperitoneal antiprotease therapy with aprotinin was shewn 
to markedly reduce tryptic amidase activity in the peritoneal cavity 
during the first 8 hours of therapy.
In this preliminary report intraperitoneal antiprotease therapy 
with aprotinin produced no clear benefit in terms of the clinically 
important end points of death and incidence of major morbidity. There 
was a trend suggesting possible benefit with reduction in the 
incidence of shock and early death from fulminant acute pancreatitis, 
but too few patients had been studied at this point to permit formal 
statistical analysis and exclude a type 2 error.
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Acute pancreatitis is an increasingly caimon condition the 
mortality of which has remained static at Glasgow Royal Infirmary 
over the period 1974 to 1984. No systemic therapy has yet been shown 
to significantly alter the outcome when investigated in a properly 
conducted prospective trial. The evidence presented in this thesis 
supports the theory of toxicity of peritoneal exudate in experimental 
pancreatitis in association with saturation of the peritoneal 
antiprotease defences. Similar, although less marked changes in the 
protease-antiprotease balance, have been demonstrated in the 
peritoneal exudates from patients with acute pancreatitis. It is 
suggested, but has not been proven, that overwhelming of these 
defences may occur occasionally in man.
A novel therapy comprising aspiration of the peritoneal 
exudate, a single litre saline lavage and instillation of the 
antiprotease aprotinin (5 x lO^KIU on 2 occasions during the first 8 
hours) has been investigated in a clinical study since February 1986. 
The interim results have shown no significant benefit in terms of the 
incidence of death or major complication although there appeared to 
be a trend towards some early clinical improvement with a reduction 
in the incidence of shock and early death in the treated patients 
which requires confirmation in a larger group of patients.
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APPENDIX 1. CLINICAL STUDY: PATIENT DATA
No. Sex Age
Study
group Aet
Heme/
death
(day)
Prognostic 
factor score
Glas Ranson
Out­
come Carpi i cat ions
001 F 69 C GB 15 5 7 Mild Slow settling
002 F 80 NR UK 14* 6 4 Mild No *social reasons
003 F 63 T GB >14 5 5 Mild Slow settling
004 F 60 C GB 12 2 2 Canp Resp insufficiency/ 
BWS
005 M 65 C UK 3 3 4 Died Fulminant
006 M 39 NR UK+ 4 0 1 Mild No
007 F 39 NR GB+ 5 2 1 Mild No
008 M 36 C ALC+ 58 3 4 Ccmp Necrosis
009 M 62 T GB 50 3 4 Died Necrosis
010 M 35 NR GB 7 2 2 Mild No
Oil F 66 C OTH 284 5 7 Carp Necrosis
012 M 34 NR ALC+ 4 0 0 Mild No
013 M 32 T ALC 14 2 1 Ccmp Pseudocyst
014 M 30 Ex ALC+ 9 0 0 Mild Slow settling
015 M 31 NR ALC+ 8 1 1 Mild No
016 M 89 NR GB 12 2 5 Mild No
017 M 51 T OTH 14 4 6 Ccmp Reg? insufficiency
018 M 35 NR ALC 10 2 2 Mild No
019 M 56 Ex UK 12 4 5 Mild Lap diagnosis
020 M 32 NR ALC 8 0 1 Mild DTs
021 M 31 T OTH 12 0 1 Mild No
022 M 50 T ALC 6 0 0 Mild No
023 F 66 NR GB+ 8 1 3 Mild No
024 M 25 C ALC 9 1 1 Mild Slow settling/ 
Collection
025 M 23 C ALC+ 7 0 0 Mild No
026 M 48 NR GB 4 1 1 Mild No
027 F 56 T GB 15 3 6 Carp Reg) insufficiency
028 F 39 NR UK 6 1 0 Mild No
029 F 52 T GB 14 6 6 Canp Reg) insufficiency
030 M 67 NR UK+ 7 2 2 Mild No
031 F 23 NR GB 6 0 0 Mild No
032 M 36 NR ALC+ 8 0 0 Mild No
033 M 44 NR ALC 5 0 0 Mild No
034 F 74 C GB 11 1 4 Mild No
035 M 33 NR ALC 5 2 1 Mild No
036 M 39 NR ALC 19 1 0 Mild Collection
037 M 37 NR OTH+ 11 1 1 Mild No
038 F 53 Ex ALC 38 2 3 Carp Resp insufficiency/
TYTe
039 M 70 T UK 13 2 2 Mild
Ls Jl SD
Slow settling
040 M 64 C UK 7 1 2 Mild No
041 F 82 NR GB 12 0 1 Mild No
042 M 30 NR OTH 4 0 0 Mild No
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043 F 86 Ex OTH 3 5 7 Died Fulminant/ARF
044 F 69 C GB 2 4 7 Died Fulminant/DIC
045 M 55 T ALC 9 6 9 Died Fulminant/
Ne cr os is/BWB/DTs
046 F 82 NR GB 17* 2 4 Mild No *social reasons
047 M 25 NR ALC+ 6 0 0 Mild No
048 F 36 NR GB/A+ 13 2 2 Mild DTs
049 F 26 NR GB 16* 1 1 Mild No *cholecyst
050 M 37 NR OTH+ 7 2 2 Mild No
051 M 83 NR UK 21* 1 2 Mild No *ERCP
052 M 46 NR GB/A 6 0 0 Mild No
053 M 65 T GB 9 2 3 Comp Resp insufficiency
054 M 31 C ALC 8 0 1 Mild No
055 M 73 C OTH 19 3 5 Died Necrosis
056 M 40 C ALC+ 8 1 2 Mild No
057 F 80 Ex OTH 10 3 5 Died ARF/Septicaemia
058 M 59 NR GB 6 3 2 Mild No
059 M 78 NR GB 67 2 4 Conp LVF/Septicaemia.
060 M 75 T GB+ 60 3 7 Ccmp Resp insufficiency/ 
Recurrent attack
061 F 47 NR GB/A 9 1 3 Mild No
062 F 36 T UK 18 2 4 Conp Pseudocyst
063 F 36 NR GB 16* 1 2 Mild No *cholecyst
064 M 29 NR ALC 6 0 0 Mild No
065 F 82 NR UK+ 8 0 1 Mild No
066 M 54 NR GB/A 15 5 2 Ccmp Resp insufficiency
067 M 33 T ALC 7 1 1 Mild No
068 F 52 NR ALC 4 0 0 Mild No
069 M 29 NR ALC 8 0 0 Mild No
070 F 46 Ex ALC+ 8 2 3 Mild No
071 F 60 NR UK 11 2 4 Mild No
072 F 72 NR GB 35 2 3 Ccnp Abscess
073 M 23 NR ALC+ 5 0 0 Mild No
074 M 56 NR ALC 8 1 1 Mild No
075 M 55 NR ALC+ 6 0 0 Mild No
076 M 57 T UK 64 5 9 Died Necrosis/BWS
077 M 77 NR UK 10 2 4 Mild No
078 F 49 NR ALC 10 0 0 Mild No
079 M 45 NR ALC 7 0 1 Mild No
080 M 34 NR GB 8 0 0 Mild No
081 F 29 NR GB 11* 1 2 Mild No *cholecyst
082 F 78 NR. UK 10 1 2 Mild No
083 F 46 C UK 14 1 5 Mild Slow settling/ 
Confusion
084 F 69 C GB 20 4 5 C a p Rep insufficiency
085 F 65 NR GB 16* 0 1 Mild *Cholecyst/Ketoacidosis
086 M 55 C GB 17 1 2 C a p Septicaemia
087 F 78 C GB 9 0 2 Mild No
088 F 83 T OTH 4 6 8 Died Hypothermia
089 F 39 NR GB 7 2 3 Mild No
090 M 25 NR GB 5 2 0 Mild No
252
091 F 59 C UK 14 3 4 Mild Slaw settling/ 
Confusion
092 F 64 NR GBf 7 0 1 Mild No
093 M 63 T UK 17 4 5 Comp Resp insufficiency/ 
Late abscess
094 M 85 Ex UK 5 5 5 Died PAneurysm
095 M 73 C UK 1 1 4 5 Carp Septicaemia
096 F 72 NR UK 8 0 2 Mild No
097 M 37 NR ALC 9 2 2 Mild No
098 M 33 NR ALC+ 7 0 1 Mild No
099 F 71 NR GB 1 2 1 3 Mild Slow settling
1 0 0 M 24 NR GBf 6 1 1 Mild No
1 0 1 F 77 NR GB 13 1 5 Mild No
1 0 2 M 29 NR ALC+ 6 0 0 Mild No
103 M 65 T GB 1 0 3 3 Mild Slow settling
104 M 69 NR GB 1 2 1 3 Mild Slav settling
105 M 63 NR GB 8 3 4 Mild No
106 M 56 C GB 38 6 7 Died Necrosis/BWS
107 M 79 NR UK 18 2 5 Carp Resp insufficiency
108 F 59 NR UK 14 1 3 Mild Recurrent attack
109 M 31 T ALC+ 1 2 2 3 Carp Pseudocyst
1 1 0 F 64 T GB 7 4 4 Mild No
1 1 1 F 40 NR GB 9 3 3 Mild No
1 1 2 M 29 Ex a m 29 3 5 Carp Resp insufficiency/ 
BWS
113 M 72 NR GB 2 1 * 2 2 Mild No *social reasons
114 F 29 NR GBf 2 1 * 1 2 Mild No *cholecyst
115 M 24 NR ALC+ 8 1 0 Mild No
116 M 40 NR UK+ 6 0 0 Mild No
117 F 31 NR GB 7 1 1 Mild No
118 M 37 T ALC 26 2 2 Mild Slow settling/DTs
119 M 81 NR GB 15* 1 3 Mild No *social reasons
1 2 0 M 74 NR GB 1 0 0 3 Mild No
1 2 1 F 56 NR GB 5 1 2 Mild No
1 2 2 M 56 NR UK 9 1 3 Mild No
123 M 40 NR UK+ 4 0 3 Mild No
124 F 69 NR GB 1 1 3 4 Mild No
125 F 74 C GB 1 0 4 3 Carp Resp insufficiency
126 M 41 T UK 8 0 1 Mild Slow settling
127 M 50 NR ALC 1 0 0 Mild Self discharge
128 M 56 NR ALC+ 6 0 1 Mild No
129 M 49 T ALC - - - Died Bowel
infarction
130 M 6 6 Ex ALC+ 25* 3 2 Mild No *social reasons
131 M 48 T ALC 23 5 3 Carp Pseudocyst
132 M 61 NR ALC 1 2 1 1 Mild No
133 M 40 T UK 16 2 1 Carp Pseudocyst
134 F 44 NR GB 19* 0 0 Mild No *cholecyst
135 M 2 1 NR ALC 8 1 0 Mild No
136
137
M
M
72
33
Ex
C
UK+
ALC
1 0
1 1
2
2
4
2
Mild
Mild
Slew settling 
Slow settling
138 F 39 NR UK 9 1 2 Mild No
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139
1 A A
F 69 C GB 2 0 3 6 Comp Pseudocyst
140 F 44 NR ALC 5 0 1 Mild No
141 M 58 NR OTH 5 1 1 Mild No
142 M 58 C UK 15 4 5 Ccmp Pseudocyst
143 F 69 NR GB 8 1 3 Mild No
144 F 6 8 C GB 13 4 3 Mild Slew settling
145 F 71 NR GB 28* 5 7 Mild No *social reasons
146 M 6 6 NR GB 7 2 3 Mild No
147 M 31 NR ALC+ 5 1 0 Mild No
148 M 62 NR ALC+ 9 2 2 Mild No
149 F 80 NR GB 15* 0 2 Mild No *social reasons
150 F 50 NR ALC+ 5 0 0 Mild No
151 M 29 Ex ALC 2 3 6 Died Fulminant/Necrosis/
ARF
152 F 83 NR GB 24* 1 2 Mild No *social reasons
153 F 15 Ex UK 1 0 2 4 Mild No
154 M 25 NR GB 7 0 0 Mild No/Recurrent attack
155 M 56 NR GB/A 9 2 5 Mild No
156 M 6 6 C GB/A 4 4 6 Died Fulmi nant/Ne cros is/ 
DTs
157 M 46 NR ALC 7 0 1 Mild No
158 F 2 0 NR GB 13* 0 1 Mild No *cholecyst
159 M 56 NR ALC 15* 1 1 Mild No *social reasons
160 M 53 NR OTH 9 2 2 Mild No
KEY:
Study group: NR = not randomised (mild), Ex = exclusion,
T = intraperitoneal aprotinin therapy, C = standard therapy.
Aetiology (Aet): ALC = alcohol, GB = gallstones, OTH = other,
UK = unknown, GB/A = gallstones & alcohol, + = recurrent attack.
Prognostic factor scores: Glas = Glasgow scoring system,
Ranson = Ranson scoring system, (scores ^ 3  = severe attack predicted).
Complications: ARF = acute renal failure, BW3 = body wall staining, 
collection = small peripancreatic fluid collection on ultrasound,
DIC= disseminated intravascular coagulation, DTs = delirium tremens, 
fulminant = fulminant acute pancreatitis, lap diagnosis = laparotomy 
diagnosis, LVF = left ventricular failure, necrosis = pancreatic 
necrosis, recurrent attack = recurrent attack during same admission, 
resp insufficiency = acute respiratory insufficiency.
*cholecyst/ERCP/social reasons = discharge delayed by elective early 
cholecystectcmy/ERCP/ 11 social reasons".
254
APPENDIX 2. RESULTS OF BIOCHEMICAL STUDIES OF PANCREATITIS 
EXUDATES
Tryptic
Patient TBC a2 M a-^ AP TP Alb Amylase Lipase amidase
Fatal
pancreatitis: 
Early <7days
JK 2 0 0 . 6 0 . 8 27 19 6890 16690 NA
MM 1 0 0 . 2 1.4 37 25 56900 35500 0.018
TG 80 0.5 1.4 36 23 13330 15900 NA
SK 30 0 . 6 1.4 50 24000 38390 0.324
Late >7days
BE 1 0 0 0 . 6 2 . 2 41 27 13030 8930 0.031
JS 1 2 0 0.7 3.1 38 2 1 132400 38940 NA
AP 80 0.5 1.4 34 25 24140 20780 NA
MR 60 0 . 6 1 . 1 35 2 2 35600 30430 0.191
TR 60 0.4 1 . 8 41 37400 40860 NA
WC 60 0.4 1 . 6 45 46560 35810 NA
Complicated
pancreatitis:
MW 40 0 . 8 1.4 41 28 58700 37219 0.482
JF 40 0 . 8 1 . 6 47 32 38000 0.496
DMcT 1 0 0 0.9 1.9 43 30000 30960 0.190
JR 60 0 . 8 0.9 52 14700 38560 0.600
JC 1 0 0 0 . 6 2 . 0 30 14380 15370 0.029
WM 1 0 0 0.4 2 . 2 43 5660 4510 NA
JMcG 60 1 . 0 1.7 54 2 2 0 0 0 46750 0.377
PM 0.4 2.9 33 2 1 10470 0.046
Uncomplicated
pancreatitis:
MW 40 0.7 1.4 49 33 31248 0.180
JG 80 0.7 1.4 45 30300 33610 0.150
GS 1 0 0 0 . 6 2 . 1 51 31 59000 38870 0.387
KEY:
No free proteolytic activity found on fibrin plate assay.
TBC = trypsin binding capacity (jug trypsin inhibited/lOOpl), 
a?M = alphaomacroglobulin (g/1), a-jAP = alpha1antiprotease (g/1), 
TP = total protein (g/1), Alb = albumin (g/1), Tryptic amidase = 
BAPNA splitting activity (change in absorbance units A4 Q^nm/hour), 
FPA = free proteolytic activity (mean lysis area on fibrin plate 
assay mm2.), NA = not assayable (due to haemorrhagic coloration of 
fluid sample).
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APPENDIX 3. RESULTS OF BIOCHEMICAL STUDIES OF OTHER EXUDATES 
AND PSEUDOCYST FLUID
Patient TBC a2M a-^ AP TP Alb Amylase
Tryptic
amidase FPA
Perforated 
ulcers;
MMcK 10 1 . 2 1 . 0 23 15 6000 0.072 0
m 1 0 0 . 6 1 . 0 25 13 13410 0.442 0
AB 80 0.9 1 . 6 47 30 213 0 0
WK 50 1.4 1.3 49 30 1935 0 0
DC 40 0 . 8 1 . 6 52 32 741 0 . 2 1 1 0
m c G 50 0.9 1.3 43 27 19020 0.193 0
JL 1 0 0.5 1.4 48 27 1077 0 . 0 1 1 0
Intestinal 
obstruction: 
EB 100 0 . 2 1.5 43 24 30 0.027 0
JG 1 1 0 0 . 6 1 . 8 50 31 45 0 0
FB 1 2 0 0 . 6 1.9 41 2 2 126 0 0
GD 1 2 0 0 . 6 2 . 0 45 26 51 0 0
AH 1 0 0 0.5 1.7 45 26 204 0.015 0
JF 1 2 0 1 . 0 1.7 44 26 159 0 0
JD 160 0.4 2.5 42 23 33 0 0
JR 1 1 0 1.5 2 . 2 41 25 27 0 0
Mesenteric 
infarction: 
JC 0 1 . 0 1 . 6 50 14 352000 NA 1590
Pseudocysts: 
PC 20 0.4 1 . 2 2 0 1 1 460000 0.077 0
AF 0 < 0 . 2 0.9 1 1 5 99300 0.520 254
ER < 1 0 < 0 . 2 0 . 8 5 4 54000 0.390 64
GP 1 0 < 0 . 2 0 . 8 15 8 13100 0.628 0
JR < 1 0 < 0 . 2 0 . 2 5 3 147000 0 0
EB < 1 0 < 0 . 2 2 . 0 17 1 2 1994 0.124 380
MMcN < 1 0 < 0 . 2 < 0 . 2 3 1 231360 0 64
TB < 1 0 0 . 6 2.7 33 9 58810 2.792 Trace
BC 1 0 0.7 2.4 41 25 5370 0.630 0
MM 60 0.7 2.7 59 33 20450 NA 0
AL < 1 0 < 0 . 2 0 . 8 6 1 676000 0 0
TI < 1 0 < 0 . 2 < 0 . 2 1 < 1 75540 0 113
KEY: as for appendix 2.
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